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Abstract	  
Interactions among proteins play a fundamental role in regulating all biological 
processes.  Such interactions that dictate disease progression are viable regions to target 
with chemical probes and inhibitors. With an array of interacting sites that vary in size, 
polarity, and structure, these intransigent chemical targets have been termed undruggable 
due to the difficulties to target; however, advancements in the area of chemical biology 
now allow for exploration and progress of this formidable territory.  With an estimated 
650,000 protein-protein interactions (PPIs) found in the human interactome, probes that 
can target such interactions are highly sought after due to their significance in disease 
suppression. In Chapter 2, we explore the importance of a new non-covalent interaction 
between aromatic π-systems and sulfoxide moieties that contribute to binding energy.  With 
an enrichment of aromatic amino acids at protein interfaces, the utility of this interaction 
can be exploited at protein interaction sites. We further probe protein interfaces in Chapter 
3 by incorporating oxidizable thioether-bridged a-helical peptidomimetics. These probes 
modulate the polarity, structure, stability, affinity, and permeability, thereby allowing the 
mimetics to disrupt native PPIs. We utilized a specific Protein Observed 19F (PrOF) NMR 
technique to monitor crosslinked peptide affinity, as well as circular dichroism, tryptic 
 ii 
digests, HPLC, fluorescence microscopy, fluorescence polarization, and computational 
calculations to evaluate biophysical characteristics. We further probe perfluorinated 
sulfone crosslinks in collaboration with Ratimir Derda in Chapter 3 for interactions with 
human serum albumin. By using two different methods to incorporate thioether crosslinks, 
either with an SN2 dibromoalkylation or a thiol-ene reaction as discussed in Chapter 4, we 
can alter the oxidation states of either one or two sulfur groups within the macrocycle. 
Chapter 5 is an assessment of a histone variant, H2A.Z for specific acetylation patterns to 
interact with certain bromodomains, BPTF and PfGCN5. Using PrOF NMR, a ligand 
observed NMR technique CPMG, and photo-crosslinking, we identify from of a series of 
various acetylation patterns, that H2A.Z Ack4,11 shows the highest affinity towards the 
bromodomain BPTF. We further investigate a different bromodomain, CBP in 
collaboration with Stuart Conway for interactions with five previously identified small 
molecules. Using PrOF NMR, and fluorescence polarization, we identify affinity towards 
three bromodomains: CBP, Brd4 and BrdT. 
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Chapter	  1.  Introduction	  
1.1  Introduction to peptide mimetics 
Protein-protein interactions (PPIs) play a central role orchestrating biological 
processes. While necessary, they have also been implicated in disease progression.  
Targeting of PPIs using small molecules has been a great challenge that has puzzled 
researchers, but development of molecules into useful probes could expand our 
understanding of biological processes, uncover new therapeutics, and discover novel 
diagnostics. Emerging advances in the field of chemical biology strive to mediate disease 
progression with PPI-targeted chemical probes. It is estimated to be >100,000 Protein-
protein interactions (PPIs)1; therefore, they are to be critical points of which manipulation 
may be possible. While there are numerous PPIs, not all are equally targetable.  Small 
molecules have been able to target clustered regions with increased binding affinity, termed 
‘hot spots’, Figure 1.1. ‘Hot spot’ regions of high binding affinity bind well to small 
molecule inhibitors, but unfortunately many ‘hot spot’ regions can expand over a 
significant portion of the PPI interface (1940 ± 760 Å2). This area is typically too large for 
small molecules to effectively inhibit with protein-small molecule binding areas of ~300-
1,000 Å2. Many weak binding interactions throughout a PPI that accumulate to a large 
binding energy attenuate further the difficulty small molecules face in modulating the 
expansive area. With the topology of many PPIs having vast hydrophobic, flat regions, 
researchers have turned their attention toward alternative approaches, taking inspiration 
from the protein structure to create peptide mimics. 
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1.2  Defining characteristics of protein-protein interactions (PPIs)  
PPIs are notoriously difficult to target and inhibit. The term undruggable has been used 
to name the extensive area of molecular targets not able to be targeted by either small 
molecules.2 This daunting title expresses the difficult problem researchers are facing.  PPIs 
with weak binding interactions (KD >200 nM) and extensive binding surfaces (>2,500 Å2) 
prove to be the most challenging.3,4 While small molecules can be optimized to fit into 
deep pockets, or mimic certain ‘hot spot’ residues5, the flat, hydrophobic landscape of 
many protein targets prove to be inaccessible to most small molecule inhibitors6. 
Unfortunately, small molecules are only able to target ~10% of the proteins encoded in the 
human genome, designating the majority of PPIs as currently undruggable.7,8 Moving 
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Figure 1.1 Three complexes with discontinuous protein-protein interfaces that have been targeted with 
small molecule inhibitors, shown above the respective PPI. (PDB: ZipA:FtsZ-1Y2F; IL2:IL2R-1PY2; 
hDM2: p53-1YCR). 
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beyond small molecule inhibitors, several promising methods have been developed to 
disrupt PPIs using peptidomimetics and a-helical mimicry.  
1.3  Role of the a-Helix in PPIs  
With 62% of all protein-protein interfaces mediated by an a-helix, the desire to exploit 
this ubiquitous secondary structure is evident.9 Peptides mimicking an a-helical binding 
surface allows for direct competition with the native protein. A disruption of the native PPI 
is achieved by designing stabilized a-helical peptidomimetics. With enhanced binding 
affinity, proteolytic stability and cell penetration, a disruption of the native activity can be 
achieved.   
 
 
 
 
While diverse topographies characterize PPIs, there is a high frequency of a-helices 
at the binding site.9 Researchers have begun to exploit this ubiquitous secondary structure 
i1
2
3
4
5
6
face one
face two
face three
Helical Stabilizing 
motif
α−helixΑ                            Β
Figure 1.2 A. a-helix construct with synthetic stabilizing motif encompassing one face of helix.  
B. Helical wheel with three faces separated. 
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by mimicking the natural a-helix (a-helical peptidomimetics), and stabilizing the helix 
with conformationally constraining crosslinks that expand over one face of the helix, 
Figure 1.2. A variety of modulations can dramatically enhance the mimetic compared to 
the native protein by crosslinking the peptide. 
1.4  Structural Effects 
The a-helix is a ubiquitous structure within proteins that is characterized by a 
rotation of the backbone with 3.6 amino acids within each turn. Defined torsion angles of 
the a-helix backbone, with phi (NH—Ca) being −57.8° and psi (Ca—C=O) being −47.0°, 
have been well defined using X-ray crystal structures.10 This turn creates three separate 
faces of the a-helix (Figure 1.2). An interesting feature of this secondary structure was 
first elucidated by Isabella Karle and colleagues where they determined an unstructured 
peptide could transform into an a-helix upon conformational nucleation.11 This allows for 
only a portion of the a-helix to be synthetically constrained which ultimately leads to a 
fully structured a-helix.   
Understanding the natural helical structure of peptides within the binding site is the 
first step in identifying potential utility of the cross-link motif. If the peptide does not have 
a natural propensity to fold into an a-helix when it is in the active state, an installed 
crosslink may not achieve enhanced affinity. It has been identified that robust ring-closing 
metathesis reactions with full conversion typically confers a high degree of helicity.12,13 
Certain amino acids have less propensity to fold into the a-helical secondary structure.14  
The bulky character of b-branched residues (threonine, valine, isoleucine) often reduces 
helicity. A variety of studies have assessed crosslinked helical peptides for an optimal 
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structural design. To perturb side chain interactions as little as possible, crosslinking motifs 
have been added to only one face of an a-helix, usually away from the binding side and 
solvent exposed. Synthetic constraints are placed at an initial position (i) and either 3 or 4 
residues away to encompass one helical turn.  To expand over two helical turns, i, i+7 
positions are utilized.  These sites are somewhat near in space, spanning 6.7-10 Å in 
distance, Figure 1.3. Recently, ‘stitched’ peptides have been identified as having even 
more stability.15 Two hydrocarbon constraints are placed adjacently, e.g. i,i+4+7. These 
‘stitched’ peptides have shown significant thermal stability as well as cell penetration 
capabilities.  
Stereochemistry of the amino acids used in appending constraints can greatly affect 
the reactivity, depending on the linkage size and the number of helical turns constrained (i, 
i+3,4 vs. i, i+7).  For an i, i+3 linkage, DiLi+3 stereochemistry leads to a much higher % 
product conversion, whereas for i, i+4, the same stereochemistry with DiDi+4 or LiLi+4 has 
more than 98% conversion in a model RNAseA peptide.12 A follow up study further 
investigated how stereochemistry affected a stapled BH3 peptide, and identified LiLi+4 to 
have marked enhancement of not only helicity, but also in vivo reduction of leukemic cell 
growth.16 The p53 helical stapled peptide mimics have been identified to incorporate DiLi+7 
stereochemistry (SAH p53-5) leading to 20% helicity, cell permeability, and 0.80 ± 0.05 
nM.17 There are several structural changes that can substantially affect the chemistry, as 
well as the stability, helicity, and permeability of the constructs. Identifying an optimal 
structural design can influence the effectiveness of the inhibitors, and should be prudently 
assessed before moving forward.   
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1.5  Stability 
Identifying the extent of a-helicity achieved with added structural constraints is the 
first step in achieving potent inhibitors. Circular Dichroism (CD) allows for an assessment 
of the average a-helical content within the peptides. A generic a-helix displays a double-
well minimum at 208 and 222 nm. The degree of helicity utilizes the molar ellipticity at 
222 nm, since there is overlap of other structural signatures near 208 nm, such as a random 
coil. The percent helicity for shorter peptides is the ratio of [q]222/max[q]222 where 
max[q]222 = (−40 000 X [1 − k/n]), k = 2.5, n = number of residues.18 
 
1.6  Solubility 
Achieving highly soluble crosslinked peptide inhibitors can be an issue. With the 
introduction of a highly hydrophobic cross-linker such as the all-hydrocarbon ‘staples’, 
i+3
i+4
i+7
Figure 1.3 Calculated distance between the Cβ of amino acid residues i (green) to i + 3 
(magenta), 4 (blue), and 7 (red) amino acids are 5.7 Å, 6.0 Å, and, 10.2 Å respectively. Distances 
were calculated on the CREB peptide (PDB: 1KDX). 
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caution needs to be taken towards aggregation. Often synthetic crosslinks are appended 
onto a face of the helix away from the binding site, typically solvent exposed. The lack of 
polar substituents may lead to aggregation and inactivation by serum.19–21 Furthermore, 
diminished solubility can cause disruptions to precise measurements to fully characterize 
the properties of potential drug candidates. The problematic nature warrants consideration 
of more polar crosslinking motifs.   
1.7  Protease Resistance 
Unstructured peptides rapidly undergo proteolytic degradation, but with the 
addition of a synthetic constraint, they can withstand proteolysis. Trypsin is a serine 
protease enzyme that identifies peptides with a catalytic triad made up of histidine, 
aspartate and serine, which recognize and cleave the amide bond on the c-terminal side of 
lysine and arginine residues. A synthetic crosslink disallows the peptide to unfold into an 
extended strand, and fit into the binding pocket, thus making it difficult for the protease to 
cleave the scissile bond. The constrained peptides confer resistance similar to that of small 
molecule inhibitors, and dramatically increases the stability versus the unconstrained 
peptide.18  
1.8  Intracellular Uptake 
It is still unclear as to what dictates cross-linked peptide’s membrane permeability.  
Typically, unfolded peptides do not readily pass through the membrane, except for a few 
highly basic peptides, termed cell penetrating peptides (CPPs) (Figure 1.4). These include 
TAT, penetratin, and octa-arginine. While it is not known exactly what makes these 
arginine rich peptides pass through, we do know the guanidino functional group induces 
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interactions with the cell surface. Sulfated glycans and other phosphates and carboxylates 
that have anionic character are present at the cell surface. The guanidino group on arginines 
can form hydrogen bonds with these molecules to confer an increase in hydrophobicity 
leading to cell penetration. 
 
 
 
Based on the punctate pattern seen on microscopy images, stapled peptides can be 
taken up actively through endocytosis.22,23 Export of the peptides from pinosomes into the 
intracellular matrix has also been observed.22,24 However, not all stapled peptides confer 
intracellular uptake.17,19,25–27 The overall charge, hydrophobicity, and a-helical structure 
are all believed to affect cellular penetration. Increasing the net charge of the peptide often 
leads to enhanced permeability, as well as changing the location of the cross-link.18,19,28,29   
Kfold
disordered peptide α-helix
1
2
3
Cell
Protease 
Degradation
Nucleus
Figure 1.4 Process by which a disordered protein folds into a stable a-helix (1), crosses into the 
cell membrane (2), and is finally degraded by proteases (3). 
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A variety of clever methods have been employed to add rigidity, stability, and 
affinity to a-helical peptidomimetics, including stapled peptides, hydrogen bond 
surrogates, lactam linkers, and thioether bridges, Figure 1.5.  
1.9  Disulfide Bridge 
Naturally occurring disulfide motifs inspired the first studies of stabilizing a-
helices into locked, rigid structures with disulfide tethers (Figure 1.5).31,32 The work of 
Schultz, et al. incorporated a disulfide bond into peptides, which resulted in enhanced 
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Figure 1.5 a-Helical peptidomimetics, including stapled peptides, hydrogen bond surrogates, lactam 
linkers, disulfides, and thioether bridges.  Image adapted from Azzarito et al.30 
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helicity compared to reduced, uncyclic analogs. Furthermore, the L,L enantiomers had 
increased helicity versus the L,D enantiomers.  Few disulfide bridging techniques have 
been published recently, potentially due to a major drawback of intracellular disulfide 
reductions. Reducing environments can reverse disulfide bonds back to the unconstrained 
peptide, limiting their applicability towards intracellular targets. Cystathionine thioethers, 
where one sulfur atom is replaced by a methylene group has become an alternative strategy 
that has maintained some structure and activity while eliminating the disulfide bond 
susceptible to reduction.33 This strategy has been evaluated on Compstatin, currently in 
clinical trials for macular degeneration.34 Compstatin contains a susceptible disulfide bond 
that was exchanged to a cystathionine thioether. Activity was maintained while increasing 
biological stability.    
1.10  Lactam Bridge 
Incorporation of a lactam cross-link to stabilize helical mimetics has been 
researched by several including Fairlie, Osapay, and Taylor.35–37 Lactamization on one side 
of an amphiphilic helix showed increased helicity that potentially stabilizes the peptide and 
increases binding affinity (Figure 1.5).36–38 In work done by Osapay et al., a condensation 
reaction involving a lysine residue and an oxime resin-bound aspartic acid at the i, i+4 
positions created a lactam crosslink that showed 69% a-helicity via CD. Fairlie has also 
shown peptides with increased helicity as well as increased binding affinity.35 
1.11   Stapled Peptides 
The pioneering work of Grubbs and Blackwell propelled the area of peptide 
mimetics forward (Table 1.1). Using a ruthenium catalyzed ring closing metathesis 
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reaction (for which Grubbs received the Nobel Prize in Chemistry for), they cross-linked 
short peptides on resin supports. By introducing allyl-glycine or O-allyl serine amino acids, 
they formed a new C-C bond between the two alkene moieties to afford the macrocycle 
(Figure 1.5).13 This work inspired Verdine and colleagues to use the RCM reaction to 
afford an all-hydrocarbon crosslinked a-helix peptide.12 Incorporation of  a-methyl,a-
alkenyl glycines to afford a crosslink over one or two a-helical turns were assessed for the 
optimal stereochemistry and linker length. This method of ‘Stapling Peptides’ has been 
used on a variety of PPIs by numerous laboratories, Table 1.1. Recently, Aileron 
Therapeutics published a potent stapled peptide inhibitor ATSP-7041 that targets the 
oncogenic proteins MDM2 and MDMX, Figure 1.6.39 With high a-helicity, protease 
stability, and increased cell penetration coupled with favorable pharmacokinetic properties 
and in vivo stability, they highlight the capability of stapled peptides developing as pre-
clinical drug candidates.  
 
 
 
 
 
N
H O
Glu-Tyr-NH
O
NH
Ala-GlnLeu-Thr-Phe
O
H
N
O
N
H
Ser-Ala-Ala-NH2
O
ATSP 7041
Figure 1.6 Peptide inhibitor from Aileron Therapeutics targeting MDM2 (Ki = 0.9 nM) and MDMX (Ki 
= 6.8 nM)   
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1.12   Stapled peptides in clinical trials 
Aileron Therapeutics, a pharmaceutical company exploring constrained peptide 
inhibitors have begun clinical trials on the stapled peptide, ALRN-6924 recently (Sept. 
2016). The peptide targets both MDM2 and MDMX interactions with the suppressor 
protein, p53. The protein p53 coordinates transcriptional machinery to trigger a cell death 
response. Small molecule drug targets are only able to target MDM2, making ALRN-6924 
potentially beneficial to suppress cancer cell growth.   
Table 1.1 A sample of the many targets that have been analyzed with stapled peptides. 
Stapled Peptide Target PPI target 
BID BH3, BIM BH3, BAD BH3, 
PUMA BH3, MCL-1 BH3 
BCL-2 family proteins Transcriptional machinery22,25,40–44 
mastermind NOTCH Transcriptional machinery 45 
BCL9, axin b-catenin Transcriptiona machinery 46 
P53 MDM2/MDMX Transcriptional machinery 47–50 
EZH2 EED Enzyme catalytic domain51 
HIV-1 Integrase LEDGF/p75 Viral protein and host cell co-factor52 
lasioglossin III (LL-III) and 
melectin 
bacterial cells Antimicrobial peptide and bacterial 
cell surface53 
NR coactivator peptide 2, SP1 ER- a Coactivator of estrogen receptors 54,54 
NYAD-1 gag HIV particle assembly55 
BAD BH3 glucokinase Restore mitochondrial respiration56 
neuropeptide Y galanin Anticonvulsant neuropeptides57 
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Aileron has also investigated a stapled peptide—a growth-hormone-releasing 
hormone agonist targeting an extracellular site, ALRN-5281—for the treatment of 
endocrine disorders, hormone deficiencies, and human immunodeficiency virus (HIV).58  
The drug has completed phase I clinical trials on 32 subjects with no adverse effects, dose-
limiting safety findings or, tolerability problems. The recent clinical studies on stapled 
peptides underscore the potential utility and applicability of peptides used as inhibitors.  
The need to further elucidate the role constrained peptides can have as potential clinical 
candidates is evident.   
1.13  Hydrogen Bond Surrogates 
Arora and colleagues have developed a unique method to confer helicity through 
nucleation with a covalent crosslink at the N-terminus of the peptide (Figure 1.5).59 By 
nucleating a helix at the N-terminus with a covalent C-C bond, they can conformationally 
constrain the full peptide into stable a-helical peptides. Incorporation of pentenoic acid at 
the first position of the peptide, and an aspartic acid at the fourth residue allows for a ring 
closing metathesis reaction to afford a stable covalent crosslink. By replacing a hydrogen 
bond with the covalent crosslink, they are not burdened by a crosslink covering one face 
of the helix. By freeing all sides of the peptide, they can target deep pockets that surround 
all sides of the helix. They have been able to target a variety of PPIs including the Bak 
BH3: Bcl-xL, where they synthesized a HBS Bak BH3 peptide that bound Bcl-xL with 69 
nM affinity and high proteolytic stability.60 They have also identified the HBS HIF-1a 
(hypoxia inducible factor 1 alpha) targets p300 CH1 with Kd of 420 nM.59 Due to synthesis 
and purification difficulties, they have incorporated thioether linkages (teHBS) that have 
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shown similar conformational stability and protein target potential to the hydrocarbon 
HBS.61   
1.14  Cysteine containing crosslinks 
The broad reactivity profile of thiols makes cysteine an excellent functional moiety 
to develop synthetic peptide constraints. With high nucleophilicity, thiolates can participate 
in exchange, radical, and atom-, hydride transfer, and metal binding reactions.62 Thiol 
incorporation into peptides are as simple as engineering cysteine or methionine residues at 
sites of interest in the peptide primary sequence. The facile insertion of cysteine coupled 
with the wide scope of reactivity of sulfur gives this method an advantage over other costly, 
difficult to synthesize constraints (e.g. disubstituted alkenyl glycines and click reactions).63   
1.15  Thioether crosslinks 
Taking advantage of thiol-ene reactivity, Danny Chou and colleagues have used 
dialkenyl hydrocarbons to react with a thiol on cysteine residues that are either i, i+4 or 7 
residues apart.  With both an 8 and 10 carbon linker appended, an increase in helicity and 
% inhibition of the p53: MDM2 interaction.64  
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Brunel and Dawson have synthesized thioether constraints by reacting a thiol on 
cysteine with an a-bromoamide.65  These were shown to have an increase in helicity as 
well as affinity towards the gp-41 specific antibody 4E10.  
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Figure 1.7 Thiol-ene reaction photoinitiated with 2,2-dimethoxy-2-phenylacetophenone (DMPA) 
reacting a dialkene with thiolyl radicals on two cysteine residues at positions i, i+4 or 7.64   
 
Figure 1.8 Photoisomerization of azobenzene crosslinker leads to structural changes in the helix.  
When trans, i, i+11 is stabilized into a helical constraint, whereas i, i+7 is constrained in the cis 
isomer. [64] 
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Woolley and colleagues have incorporated photoswitchable azobenzene 
crosslinkers that result in trans to cis isomerization which leads to substantial changes in 
the folding of the peptide (Figure 1.8).66 Nevola and colleagues took photoisomerization 
further by developing peptides that regulated clathrin-mediated endocytosis, and has made 
azobenezene crosslinked peptides that can pass through the membrane and target specific 
PPIs inside the cell.67 
 
 
 
 
Biphenyl staples with S-alkylation reactions at positions i, i+3, 4, 5, and 6 have 
been synthesized by Micewicz and co-workers (Figure 1.9).  They synthesized a library of 
60 constructs to identify inhibitors of the p53: MDM2/MDMX interaction.68  Recently, 
Pentelute and colleagues have utilized a novel SNAr bioconjugation approach (Figure 
1.10).69  Their approach transfers aryl groups selectively to cysteine thiolates.  They have 
HS
SSH
TCEP
NH4CO3 buffer
2h
S
Br Br
Figure 1.9 Biphenyl thioether staples synthetic scheme with peptide and dibromo-m-xylene 
crosslinker under basic conditions. 
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investigated a variety of perfluoroaromatic species, which can then be monitored with 19F 
NMR. 
 
 
 
 
1.16  Tetrazine staples and tricysteine 
 
 
 
S,S-tetrazine macrocycles have been synthesized using cysteine amino acids 
positioned 2-27 away from one another (Figure 1.11).70  The constraint can then be broken 
photochemically to regenerate the free thiol.  Furthermore, the tetrazine can be used in an 
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F
F
F
F
F
F S
FF
F F
S S
aq. NaH2PO4, CHCl3
1 minCl
N N
NN
Cl
S
N N
NN
S
hv
NN
HS SH
Cysteine
Figure 1.10 Perfluoroaryl thioether constructs utilizing an SNAr bioconjugation approach 
Figure 1.11 S-tretrazine reversible macrocycles able to convert back to initial free thiol peptide 
with light. 
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inverse demand Diels-Alder reaction to append a fluorescein tag.  While this 
conformationally constrains the peptide, it is not stabilized into the specific a-helical 
structure, but rather a large macrocyclic ring.    
The wide variety of sulfur chemistry used to form macrocyclic peptides highlights 
the vast utility cysteine-based strategies have become.  With the growing methods, we can 
identify bioactive molecules for therapeutic based drugs more readily.  
 
1.17   Transcription Factors and Coactivators  
Transcription factors can be classified as intrinsically disordered proteins that bind 
tightly (nM-pM) to a response element on DNA. Once bound, RNA polymerase II is 
recruited via the transcriptional activation domain, and co-activator complexes. Activation 
of the promoter then initiates transcription. These dynamic complexes rely on timing, 
specificity, and coactivators in order to initiate transcription of various genes.71  One 
transcription factor may have several coactivators that bind to several areas of the basal 
transcription machinery.72,73  These coactivators may be allosterically regulated, such that 
the binding of one ligand affects the binding of another.74  CREB binding protein is a large 
multidomain protein that contains one domain, KIX (kinase-induced domain interacting 
domain) that can interacts with over a dozen transcriptional activators including CREB, c-
Myb, and MLL.75  The various types of binding affect what genes will be upregulated.  The 
binding of CREB to CBP induces transcription of cyclin A1, B-cell lymphoma 2 (bcl-2), 
and early growth response gene 1 (egr-1) allowing for survival, proliferation, and 
differentiation, respectively (Figure 1.12).76,77  
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1.18  CREB/MLL-KIX binding interactions 
 
 
1.18.1  Defining characteristics of the CREB binding protein 
A large portion of proteins has been classified as intrinsically disordered proteins 
(IDPs).  IDPs lack a defined structure in native conditions, but are often still able to 
functionally engage in protein-protein or protein-DNA recognition complexes.78 
Conformational transitions of peptides have great importance on their ability to interact 
and ultimately activate specific processes, but it is still unclear as to what induces such 
conformational switches.79–81 It has been shown that binding precedes folding in the 
transactivation domain of c-Myb.78 
 The binding of CREB to CBP induces a random coil-to-helix transition that 
stabilizes binding82,83 and creates an amphipathic helix with hydrophobic groups lining one 
face of CREB so as to interact with the shallow groove of KIX through a coupled folding 
CREB
KIX
P
cAMP CBP
PKA
Cyclin A1
bcl-2
Egr-1
Survival 
Proliferation
DifferentiationCRE
Pol II
KID
Figure 1.12 Transcriptional activation machinery directed by the CREB:KIX binding interaction upon 
Ser-133 phosphorylation.  Adapted from Sakamoto. 28 
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and binding mechanism84 (Figure 1.13A).  About 1200 Å2 of surface is buried upon pKID: 
KIX complex formation, and is predominately hydrophobic.  To supplement the interaction 
between the proteins are electrostatic interactions.  What seems to be an important 
interaction is the salt bridge formation of Lys-606 of KIX with Asp-140 of pKID. Acidic 
residues at this position have also been invariant within the CREB family.82  
Another proto-oncogene, c-Myb binds at the same site CREB binds on KIX, also 
via an amphipathic helix.85 Ongoing research in several laboratories is continuing to 
elucidate the key components of CREB necessary to bind including Montminy and 
colleagues.83  Their discovery of an 8-amino acid synthetic peptide derived from phage 
display has shown a 16.1 µM affinity towards the KIX domain as well as potent 
transcriptional activation.86  
The interactions between KIX and its many binding ligands create a complex 
system that intertwines dynamic allostery with affinity, Figure 1.13.  The distal binding 
site where mixed lineage leukemia (MLL) binds has been shown to affect the pKID: KIX 
complex with the binding of MLL enhancing KIX interactions with c-Myb and CREB.  
CREB: KIX or c-Myb: KIX has a 2-fold higher affinity when MLL is also bound compared 
to the KIX domain alone. However, the complexity of activation in this interaction proves 
to be difficult to modulate and control.71,87 
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CREB has been found to play a critical role in regulation of several biological 
processes including circadian rhythms, memory formation, and hematopoiesis.88 It is also 
important in normal T-cell formation and the regulation of gluconeogenesis.89 This 43 kDa 
basic leucine zipper (bZip) is conserved from Drosophila to humans, and is a part of the 
CREB/ATF-1 transcription factor family.90 The binding of CREB to KIX is activated 
through a cascade of signals.  Activation of Cyclic AMP leads to the phosphorylation of 
Ser-133 of CREB via protein kinase A (PKA). Once phosphorylated, CREB induces 
transcriptional activation by interacting with CREB binding protein (CBP), which acts as 
a ‘bridge’ to allow the recruitment of Polymerase II (Pol II), which allows transcription to 
occur.76,77,90,91 The transcription of distinct genes is highly regulated by the interactions 
between CBP and the many transcription coactivators that bind.92  Transient PPIs, such as 
CREB binding Domain: TDSQDRREILSRRPSPYRKILNDLSSDAP
119 146 MLL binding Domain (blue): SDDGNILPSDIMDFVLKNTPSMQALGESPES
839 869
c-Myb binding Domain (green): KEKRIKELELLMSTENELKGQQAL
291 315
A     B
L12-G2 loop
310 helix
Figure 1.13 3D structure of the KIX complex in solution. A.  KIX interaction with CREB (cyan) 
(PDB: 1KDX)  B. KIX binding with two partners, MLL (blue) and c-Myb (green), where c-Myb 
overlaps in binding site with CREB. 
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transcription factor binding interactions, are not only central to cell growth and 
development, but also to the progression of disease, such as acute myeloid leukemia 
(AML).         
1.18.2  Defining characteristics of the MLL binding protein 
Mixed lineage leukemia (MLL) binding to KIX induces the formation of the 310-
Helix (residues 591-594) and displaces a loop region (residues 614-621) which allows for 
hydrophobic contacts with MLL, including F612, and L628, Figure 1.13B.93  L628 has 
shown to be a critical contact necessary for a conformational transition important for the 
MLL transcriptional activation domain to bind, as indicated through HSQC NMR studies.94 
The interactions between KIX and MLL create a complex system that intertwines dynamic 
allostery with affinity, Figure 1.13.  The distal binding site where MLL binds has been 
shown to affect the pKID: KIX complex with the binding of MLL enhancing KIX 
interactions with c-Myb and CREB.  CREB: KIX or c-Myb: KIX has a 2-fold higher 
affinity when MLL is also bound compared to the KIX domain alone.95 However, the 
complexity of activation in this interaction proves to be difficult to modulate and 
control.71,87 
1.19  Acute Myeloid Leukemia 
A deadly disease that is characterized by abnormal myoblast cell formation within the 
blood inside bone marrow has been treated with chemotherapy cocktails, radiation therapy, 
or bone marrow transplants.  The dismal outlook of a 24.2% 5-year disease-free survival 
rate for AML patients has not changed since 2003.96,97 This deadly cancer affected 14,000 
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individuals in 2012, most of which were adults.96 Children have less than 50% survival 
rate.90 A few small molecules are in clinical trials including Dexamethasone, 
Pomalidomide, and pembrolizumab.98 None of the options are ideal, as they are either kill 
numerous healthy cells in the process, or don’t target the root cause of the issue.99 Methods 
to target specific locations without detrimental off-target effects would allow for a 
beneficial drug to ease the difficulties AML patients must endure. 
While CREB is an important transcription factor for regulating normal processes in the 
body, over regulation has been implicated in AML. It is thought that if the distinct CREB: 
KIX binding interaction can be inhibited, then the transcription of cancer cells may be 
reduced without affecting transcription of other genes. 75,77,90,91,100  Research on AML has 
shown that CREB is necessary for the proliferation of hematopoietic stem cells as well as 
leukemia cells.90 The upregulation of cyclin A1 by overexpression of CREB leads to 
aberrant cell cycle progression.77 While CREB is overexpressed in leukemic blast cells in 
patients with AML, it is not enough to induce leukemia growth in vivo.  It is unclear if the 
activation of CREB drives cancer cell growth, or if it is simply a byproduct of an activated 
pathway upstream.76,88 It appears most leukemias are a result of collaborations of several 
mutations.77 More research is critical to better understand the role of CREB in acute 
leukemia progression. 
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1.20  Preface to this Dissertation 
The following chapters describe my contribution to the modulation and 
understanding of interactions between proteins with the use of peptidic probes.  Chapter 2 
identifies a non-covalent interaction between sulfoxide functional groups and aromatic 
rings. We first evaluated structural databases to understand the prevalence of the 
interaction. Experimentally we further confirmed the interaction with NMR, and CD 
thermal melts to identify the energy associated with the noncovalent interaction to be -1.24 
kcal/mol, which correlated with the computational studies. This interaction was further 
evaluated within the protein calmodulin. Chapter 3 describes the synthesis, and 
characterization of thio-ether bridged macrocycles. Due to the chemical plasticity of sulfur, 
we evaluated a variety of oxidation states. The biophysical characteristics including 
polarity, helical propensity, tryptic stability, and cell permeation were evaluated, as well as 
affinity towards the KIX protein using Protein Observed 19F (PrOF) NMR and fluorescence 
polarization. In collaboration with Derda and colleagues, we analyzed a perfluorinated 
crosslinked peptide for affinity towards human serum albumin using PrOF NMR.  To attain 
varied oxidized sulfur containing peptides, we employ a specific synthetic reaction, the 
thiol-ene reaction, investigated in Chapter 4. This reaction incorporated non-natural 
cysteine derivatives that can be incorporated into peptides during solid phase peptide 
synthesis (SPPS). These cysteine derivatives can be oxidized to various oxidation states, 
allowing for further elaboration of thioether crosslinked peptides. Chapter 5 investigates 
epigenetic interactions of a histone variant, H2A.Z that is highly enriched at transcription 
start sites, and may provide an effective site to suppress specific transcriptional sites.  
H2A.Z has 5 lysines that can be acetylated an identified by bromodomains. We evaluated 
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the histone variant H2A.Z for specific acetylation patterns that are necessary to interact 
with bromodomains. We identify two bromodomains (BPTF and PfGCN5) to have 
interactions with a diacetylated pattern on H2A.Z—H2A.Z AcK4,11. In Collaboration with 
Stuart Conway, we investigated series of dihydroquinoxalinone small molecules for their 
affinity towards three bromodomains: CBP, BrdT, and Brd4.  Utilizing both PrOF NMR 
and FP, we identify small molecules with affinity and specificity towards the 
bromodomains.   
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Chapter	  2.  Sulfoxide-­‐Pi	  Interactions	  within	  biological	  systems	  
 
Reproduced with permission from “Oxidation increases the strength of the 
methionine-aromatic interaction” Andrew K Lewis, Katie M Dunleavy, Tiffany L. Senkow 
Cheng Her, Benjamin T. Horn, Mark A. Jersett, Ryan Mahling, Megan R. McCarthy, 
Gabriella T. Perell, Christopher C. Valley, Christine B. Karim, Jiali Gao, William C. K. 
Pomerantz, David D. Thomas, Alessandro Cembran, Anne Hinderliter, and Jonathan N. 
Sachs. Nature Chemical Biology 2016, 12, 860-866. Copyright 2016 Nature. 
 
Motivation: 
We collaborated with researchers from the Sachs, Gao, Thomas, Cembran, and 
Hinderliter labs to identify sulfoxide interactions with aryl rings.  While the methionine-p 
interaction has garnered significant attention, the sulfoxide-p interaction has not been 
evaluated.  The prevalence of the interaction was identified within both the PDB and CSD, 
computational and experimental work on the energy associated with the interaction, as well 
as analysis within the Calmodulin protein to provide evidence for the sulfoxide-p non-
covalent interaction.  The work I contribute to this project includes the CSD data-mining 
evaluations, as well as the NMR (ROESY and 1H) to identify the sulfoxide-p interaction.  
To put this work in context, the entire work has been reproduced, and an introductory 
section expanded on the role of sulfur-aryl noncovalent interactions. 
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2.1  Methionine-π interactions 
The role sulfur plays within a biological context is vast, and understood quite well 
for cysteine residues. Cysteine can partake in catalysis, metal binding, and redox regulation 
as well as within a structural context through disulfide formation.101–103 The role 
methionine plays, however is still emerging. Methionine is highly susceptible to oxidation.  
The reversible posttranslational modification, methionine sulfoxide, may guard against 
reactive oxygen species, thus protecting proteins from oxidative damage.104 Methionine 
further plays a beneficial role through its contribution to binding energy, such as 
methionine-p  interactions. Due to the high frequency of sulfur contacts with aromatic rings 
in proteins— 50% of Protein Data Bank have sulfur atoms interacting with aromatic 
rings105— Waters and colleagues evaluated the contribution of energy associated with 
methionine and a variety of aromatic residues using a double mutant cycle.106 A double 
mutant cycle places two residues of interest diagonal to one another within a b-hairpin 
peptide structure where the side chains are in close proximity. The interaction between 
either Phe or Trp with methionine stabilized the construct by -0.3 to -0.5 kcal/mol.106  
Serrano and Viguera have also observed increased stabilization between Phe and Met or 
Cys within an a-helix. By placing residues at an initial position, i and four residues away, 
i+4 they evaluated the interactions between side chains. With Phe at an i position and Met 
at i+4, a free energy of interaction was calculated to be -0.65 kcal/mol.107 Further validation 
of methionine stabilization properties were reported by Yamaotsu et al. where substitution 
of methionine with Leu in staphylococcal nuclease has also been shown to decrease the 
stability of the protein by 0.8 kcal/mol.108   
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2.2  Cation-π interactions 
Significant work on cation-π interactions have also been assessed by Dougherty109,110 
and others.109,111 The interaction is dictated by both an electrostatic interaction and 
induction effect112 between the π-system of an aryl group and a positively charged group 
such as the side chains of lysine and arginine,113 as well as ammonium and sulfonium 
substituents.110,114 While it is observed that methionine oxidation plays a beneficial role 
within biological systems and the sulfur-π interactions lead to enhanced affinity, no 
significant work had evaluated sulfoxide prevalence or interaction scope. We sought to 
further explore how oxidation of methionine plays a critical role in stabilizing protein 
interactions. 
2.3  Introduction 
The methionine-aromatic motif is a promiscuous, highly stabilizing, and prevalent 
noncovalent interaction that forms between methionine thioether sulfurs and the aromatic 
rings of nearby (~5 Å) Tyr, Trp and Phe residues.105,115–119 Methionine-aromatic 
interactions have been detected in several bioinformatics studies118,119 including our 
exhaustive analysis of the Protein Data Bank (PDB). Sulfur-aromatic (S-Ar) interactions 
between the C-S-C divalent sulfur motif and aromatic groups have been similarly found in 
the Cambridge Crystal Structural Database (CSD).116 The motif is substantially stronger 
than a purely hydrophobic contact, suggesting that it has a unique role in stabilizing protein 
structure and ligand-receptor binding. In a thermal unfolding experiment using a synthetic 
helical peptide, the Met-Phe interaction has been measured to be −0.65 ± 0.15 kcal/mol.120 
Quantum calculations have revealed an interaction energy of 1−3 kcal/mol at a range of 
4−6 Å between dimethyl sulfide (DMS) and benzene.117 Our own quantum calculations 
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expanded the analysis to include DMS interactions with phenol and indole (Tyr and Trp 
analogs, respectively) and revealed that dispersion interactions are the major contributor to 
stability.115 In addition to forming highly stabilizing interactions with aromatic residues, 
methionine is uniquely important because its thioether can undergo modification with the 
addition of one or two sulfonyl oxygens to become methionine sulfoxide (MetOx) or 
sulfone, respectively, in oxidizing environments.121 Elevated levels of methionine 
sulfoxide have been detected in diseased tissues, but methionine sulfone is rare.122 
Methionine sulfoxidation is known to regulate the activity of certain proteins. In other 
cases, methionine-rich domains protect critical amino acids from oxidation by removing 
free radicals and regulating the local redox environment.104 Despite this functional 
importance, the specific molecular mechanism through which proteins sense and respond 
to oxidative modification of methionine residues has not been fully characterized. It has 
been posited that polarization of the methionine thioether by oxidation could weaken the 
methionine-aromatic interaction by ablating the hydrophobic contribution,123 but this has 
never been tested experimentally to our knowledge. In the present study, we found the 
opposite to be true: that oxidation of methionine strengthened its interaction with aromatic 
residues, and has the potential to disrupt native conformation and alter protein function. 
We found that the interaction was strengthened even in the absence of a hydrogen bond 
between the sulfoxide oxygen (acceptor) and donor hydrogens (on Tyr or Trp). Through 
quantum mechanical calculations, we showed that the interaction between the dipole 
moment of dimethyl sulfoxide (DMSO) and the aromatic ring quadrupole moment was the 
main contribution to the increased stability of the motif. We started by analyzing both the 
PDB and the CSD to identify and characterize interactions between DMSO (a small-
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molecule analog to MetOx) and aromatic groups in the crystal structures of proteins and 
small molecules. We performed quantum mechanical calculations on model compounds to 
determine the strength of the sulfoxide-aromatic interaction, and assessed the potential 
contribution of hydrogen bonding on the motif in a variety of solvent environments. We 
then isolated and determined the strength of the specific interaction between unoxidized 
and oxidized methionine, and the side chain of phenylalanine by extending a previously 
described helix unfolding experiment and performing a double mutant cycle analysis.120 
We investigated the effects of site-specific methionine oxidation on the methionine-
aromatic interaction in two biologically important proteins. First, using a combination of 
electron paramagnetic resonance (EPR) spectroscopy and replica exchange molecular 
dynamics (REMD) simulations, we probed the effects of oxidation on the structure of 
calmodulin (CaM). Second, we investigated lymphotoxin-α (LTα) binding to tumor 
necrosis factor receptor 1 (TNFR1), which we have previously shown is stabilized by a 
methionine-aromatic interaction between Met120 of LTα and Trp107 of TNFR1.115 
2.4  Results and Discussion 
2.4.1  DMSO-aromatic interactions in crystal structure databases  
To find examples of sulfoxide-aromatic interactions, we searched the PDB and 
CSD for occurrences of DMSO molecules near aromatic rings (Figure 2.1). The PDB is a 
repository containing crystal structures of proteins and the CSD is the analogous repository 
for organic and metal-organic small molecules. DMSO solubilizes tryptophan more readily 
than leucine, alanine and glycine,124 so we expected to find that it specifically interacts with 
aromatic side chains. Our PDB search yielded 205 unique structures containing a total of 
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872 DMSO molecules.  In Figure 2.1A, we show a representative DMSO-Tyr interaction. 
When compared to all amino acids, or just the aliphatic amino acids, aromatic residues 
were enriched 4−7 Å from DMSO sulfurs, with a maximum at 5 Å, resembling the radial 
density function for methionine-aromatic interactions from our previous study (Figure 
2.1B).115 We found 451 (51.7%) DMSO molecules within 7 Å of the nearest aromatic 
residue. Only 32 of these (7.1%) were in position to accept a hydrogen bond from either 
Trp or Tyr. Thus, hydrogen bonding did not drive DMSO-aromatic bonding in the proteins 
found in the PDB. Our CSD search similarly found ~50% enrichment of DMSO-aromatic 
contacts (e.g., Figure 2.1C) compared to C-CH2-C-aromatic pairs (Figure 2.1D), which 
had been used previously as a noninteracting control to show the enrichment of the Met-
aromatic motif.116  Again, few DMSO-phenol or DMSO-indole pairs in the CSD were in 
position to form a hydrogen bond (<14%). 
 
  
  
  
Figure 2.1 (a) Representative snapshot of a DMSO-aromatic interaction taken from the PDB (4KAD). d, 
distance between aromatic center and sulfur atom. (b) Radial distributions of indicated amino acids relative 
to DMSO. (c) Representative snapshot of a DMSO-aromatic interaction taken from the CSD (AWUHEF125). 
(d) Radial distributions of aromatic groups relative to DMSO sulfur and relative to C-CH2-C motifs, which 
are noninteracting. (e) Frequency of DMSO interactions with each aromatic amino acid. These values are 
normalized against the abundance of each aromatic group in the PDB subset analyzed and shows enrichment 
of interactions with Tyr and Trp compared to DMSO-phenylalanine interactions. (f) Interaction energies 
calculated at the MP2/6-311+G(d,p) with CP corrections for the complexes between benzene, phenol and 
indole, and DMSO. Structures excluded hydrogen bonding and were calculated using ensembles of 
configurations from the MD simulations. 
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We then parsed the frequency of methionine-aromatic interactions in the PDB <7 Å 
between DMSO and the centers of Phe, Tyr and Trp individually. The interaction was more 
prevalent with Tyr and Trp than with Phe when normalized by the relative abundance of 
each of these amino acids in the analyzed structures (Figure 2.1E). This trend is not 
explained by relative solvent accessibility, as Trp and Phe have similar solvent 
accessibilities, whereas that of Tyr is somewhat higher.126  We calculated a 1.3-fold and 
1.4-fold preference for Tyr and Trp over Phe, respectively, translating to a ~0.3 kcal/mol 
increase in MetOx-Tyr and MetOx-Trp stability compared to MetOx-Phe. Therefore, these 
database results suggested that, although hydrogen bonding is not common in the 
interaction motif, DMSO interacts more favorably with Tyr and Trp than with Phe. This 
has similarly been observed in cation-π interactions in proteins, where the more electron-
rich π systems of Trp and Tyr relative to Phe make them more attractive to positively 
charged ligands.113 
2.5  Oxidation strengthened interaction in quantum calculations (Cembran lab) 
We report interaction energies between the reduced (DMS) and oxidized (DMSO) 
models of methionine with the model aromatic compounds benzene, phenol and indole 
(Table 2.3 and Table 2.1). The data showed that upon oxidation of DMS to DMSO, the 
complex with benzene was 0.9 kcal/mol more stable. To understand the origin of this 
stabilization, we first tested the possible contribution of dispersion interactions. Dispersion 
energy contribution for DMS-benzene was −8.4 kcal/mol, and for DMSO-benzene it was 
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 −8.2 kcal/mol (Table 2.2). This change in contribution was small (0.2 kcal/mol), and was 
more stabilizing for the DMS-benzene interaction than for the DMSO-benzene interaction. 
Therefore, dispersion interactions were not the source of the stronger interaction energy in 
the oxidized complex. Rather, the stronger interaction can be explained in terms of the 
interaction between the dipole moment of DMSO and the aromatic ring quadrupole 
moment. The calculated dipole moment for DMS was 1.8 Debye, whereas in DMSO the 
enhanced polarization owing to the presence of oxygen resulted in a dipole moment of 5.0 
Debye, roughly aligned along the S=O bond. Both DMS and DMSO maximized dispersion 
interactions with the benzene ring by aligning the Me-S-Me moiety over the ring plane; as 
a result, in the DMS-benzene complex the orientation of the small dipole of DMS is 
orthogonal to the benzene quadrupole moment, whereas in DMSO-benzene, the angle 
between the S=O bond and the ring is approximately 120°, which is well poised for a 
favorable dipole-quadrupole interaction. The natural bond orbital (NBO) charge analysis 
for the complex and isolated species (Table 2.4 and Figure 2.2) supported this explanation, 
showing a large positive charge (+1.19 e) on the sulfur that can interact with the π electron 
cloud, balanced by a negative charge (−0.96 e) on the oxygen pointing away from the 
benzene ring, Table 2.2. 
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Figure 2.2  NBO average charges for the ABF simulations. NBO charges were computed as the average for 
the 128 structures for the simulations of DMS/DMSO and benzene in EtOAc using the MP2/6-311+G(d,p) 
electron density. In red the charges for benzene/DMS are reported, and in black for benzene/DMSO. 
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Table 2.1 Interaction energies for DMS and DMSO with benzene, phenol, and indole. Computed interaction 
energies in kcal/mol for the complexes of benzene, phenol, and indole with DMS and DMSO, images shown 
below table. M06-2X and MP2 data are reported for structures fully optimized at the corresponding levels of 
theory with the 6-311+G(d,p) basis set. Interaction energies corrected for basis set superposition error are 
reported in parenthesis. 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Dispersion energy interactions. Dispersion energy interactions are calculated in kcal/mol for the 
complexes of benzene with DMS and DMSO as the difference between the MP2/6-311G(d,p) interaction 
energies and the HF/6-311+G(d,p) calculated as single point on the MP2 minima. 
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Benzene	   Phenol	   Indole	  
Full	  Optimization	  
DMS	   -­‐2.4	   -­‐4.9	   -­‐4.7	  
DMSO	   -­‐3.3	   -­‐10.6	   -­‐10.0	  
Molecular	  Dynamics	  
Simulations	  
DMS	   -­‐0.9	   -­‐1.0	   -­‐1.3	  
DMSO	  non-­‐H-­‐
bonded	  
-­‐1.4	   -­‐2.2	   -­‐2.7	  
DMSO	  H-­‐bonded	   	   -­‐9.0	   -­‐7.5	  
 
 
 
Table 2.3 Interaction energies for DMS or DMSO with benzene, phenol, and indole. 
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Table 2.4 NBO Charges analysis of the benzene complexes with DMS and DMSO, and of the isolated 
species based on the MP2/6-311+G(d,p) electron density.
 
For phenol and indole, the change in interaction energy upon DMS oxidation (−5.7 
kcal/mol and −5.3 kcal/mol, respectively; Table 2.3) was of larger magnitude than for 
benzene. Such a large change cannot be explained in terms of enhanced dipole-quadrupole 
interactions, and is a result of hydrogen bonding between the DMSO oxygen and the 
hydrogen of the phenol hydroxyl group or the indole amine (Figure 2.3). To determine the 
relevance of hydrogen bonding in sulfoxide-aromatic interactions in a range of 
environments, we ran molecular dynamics simulations of DMSO and phenol or indole in 
hexane, ethyl acetate (EtOAc) and water using the adaptive biasing force (ABF) module in 
the NAMD parallel molecular dynamics (MD) simulation package. We found (Figure 2.4) 
that DMSO hydrogen-bonded with phenol and indole in hexane. Thus, in this nonpolar 
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environment, we expect the contribution of the hydrogen bond to outweigh the increased 
interaction energy of the S-Ar motif. In EtOAc (a polar nonprotic solvent with dielectric 
constant of 6, representative of the protein interior), hydrogen bonding occurred less 
frequently. Therefore, the S-Ar motif had a role in the stabilization of the complex in this 
environment. Finally, in water, hydrogen bonding between DMSO and the aromatic group 
was essentially absent; rather the sulfonyl and aromatic hydrogens were solvated by water. 
This environment mimicked interfacial residues on the protein, which are often involved 
in protein-protein interactions.127 
 
Figure 2.3 Minimum energy structures. The minimum energy structures for the complex between DMS or 
DMSO and benzene, phenol, and indole, calculated from full optimizations at the MP2/6-311+G(d,p) level. 
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Figure 2.4  Fraction of structures in which the DMSO sulfonyl accepts a hydrogen bond from the aromatic. 
Structures were extracted from the ABF simulations of DMSO and aromatic amino acid analogs in three 
solvents. The fraction of structures that are hydrogen bonded (H-acceptor distance < 2.5Å) along all sulfur-
aromatic distances is plotted. Hydrogen bonding occurred in nearly all configurations that were in range in 
hexane (a, b), fewer configurations in EtOAc (the frequency of hydrogen bonding was reduced by ~60%) (c, 
d), and almost none of the configurations in TIP3P water (e, f). EtOAc is able to accept hydrogen bonds from 
the aromatic group and TIP3P is able to donate and accept hydrogen bonds, which results in the lower 
prevalence of bonding between the DMSO and aromatic group. 
 
 40 
To disentangle the energy contribution owing to hydrogen bonding from that of 
sulfur-aromatic interaction, we performed quantum mechanical calculations on 
configurational ensembles from our simulations in EtOAc for both DMS and DMSO 
complexes with aromatic residues. The intermediate dielectric constant of EtOAc and its 
ability to accept hydrogen bonds allowed complexes between DMSO and either phenol or 
indole to sample hydrogen-bonded and non-hydrogen-bonded conformations with similar 
probability. We analyzed non-hydrogen-bonded and hydrogen-bonded ensembles as 
mimics of the interactions on the protein surface and in its hydrophobic core, respectively. 
The results (Table 2.1 and Figure 2.1F) agreed with the data from the full optimization, 
and together indicate that (i) in the absence of hydrogen bonding, oxidation of DMS to 
DMSO strengthened the sulfur-aromatic interaction by 0.5−1.5 kcal/mol, and (ii) in 
hydrogen-bonded structures (rare in proteins) the complex was stabilized by up to 8 
kcal/mol. 
2.6  Evaluation of oxidation in a model peptide scaffold 
To experimentally assess the database findings and quantum results, we used 
thermal denaturation (monitored with circular dichroism (CD)) and NMR spectroscopy to 
investigate a previously reported 15-residue peptide scaffold,120 designed such that the 
strength of the interaction between i, i + 4 amino acids would determine the thermal 
stability of the peptide secondary structure. In that study,120 the Met-Phe pair had been 
found to interact, with a Gibbs free energy of interaction (ΔGint) of 0.65 kcal/mol. We first 
confirmed a direct interaction between oxidized Met and Phe (Table 2.5) using NMR 
spectroscopy. We observed the strongest signals from nuclear Overhauser effects (NOEs) 
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to the aryl hydrogens meta to the side chain methylene (3,5 position) (Figure 
3.9A and Figure 2.1). NOEs to the hydrogen at the 4 and 2,6 positions were present at 
lower levels and overlap. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 All peptides used in CD thermal studies, their appropriate abbreviation and their sequences.  
Only residues 9 and 13 were varied, shown in bold. 
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Figure 2.5 1H-1H rotating frame Overhauser effect NMR spectroscopy (ROESY) and chemical shift analysis 
of α-helical peptide mixtures of two diasteriomers containing the R and S sulfoxide of methionine. (a) 1H-1H 
ROESY NMR spectroscopy correlating NOEs from the two diastereomeric ε-methyls (denoted ε1 and ε2) of 
oxomethionine to the aromatic resonances of phenylalanine. The strongest NOEs correlating with the aryl 
protons of the phenylalanine 'ii' are indicated by double-headed arrows. (b) Analysis of Phe-MetOx and Ala-
MetOx 1H NMR spectroscopy experiments indicating an upfield shift of the ε-methyl resonances of 
oxomethionine when an aromatic ring is present (top) relative to a methyl group (bottom). 
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Figure 2.6 A close-up of the Phe-Metox 1H-1H ROESY NMR spectrum taken in acidic (pH 4.0) D2O at 4oC 
with reversed axis.  NOEs shown between the ε-S-methyl sulfoxide diasteriomeric resonances and the 
aromatic protons of phenylalanine.   The strongest NOEs are observed with Hb at the 3,5 position of 
phenylalanine.  The upfield doublet is from one of the N-terminal tyrosine resonances.  
 
To further probe the details of the sulfoxide-aromatic (SOx-Ar) interaction in the 
helical state, we compared the chemical shift of the ε-S-methyl groups on the sulfoxide-
containing peptide when it was in an i +4 relationship with phenylalanine (Phe-MetOx) 
versus alanine (Ala-MetOx) in methanol. We purified oxidized peptides as a 1:1 mixture of 
diastereomers due to the new stereocenter from the sulfoxide. As such, we observed two 
singlets corresponding to the methyl group of each diastereomer (Figure 3.9B). DMSO 
methyl resonances in methanol have been reported at 2.65 p.p.m.128 Similarly, in our 
measurements for Ala-MetOx, they were at 2.65 p.p.m. and 2.64 p.p.m. However, for Phe-
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MetOx, we observed both ε-S-methyl resonances shifted upfield at 2.57 p.p.m.and 2.47 
p.p.m. The chemical shift of the DMSO methyl resonances in benzene has also been shown 
to be upfield at 1.68 p.p.m.128 Owing to ring-current shielding effects from aromatic rings, 
we interpreted these results to be consistent with the ε-S-methyl groups of oxomethionine 
approaching from above the aromatic ring of phenylalanine (Figure 2.1 A, C). Both the 
NOE experiments and chemical shift information indicated an interaction between the 
sulfoxide group over top of the aromatic ring. 
We then used CD to measure the change in the strength of the S-Ar interaction upon 
methionine oxidation. Our experiments reproduced the original S-Ar result for Met-Phe 
(ΔGint = 0.62 kcal/mol). The interaction strength was doubled (strengthened by 0.62 
kcal/mol) upon methionine oxidation. Associated with this change in free energy, oxidation 
increased the enthalpy of the S-Ar interaction by 1.1 kcal/mol (Figure 2.7), consistent with 
the quantum result. We note that although CD spectra had been used in the original S-Ar 
study to extract energetics of side-chain interactions, it is not possible to draw a direct 
correlation between peptide helicity and free energy.120,129  Rather, fitting of the CD spectra 
is necessary to extract energetics. Two aspects of our approach differed from the original 
study. First, we performed a double mutant cycle to isolate the methionine-aromatic 
interaction from possible interference owing to neighboring residues (Figure 2.15 
and Figure 2.8). This approach solidified our reported interaction free energies, and was 
especially important in the case of oxidized methionine because of the increased likelihood 
of hydrogen bonds and electrostatic interactions with the other residues in the peptide, 
Figure 2.7). We justified applying a two-state approximation and hence using the GHE by: 
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(i) observation of complete reversibility (overlap) in the heating and cooling curves 
(Figure 2.10), and (ii) the presence of a molar ellipticity isodichroic point in all constructs 
(Figure 2.9).130  Additionally, principal component analysis131 of the CD spectra yielded 
only two components that dominated the CD spectra (Figure 2.11 and Figure 2.6), again 
consistent with the two-state assumption. Together with the addition of the double mutant 
cycle, the fact that we obtained nearly identical values for the Met-Phe energy as in the 
original study107 (compare 0.62 ± 0.09 kcal/mol to 0.65 kcal/mol) reinforced the robustness 
of our approach. Thus, our peptide study lends experimental support to the conclusions 
drawn from the quantum calculations: oxidation increased the strength of the methionine-
aromatic interaction. 
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Figure 2.7  Representative data sets and global fits for three replicas of Phe-Met (Left, solid squares) and 
Phe-MetOx (Right, solid circles). Signal was acquired at 222nm. For each peptide, a black solid line 
represents the global fit to all three datasets using the Gibbs Helmholtz equation, as described in Methods. 
The fitting parameters are, for Phe-Met: ∆HTm = 26.0 ± 0.7 kcal/mol, ∆CP = 0.2 ± 0.2 kcal/mol°C and Tm 
= 18.3 ± 0.3 °C; and for Phe-MetOx are: ∆HTm = 27.1 ± 0.1 kcal/mol, ∆CP = 0.21 ± 0.02 kcal/mol°C and 
Tm = 21 ± 1°C were determined for Phe-MetOx peptide. Raw ellipticity signal varies for each peptide sample 
set due to variations in each individual peptide experiment (~150µM concentration). Free energy values were 
extracted from the global fit at T=0°C and are presented in Figure 2.8. 
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Figure 2.8 Double-mutant cycle. Thermodynamic double mutant cycle of FM (a) and FM(ox) (b) peptides. 
Nomenclature is: Wild-type peptide (FM and FM(ox)), singly mutated peptide (FA, AM and AM(ox)) and 
doubly mutated peptide (AA). F, M and A represent phenylalanine, methionine (un-oxidized or oxidized) 
and alanine, respectively. Free energy of each peptide denaturation is represented as ΔG at each step in the 
cycle. ΔΔG values are determined by the difference in ΔG denaturation values of peptides at 0°C, which were 
used to determine the ΔΔΔG. For simplicity, and as described in the Methods, we assign the nomenclature 
ΔGint to reflect the change in interaction free energy between Met/Phe and Met(ox)/Phe (SOx/Ar- S/Ar = 
1.24 - 0.62 = 0.62 kcal/mol). Thus, there is a doubling of the strength of the interaction upon oxidation. Error 
was calculated through a total differential approach, where the derivatives of the GHE with respect to ΔH, 
ΔCp and Tm were calculated. The error for each thermal denaturation ΔG is the sum of the products of each 
derivative and their respective individual error values. Error was then calculated with ΔG values for each 
side of the thermodynamic cycle for ΔΔG and ΔGInt. 
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Figure 2.9 Combined Ala-Met spectra observed from 200 to 260nm at increasing temperatures from -2°C to 
60°C. Crossing of all spectra at ~202 nm indicates isodichroic point seen in inset plot. This plot is 
representative of the all peptide constructs used in the double mutant cycle, where an isodichroic point is also 
observed. 
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Figure 2.10 Overlaid heating and cooling melt curves for FM, FMOx, FA, AM, AMOx , and AA peptides. 
Raw Elliptical signal (mdeg) at 222nm was normalized from 0-1 for each peptide construct. Heating curves 
are represented by a black solid line, and cooling curves are represented by a red dashed line. Ellipticity 
displayed as a fraction of unfolded peptide. FM heating and cooling melt (a), FMOx heating and cooling melt 
(b), FA heating and cooling melt (c), AM heating and cooling melt (d), AMOx heating and cooling melt (e), 
and AA heating and cooling melt (f). 
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Figure 2.11 Principal Component Analysis. The variance for all principal components is shown as gray bars, 
and the cumulative percent variance is shown as red lines for all peptides. 
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Table 2.6 Principal Component Analysis. The details of PCA for each peptide are shown as standard 
deviations, proportion of variance, and cumulative proportion of variance. 
 
2.7  Oxidation rearranges Met-aromatic contacts in calmodulin 
To test the impact of the increased strength of the SOx-Ar motif in proteins, we first 
investigated the effects of methionine oxidation in an already well-characterized protein, 
CaM. The C-terminal helix of CaM has high methionine content and is sensitive to 
oxidative stress in vivo, which alters the protein's structure and function.132–137  In the  
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crystal structures of CaM, both in its calcium-bound (halo, 3CLN)138 and unbound 
(apo, 1CFD)139 forms, a C-terminal methionine forms an S-Ar interaction with Phe141 
(Met144 in apo (Figure 2.12A) and Met145 in halo). It has been speculated previously that 
oxidation at Met144 and Met145 might destabilize the protein by altering an important, 
nearby hydrogen bond between Tyr138 and Glu82 that connects the short C-terminal helix 
to the central linker.135,140  No specific molecular mechanism for this effect has been 
proposed or tested. 
 
 
Based on our results above, one possibility is that oxidation of Met144 anMet145 
increases the likelihood of an SOx-Ar interaction with Tyr138, which would be manifest in 
a spatial rearrangement within the C-terminal domain that should be observable by EPR 
spectroscopy. As Met144-Met145 and Tyr138 are on opposite ends of a short helix, such 
an interaction would require helical unwinding, an effect that has been observed using 
NMR spectroscopy.141  We ran REMD simulations of the isolated, Ca2+-free (apo) C-
terminal peptide fragment (residues 136−146) of CaM to guide the design and 
Figure 2.12 REMD simulations and EPR spectroscopy measurements of CaM. (a,b) Structure of unoxidized 
apo-CaM fragment (residues 136−146; PDB: 1CFD) where Phe141 interacts with Met144 (a) compared to a 
representative structure of the Tyr138 aromatic interacting with oxidized Met144 (b) from REMD 
simulations. (c,d) Distance distribution calculated between Cα atoms of Thr136 and Val146 from REMD 
simulations (c) and best-fit models of the distance distribution from dipolar EPR spectroscopy at 
submicromolar [Ca2+] with maleimide spin labels at Cys residues 136 and 146 (d). 
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interpretation of experimental EPR spectroscopy measurements on full-length protein. We 
simulated both the unoxidized and doubly oxidized (at Met144 and Met145) forms. 
Because of the expectation of helical unwinding, a computational investigation of full-
length CaM is hampered by limitations in sampling efficiency. Thus, although the peptide 
fragment is an abstraction of the real system, it is nevertheless a useful tool because it 
accelerates the sampling of relevant conformational space. Furthermore, the simulations 
were useful in (i) establishing Val136 and Thr146 as appropriate sites for spin labels to test 
the impact of oxidation on the full-length protein; and (ii) providing molecular-scale details 
unavailable from EPR spectroscopy experiments that correlate distance changes to the 
potential presence of an SOx-Ar motif. 
In the simulation of the unoxidized peptide, an S-Ar interaction formed between 
Tyr138 and Met144 or Tyr138 and Met145 only 3.3% of the time. On the other hand, an 
SOx-Ar interaction formed 22.7% of the time when both Met144 and Met145 were oxidized 
(Figure 2.12B and Error! Reference source not found.). In only 1.2% of these interactions 
id a hydrogen bond form (Figure 2.14). The SOx-Ar interaction with Tyr138 led to a spatial 
rearrangement that brought together Val136 and Thr146 (Figure 2.12B), and the 
distribution of the distance between the Cα atoms of those two residues is shown in Figure 
2.12C. Likewise, the frequency of the native interaction between Met144 and Phe141 also 
increased upon oxidation (49% versus 12% of frames; Figure 2.12). Thus, oxidation 
increased the total percentage of simulated frames in which an S-Ar interaction occurred 
by 3.7-fold (72% versus 15%). Based on Boltzmann's law, this change reflects a roughly 
1.6 kcal/mol increase in the free energy of the interaction upon oxidation. This value 
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compares well to the results of our peptide experiment (0.62 kcal/mol) and supports the 
underlying conclusion of increased interaction strength upon oxidation of the S-Ar motif, 
even in the absence of hydrogen bonds. It is important to note that the simulations of the 
short, unoxidized peptide fragment sampled unfolded conformational states that were not 
represented by the crystal structure (where residues 138−146 are helical) and may not be 
accessible in a simulation of the full-length protein. Nonetheless, the emergence of a 
second population of states containing the SOx-Ar motif (with Tyr138), only in the oxidized 
simulation, motivated experiments to explore whether this subpopulation exists in the full-
length protein when oxidized. 
 
Figure 2.13 S/Ar interactions in CaM simulations. The fractional occupancy of the unoxidized (black) and 
oxidized (gray) methionine aromatic interaction involving either M144 or M145 from the REMD simulation. 
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Figure 2.14 Hydrogen bonding of MOx144 and MOx145 with Y138 in the calmodulin simulations. The 
histogram shows that only a small fraction of Met-aromatic interactions involve a hydrogen bond. The 
methionine-aromatic distances were binned, and then the fraction of structures that were hydrogen bonded 
in each bin was plotted. 
 
To test the effects of oxidation of CaM's C-terminal helix in the full-length protein, 
we used dipolar EPR spectroscopy to detect intramolecular structural perturbations at 
submicromolar [Ca2+] (Figure 2.12D).  The EPR spectrum of the unoxidized protein was 
best fit to a single broad Gaussian distance distribution, centered at 13.7 Å. After 
methionine oxidation, the data were best fit to a two-population model in which one 
population was centered at a similar distance to that observed in the absence of oxidation 
(14.0 Å), and there was a new population at shorter distance (8.9 Å). These experimental 
EPR spectroscopy results confirmed key predictions from MD simulations (Figure 2.12C): 
the long-distance population became narrower, and a new well-ordered short distance 
emerged. It is not surprising that the EPR spectroscopy distance distributions did not match 
precisely those predicted by MD simulation, as the MD simulations report distances 
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between Cα atoms, whereas EPR spectroscopy distances are between nitroxide groups at 
the ends of flexible side chains. EPR spectra do not directly detect Cα-Cα distances, but 
changes in such distances have been shown to correlate well with EPR data.142  The 
convergence of the simulated and experimental results strongly suggests that upon 
oxidation of CaM, a new SOx-Ar interaction forms between either Met144 and Tyr138 or 
Met145 and Tyr138. Additional work is needed to definitively show that this minor 
component in the overall accessible conformational space (Figure 2.12C, D) is responsible 
for disruption of the Tyr138-Glu82 hydrogen bond and alters the protein's function. 
 
Figure 2.15 Oxidation of LTα, but not TNF ablated its interaction with TNFR1.(a) Western blot analysis of 
IκBα degradation in response to treatment with oxidized (+) and unoxidized (−) LTα and TNF. (b) 
Immunoprecipitation (IP) of TNFR1 with oxidized (+) and unoxidized (−) ligands. Western blots (WB) are 
representative of at least two independent experiments. Full gels are shown in Figure 2.21. 
 
2.8  Oxidation of LTα prevented ligand-receptor binding 
We investigated the effects of oxidation on the bioactivity and binding of LTα and 
TNF in live cells. We have previously shown that the interaction between LTα and TNFR1 
is stabilized by a methionine-aromatic interaction via Met120 of LTα and Trp107 of 
TNFR1. Substitution of Met120 to alanine interrupts ligand binding, resulting in a more 
than tenfold loss in ligand function.115 Thus, we hypothesized that the increased strength 
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of the S-Ar interaction upon oxidation should stabilize binding via the Met120-Trp107 
interaction. Tumor necrosis factor (TNF) is structurally homologous to LTα and similarly 
activates TNFR1, but notably lacks methionine residues. Therefore, we expected its action 
to be unaffected by oxidative stress. Western blot analysis (Figure 2.15A) showed that 
untreated LTα and TNF efficiently induced downstream signaling, as has been definitively 
established. To our surprise, LTα pretreated with H2O2 did not induce IκBα degradation. 
To isolate the impact of oxidation of Met120 on LTα function and binding, we 
substituted Met20 and Met133 to remove their susceptibility to oxidization. This mutant 
ligand, denoted here as Met120 or MetOx120 when oxidized, triggered IκBα degradation in 
the unoxidized form to the same extent as wild-type (indicating that two other substituted 
methionine residues, Met20 and Met133, were not important for activity). Site-specific 
oxidation (MetOx120) rendered LTα inactive (Figure 2.15A). Co-immunoprecipitation 
experiments explained this loss in function as a result of lost binding of the MetOx120 
ligand to TNFR1 (Figure 2.15B). Thus, we concluded that oxidation of LTα inhibited its 
activity by disrupting the critical Met120-Trp107 methionine-aromatic interaction, thereby 
preventing binding to TNFR1. 
To explore the molecular basis for this loss in binding, and to explain this apparent 
contradiction (decreased binding despite increased S-Ar interaction strength), we used 
molecular dynamics simulations and quantum calculations. Analysis of the ligand-receptor 
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crystal structure (1TNR) revealed aromatic residues in the ligand (Tyr96 and Tyr122) that 
are near to and on the same chain as Met120 (Figure 2.16A).  
Given their spatial proximity,   it is likely that Met120 forms S-Ar contacts with 
either or both of these tyrosines. MD simulations of the unbound ligand showed this to be 
the case in approximately 70% of the simulated frames (the Met120-Tyr122 interaction 
was approximately twice as frequent as the Met120-Tyr96 interaction (Figure 2.16A)). 
Oxidation of Met120 increased the interaction strength of Met120 with Tyr96; again, using 
the Boltzmann equation we calculated an increased affinity of 0.35 kcal/mol. This value is 
lower than that described above for CaM, but once again is consistent with our general 
conclusion that oxidation strengthens S-Ar interactions. There was no oxidation-induced 
change in the frequency of Met120-Tyr122 contacts. These data raise the possibility that 
Tyr122 and Tyr96 interact differently with Met120 under oxidative conditions. We 
confirmed that hydrogen bonding was not a major factor in the interaction (Figure 2.17). 
We again used the simulations to generate an ensemble of configurations for quantum 
energy calculations. As was the case with our calculations on the non-hydrogen-bonded 
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ensemble of DMS-phenol or DMSO-phenol configurations, oxidation increased the 
strength of the S-Ar interaction by 1−2 kcal/mol (Figure 2.16C).  
 
 
 
Figure 2.16 Molecular dynamics simulations of LTα with Met120 oxidized showed that competitive 
interaction of Met120 with Tyr96 prevented its interaction with Trp107. (a) In the receptor bound state, Tyr96 
is folded upward so that it interacts with the backbone of the receptor, allowing Met120 to form a stable 
methionine-aromatic interaction with Trp107. (b) When Met120 is oxidized, it draws Tyr96 downward where 
it interferes with assembly of the ligand-receptor complex. (c) Interaction energy between Met120 and Tyr96 
or Tyr122 calculated from 128 structures taken from the MD simulations. The histogram was smoothed with 
the Gaussian kernel smoothing function 'density' of the program R. (d) Bond occupancy of Met120 and Tyr96 
or Tyr122 (black) and Met120-Trp107 (gray) interactions for the unmodified crystal structure (1TNR), the 
Met120-Tyr122 interacting configuration (Tyr122 config.), and the Met120-Tyr96 interacting configuration 
(Tyr96). (e) Snapshot of the Tyr96 interacting system with Tyr96 blocking the Met120-Trp107 interaction. 
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Figure 2.17 Hydrogen bonding in the molecular dynamics simulations of LTα. The fraction of frames in 
which hydrogen bonding occurs for the range of methioninearomatic distances. The methionine-aromatic 
distances were binned, then the fraction of structures that were hydrogen bonded in each bin were plotted. In 
all three simulations, the fraction of structures that are hydrogen bonded is small. 
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We hypothesized that the strengthened MetOx120-Tyr96 interaction could lock the 
ligand in a configuration that prevents MetOx120-Trp107 interaction, thereby interrupting 
binding. To test this, we first needed to test whether the addition of a sulfonyl oxygen to 
Met120 in the crystal structure binding configuration does not itself destabilize the binding 
pocket by steric overlap or electrostatic repulsion. We first simulated the unoxidized crystal 
structure of the ligand-receptor complex. In Figure 2.16D we highlight the stability of the 
Met120-Trp107 interaction, and show the infrequent instances of Met120 interaction with 
either Tyr122 or Tyr96. We then started a simulation of the ligand-receptor complex in a 
configuration in which the MetOx120-Tyr122 pair was pre-formed (using a configuration 
generated from the unbound ligand simulation). Tyr96 was allowed to remain in its 
receptor backbone binding position. The binding cavity organization reverted to that of the 
crystal structure configuration after 50 ns (Figure 2.16D) and was stable throughout the 
remainder of the simulation (Figure 2.18). Therefore, we concluded that loss of ligand-
receptor binding was not caused by intrinsic steric clashes with MetOx120 that disrupt the 
binding pocket. We also concluded that MetOx120-Tyr122 interactions did not prevent 
MetOx120-Trp107 interactions and ligand binding. 
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Figure 2.18 RMSD of the binding pocket for the MOx120-Y122 interacting configuration. The RMSD is 
shown for the binding pocket (all ligand and receptor residues within 15 Å of MOx120) for the 3 ligand 
chains. All three binding pockets are stable. 
 
We then started a second oxidized ligand-receptor simulation, this time with a pre-
formed MetOx120-Tyr96 pair. We observed two distinct effects of oxidation, both of which 
are consistent with loss of receptor binding. In two of the three chains (of the symmetric 
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ligand trimer), MetOx120 remained stably bound to Tyr96, preventing it from forming the 
critical S-Ar motif with Trp107 (Figure 2.16D) as well as preventing Tyr96 from binding 
the receptor backbone. In these cases, the MetOx120-Tyr96 pairing (Figure 2.16E), along 
with the surrounding binding pocket, remained stable throughout the simulation. In the 
remaining chain, Tyr96 released from MetOx120, and in this process disrupted the binding 
pocket while ejecting the receptor. Collectively, the results suggest that increased stability 
of the MetOx120-Tyr96 pair prevented the critical Met120-Trp107 interaction and 
destabilized the bound state. 
2.9  Discussion 
Oxidative stress has a prominent role in a number of normal and pathological 
biological functions. However, the precise chemical and physical mechanism through 
which oxidative modification of proteins influences their structures and functions is largely 
unknown. We showed that oxidation of methionine strengthened the methionine-aromatic 
interaction motif, independent of hydrogen bonding, by at least 0.5 kcal/mol and up to 1.5 
kcal/mol. In the vast majority of instances in the PDB and CSD as well as the two proteins 
studied here in detail, the aromatic group did not form a stable hydrogen bond with the 
sulfoxide owing to solvation of both the donor and acceptor by water. Hydrogen bonding 
may enhance the interaction in hydrophobic and aprotic environments, but we did not 
observe that in our two test cases where the motif was solvent-exposed. In LTα-TNFR1 
and CaM, we showed that competing interactions between methionine sulfoxide and 
nearby aromatic residues contributed to the modulation of protein structure and function. 
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To conclude, noncovalent interactions are the cornerstone of biological molecular 
recognition events. For bioactive small-molecule development, which exploits these 
interactions, sulfur is the third most commonly incorporated heteroatom in pharmaceuticals 
after nitrogen and oxygen.143 The sulfoxide-aromatic interaction provides a new handle for 
tuning affinities of small molecules for chemical probe and therapeutic development as 
well as altering protein function. Moreover, the dynamic nature of methionine oxidation 
provides a reversible switch that can be used for introducing responsive molecules to 
changes in redox environment. The energy range of these altered interactions corresponded 
to a twofold to a tenfold change in the equilibrium constant, which together with the 
ambivalent character of sulfoxide functional groups, the dynamic nature of their formation, 
and their prevalence in biology and pharmaceutics, offers medicinal chemists and chemical 
biologists a useful tool to probe biological systems. 
2.10  Experimental 
2.11  Structural bioinformatics analysis of the Protein Data Bank. 
We analyzed a nonredundant subset of the PDB, comprised of all structures 
containing at least one DMSO molecule using the Biopython toolset and a custom Python 
script adapted from our previous study.115 Structures sharing >90% sequence identity were 
represented by a single structure with the highest score as ranked according to RCSB PDB 
quality factor algorithm. Redundant structures were excluded, as they do not represent truly 
independent data points for the purposes of our informatics study. Distances were defined 
between the DMSO sulfur and the center of the aromatic ring. Distance data were collected 
up to a cutoff of 20 Å. Hydrogen bonds were defined as having a heavy-atom donor to 
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sulfonyl oxygen distance of < 3.5 Å. For the radial density function (RDF), the distances 
from each DMSO to aromatic groups were binned, and the histogram was normalized by 
shell volume. Each RDF was normalized by the relative population of amino acids in the 
analyzed PDB files (divided by 9.25% for Phe, Tyr and Trp, by 22.47% for Leu, Ile, and 
Val, and by 100% for all standard amino acids). The resulting plots were normalized by 
the mean value at the long distance, non-interacting region of the 'all amino acids' RDF to 
shift the bulk density to 1 and to cast the y axis as an enrichment factor. 
2.12  Structural bioinformatics analysis of the Cambridge Structural Database. 
Searches were executed in the Conquest program of the CSD (version 5.35, 2014 
release), and structural analyses were performed using the Mercury program (v 1.5). The 
distance was defined as in the PDB. C-CH2-C was used as a noninteracting analog to C-S-
C, following a previous CSD analysis.115 The sulfur (or carbon in control) atom to aromatic 
distance was constrained to 0−10 Å. For the radial density function (RDF), the distances 
from each DMSO (or C-CH2-C) to all aromatic groups were binned and divided by shell 
volume, then normalized by the total number of contacts. The resulting RDFs were shifted 
to 1 as in the PDB analysis, by normalizing to the value at the flat region of the C-CH2-C 
RDF. A total of 20,630 DMSO-aromatic pairs were found in 840 structures, and 3,093,875 
C-CH2-C-aromatic pairs were found in 72,745 structures. 
2.13  Adaptive biasing force simulations of DMSO and aromatic groups in three 
solvents. 
Simulations were performed using the adaptive biasing force (ABF) module in 
NAMD 2.9 using the CHARMM 36 generalized force field. The ABF module was used so 
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that the system could overcome free-energy barriers and fully sample all conformational 
states. Parameters for DMS were adapted from those for ethylmethylsulfide. The distance 
between the DMSO thioether and the center of mass of the six-membered ring of phenol, 
or indole was used as the reaction coordinate of the mean force calculation. The system 
potential along the reaction coordinate was negated by the adaptive biasing force to 
simulate a flat free energy landscape. Each system was solvated in a ~45 Å3 periodic box 
of TIP3P water, hexane or ethyl acetate, for a total of 18 systems. The adaptive biasing 
potential was applied between 2.5 Å and 14 Å with a bin width of 0.1 Å, and simulations 
were carried out for at least 7.5 × 106 steps. All other simulation parameters were set as in 
our traditional MD (see molecular dynamics simulations of LTα and TNFR1 
methods). Table 2.7 shows the effects of solvation on the calculated interaction energy 
between DMS or DMSO and each aromatic compound. The calculated PMF was not used 
in our analysis. Figure 2.19 shows the distance between the aromatic ring and each heavy 
atom of the DMSO molecule and demonstrates no strong bias for the methyl groups to 
interact with the aromatic ring. 
Table 2.7 Effects of solvation on quantum mechanical interaction energy. The effect of solvation on quantum 
mechanical interaction energies has been tested for the complex of benzene with DMS and DMSO. The 
interaction energy in kcal/mol for the complexes optimized in gas phase at the M06-2X level was calculated 
in the gas phase and with single point PCM calculations to describe the effect of solvation in EtOAc and 
water. The basis set employed was 6-311+G(d,p). The ΔEint entry shows that the effect of solvation is less 
than 0.4 kcal/mol. 
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Figure 2.19  Histogram of distances from each DMSO atom to the center of the aromatic ring. Non-hydrogen-
bonded DMSO-aromatic pairs from the ABF simulations were analyzed and show no strong bias for the 
methyl groups to interact with the aromatic ring. Benzene (a), phenol (b), and indole (c). 
 
2.14  Peptide synthesis. 
To study the appropriate pair sequences in a peptide chain, the unoxidized amino 
acid Met or oxidized Met was inserted into the designed sequence framework, producing: 
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(i)-Tyr-Gly-Gly-Ser-Ala-Ala-Glu-Ala-aromatic-Ala-Lys-Ala-Met-Ala-Arg-NH2, (ii)- 
Tyr-Gly-Gly-Ser-Ala- Ala-Glu-Ala-aromatic-Ala-Lys-Ala-Metox-Ala-Arg-NH2. The 
peptides were assembled on Fmoc-PAL-PEG-PS resin by Fmoc chemistry using a PE 
Biosystems Pioneer protein synthesis system. Single Met oxidation was accomplished by 
incorporation of Fmoc-Metox-OH during synthesis. Standard N-[(dimethylamino)-1H-
1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide (HA TU)/N,N- diisopropylethylamine (DIEA) (1/2.4 eq.) 
activation, in 1-methyl-2-pyrrolidinone (NMP), was applied. Fmoc deprotection was 
achieved with 20% piperidine in NMP. The final release of the peptides, with removal of 
the side-chain protecting groups, were accomplished by exposure of the peptide resin to 
82.5% trifluoroacetic acid (TFA), 5% phenol, 5% thioanisol, 2.5% 1,2-ethanedithiol, 5% 
water (Reagent K). The peptides were precipitated with cold methyl-t-butyl ether, 
vortexed, centrifuged, decanted and dried over argon. The dried peptides were dissolved in 
degassed water and purified by high-performance liquid chromatography (HPLC) using a 
reversed-phase C8 HPLC column. Peptide elution was achieved with a linear gradient from 
0 to 34% B (95% acetonitrile, 5% water and 0.1% TFA) in 40 min at a flow rate of 2.5 
mL/min with detection at 280 nm using a System Gold Beckman Coulter system. The 
HPLC fractions were collected and analyzed by mass spectrometry (MS). 
2.15  Peptide scaffold design. 
The peptide scaffold used for defining the energetic impact of oxidation on Met-
aromatic interaction had a number of specific design elements. The helical content was 
optimized to reside within a range that enabled sensitive detection of its change by CD. 
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The capping box motif at the N terminus is the sequence Ser/Thr-X-X-Glu/Gln and is a 
helix stop signal. This stop signal has Ser or Thr as the N-cap and a Glu or Gln residue at 
position I + 3, specifically; the sequence Ser-Ala-Ala-Glu is the capping motif in each of 
the peptides of the double mutant cycle. The N terminus had a tyrosine added for 
concentration determination. The C terminus was blocked by changing the COO− to a 
CONH2 to mediate this effect of dipole destabilization and to increase helical propensity.144 
2.16  Electrospray Ionization (ESI)-MS. 
The peptides were analyzed on a LC-MSD ion trap (Agilent). ESI-MS spectra were 
acquired in positive ion mode. The solvent contained 40% acetonitrile and 0.1% formic 
acid. 10 to 30 µL sample were directly injected at a flow rate of 10 µL/min with a source 
temperature of 300 °C. The applied spray voltage was 3,500 V, and the skimmer voltage, 
40 V. MS scans were acquired over an m/z range of 200 to 2,000. The scan for the native 
mass 1,499.69 Da of the sequence Tyr-Gly-Gly-Ser-Ala-Ala-Glu-Ala-Phe-Ala-Lys-Ala-
Met-Ala-Arg, showed the single charged ion with m/z1,500.0 and the double charged 
ion m/z 750.7. The scan for the MetOx-Phe sequence pair (1,515.69 Da) showed the singly 
charged ion with m/z of 1,515.7, the double charged ion m/z of 758.4, and the triple charged 
ion m/z of 505.9. The observed masses for the respective molecular ions agreed with the 
theoretical peptide scaffold design. 
2.17  Circular dichroism spectroscopy. 
All peptides were stored in tetrafluoroethylene (TFE) after synthesis, which was 
removed by evaporation using nitrogen gas before use. To ensure complete removal of the 
TFE, the sample was then put under vacuum for one hour. The dried peptide was 
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reconstituted in 10 mM KH2PO4, 100 mM KCl at pH 7.5, and prepared for CD data 
collection. All CD experiments were performed on a Jasco J-815 CD Spectrometer using 
a 0.1 cm quartz cuvette at ~150 µM peptide concentration. Concentrations of the peptide 
samples were determined using a Nanodrop spectrometer. To display helical content and 
the presence of an isodichroic point ellipticity was measured between 200 nm to 260 nm 
in 1-nm increments from −2 °C to 60 °C for the Phe-Met, Phe-MetOx, Phe-Ala, Ala-Met, 
Ala-MetOx and Ala-Ala peptides. Once these characteristics were established for each 
construct, one data point was collected at 222 nm at each 0.5 °C or 2 °C change as 
temperature increased from −2 °C to 60 °C. Cooling melts were also collected, recording 
the signal at 222 nm, on all peptides as temperature decreased from 60 °C to −2 °C. All 
collected data points were averaged from three acquisitions of the recorded ellipticity. 
2.18  Analysis of CD data. 
To extract the free energy of interaction from the temperature dependence of the 
CD, spectra were collected from the lowest experimentally accessible temperature (−2 °C) 
to a temperature beyond which there were no observable changes in spectral shape for all 
peptides (60 °C). The spectra are given in Figure 2.9. Following Greenfield et al.,145 we 
used the signal, Θ, at 222 nm to report on changes in peptide structure. This wavelength 
was chosen because it reflects helical content and is also the wavelength at which the 
overall change in ellipticity is greatest across the temperature ramp. Following the same 
rationale we used previously,146 the CD signal is given by: 
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where Θinitial is the value at 222 nm recorded at −2 °C, and Θfinal is the value at 222 nm 
recorded at 60 °C. Because K = e−δG/RT, we rewrote this equation as: 
 
We then fit the temperature dependent data, ΘT, by substituting the Gibbs-Helmholtz 
equation into equation (4), 
 
and varying the three parameters: enthalpy (ΔHTm), heat capacity change (ΔCp), and 
transition temperature (Tm). Data for Phe-Met and Phe-Metox are given for each replica 
in Figure 2.7. By varying the concentrations of the peptide in each of its three replicates, 
the measured signal varies for each replica. The three replicates are globally fit 
simultaneously, an approach that improves the stringency of the parameter fits for each 
peptide. The free energy is then extracted from the fit at the desired temperature (T = 0 °C 
in this case). The change in free energy for each leg of the double mutant cycle is reported 
in Figure 2.8. 
2.19  Double mutant cycle. 
To construct a double mutant cycle, peptides were synthesized in which the 
aromatic residue and Met (or MetOx) was replaced first individually, then concurrently by 
the neutral residue, Ala. The difference in ΔG between the Met-aromatic (oxidized or 
unoxidized) and its respective singly substituted construct, or between the singly 
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substituted construct and the doubly mutated construct gives a ΔΔG. The difference of the 
respective ΔΔG values produces a ΔΔΔG, which indicates whether the specific interaction 
is contributing to the stabilization of structure. ΔΔΔG is simplified here as ΔGint to match 
the free energy of interaction reported (the two expressions are thermodynamically 
equivalent, although the cited study did not use a double mutant cycle).120 If ΔGint equals 
zero, the interaction observed is not contributing to the structural stability; if greater than 
zero, the interaction is stabilizing; and if less than zero, destabilizing.147–149 
2.20  Principal component analysis. 
Principal component analysis for each of the Phe-Met, Phe-MetOx, Phe-Ala, Ala-
Met, Ala-MetOx, and Ala-Ala peptides data sets was carried out with the 'prcomp' function 
of the program R (v. 3.2.1). For each data set only one of the three replicates was used. To 
increase the sensitivity of the analysis, we focused on the isodichroic point region by 
analyzing only the wavelengths between 200 nm and 210 nm (11 data points), while the 
entire temperature range was included in the analysis. The correlation matrix was 
calculated between the mean-centered vectors of wavelengths: 
 
where Cij is the covariance between the temperatures i and j, and Ti(λ1,λ2,...,λN)is 
the vector of absorbances at the temperature i at the wavelengths λ1,λ2,...,λN. 
The results reported in Figure 2.11 and Table 2.6 show that the first two principal 
components describe 94% or more of the total variance, which is consistent with the 
assumption that the change in molar ellipticity is dominated by only two sources of signal. 
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2.21  NMR spectroscopy experiments. 
Concentrations of peptide samples were obtained using ultraviolet absorbance of 
tyrosine (ε = 1,450 L mol−1 cm−1) in 8 M urea. Peptide Tyr-
MetOx (YGGSAAEAFAKAM(ox)AR-NH2) was dissolved in deuterated methanol (3 mM). 
Phe-MetOx (YGGSAAEAFAKAM(ox)AR-NH2) was dissolved in acidic (pH 3.5) D2O, 
taken at 4 °C. 1H-1H ROESY experiments (mixing time = 200 ms) were performed on a 
Bruker 700 MHz spectrometer with a CryoProbe: 5 mm TXI probe of z-axis gradient. 1H 
experiments comparing control peptide, Ala-MetOx to Phe-MetOx in MeOD were performed 
on a Bruker Advance III HD 500 MHz instrument with a 5 mm Prodigy TCI cryoprobe 
with z-axis gradients. Data were processed and analyzed using Bruker Topspin 3.2. 
2.22  Dipolar EPR spectroscopy of spin-labeled calmodulin. 
A mutant, encoding mammalian CaM with Val136 and Thr146 both substituted to 
Cys, was prepared by site-directed mutagenesis (QuikChange II kit, Agilent), confirmed 
by DNA sequencing, expressed and purified as described previously,150 and dialyzed 
overnight at 4 °C against 10 mM NaCl and 10 mM Tris (pH 7.0). Spin-labeling with 
maleimide spin label (MSL, N-(1-oxyl-2,2,5,5-tetramethyl pyrrolidinyl) maleimide, 
Toronto Research Chemicals) was carried out by incubating 120 µM CaM with 480 µM 
MSL in CaM buffer (10 mM NaCl, 10 mM Tris, 5 mM EGTA, pH 7.0) for two hours at 22 
°C (followed by overnight dialysis against CaM buffer to remove unreacted label), 
resulting in complete labeling of the two Cys residues, as shown by MS. To oxidize 
methionine side chains, spin-labeled CaM was incubated in 500 mM hydrogen peroxide 
for 30 min, followed by dialysis into CaM buffer. As shown previously under similar 
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conditions,150 MS was used to verify that all of the nine methionine residues of CaM were 
oxidized. X-band (9.5 GHz) EPR spectra of 200 µM CaM (in CaM buffer plus 10% 
glycerol) were acquired at 200K with a Bruker ER500 spectrometer, using 1 G modulation 
amplitude and subsaturating microwave power (0.63 mW). EPR spectra were analyzed to 
determine the distribution of distances between the two spin labels, as described 
previously.151 
2.23  Ligand preparation and treatment. 
Plasmids with sequence encoding human LTα and human TNF with an N-terminal 
FLAG tag, downstream from an inducible T7 promoter were subcloned using standard 
cloning techniques. Plasmids were transformed into chemically competent BL21 bacteria, 
plated on LB agar plates, and cultured in LB to an OD600 of ~0.5. Cultures were then cooled 
to 18 °C, induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside, and grown for 18 
h. The bacteria suspension was centrifuged, and then lysed by sonication in ice-cold PBS. 
The lysate was column purified using anti-FLAG M2 Affinity Gel (Sigma) according to 
the manufacturer protocol, dialyzed exhaustively against MilliQ H2O, and then lyophilized. 
FLAG-LTα, as prepared in our laboratory, contained four methionine residues, of which 
Met120 and Met133 potentially play structural and functional roles in the ligand-receptor 
complex. Met133 is buried between two folds of a β-sheet, and its precise functional role, 
if any, has not been established. For the LTα-Met120 variant, we substituted Met133 to 
valine and Met20 to alanine to match the homologous residues found in Bos taurusLTα, 
which shares 73% sequence identity and 81% sequence similarity (Sequence Manipulation 
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Suite), but lacks methionines except for its N terminus. TNF, which also binds to and 
activates TNFR1 with similar potency152 was used as a control. 
Oxidative stress was applied by dissolving 8 µg of ligand in buffer containing 10 
mM HEPES, 100 mM KCl, 1 mM MgCl, 1 mM CaCl, then adding 100 mM H2O2 to a total 
volume of 100 µL. The oxidation reaction was allowed to proceed for 18 h at room 
temperature, then stopped by removing H2O2 in two sequential stages using Zeba 7 kDa 
molecular weight cutoff spin columns. Removal of H2O2 was confirmed by Amplex red 
assay, and the residual concentration of H2O2was determined as insufficient to induce 
autophagy. We measured tryptophan fluorescence to confirm that oxidation does not lead 
to gross unfolding of LTα, finding no shift in the emission spectrum when excited at 280 
nm (Figure 2.20). 
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Figure 2.20 Tryptophan fluorescence of LTα after exposure to oxidative stress. LTα was left untreated or 
oxidized as in cell experiments, and its fluorescence emission spectrum was measured after ~18 hours. The 
unfolded control sample was dissolved in 8M urea for several hours before measuring its emission spectrum. 
Fluorescence emission wavelength scans from 300 – 400 nm were taken on a Varian Cary Eclipse 
Fluorescence spectrometer at an excitation wavelength of 280 nm and a scan rate of 30 nm/min. Excitation 
and emission slits were set to 5 nm. The emission spectra were normalized between 0 and 1. Total unfolding 
in 8M urea causes tryptophan residues to become exposed to polar solvent, resulting in a red-shifted emission 
spectrum (red). Exposure of LTα to oxidative stress does not result in red-shifting of the emission spectrum 
(blue) compared with the untreated LTα spectrum (green), indicating that the ligand is stably folded. 
 
 
2.24  Western blot analysis of IκBα. 
HEK 293 cells were maintained in DMEM supplemented with 10% FBS, 
penicillin/streptomycin, and 2 mM L-glutamine. Confluent cells were split at 1:12 into 6-
well plates and used for experiments on day 3. Untreated and oxidized ligands were added 
to cells to final concentrations of 200 ng/mL and 20 ng/mL for LTα and TNF respectively, 
and incubated for 20 min at 37 °C. Cells were then washed once and gently sheared from 
the plate with ice-cold PBS, then centrifuged and resuspended in radioimmunoprecipitation 
assay (RIPA) lysis buffer. Cell lysates were normalized to equal protein concentrations, 
and 60 µg were loaded onto 4–12% Bis-Tris gradient gels for western blot analysis. 
IκBα was detected rabbit α-IκBα (Cell Signaling Technology, #9242, 1:1,000) and 
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horseradish peroxidase (HRP)-conjugated α-rabbit IgG (Amersham, 1:10,000). Full gels 
are shown in Figure 2.21. 
 
Figure 2.21 Full gels from Western Blots and immunoprecipitation. IκBα degradation is induced by 
unoxidized LTα and unoxidized or oxidized TNF. Oxidation of LTα prevents it from inducing IκBα 
degradation. M120A is a reduced-binding mutant negative control and was not the subject of this 
investigation (a). A second iteration of the same experiment is shown with the M120 control (b). The full 
immunoprecipitation blots are shown with short and long exposure times (c). 
 
2.25  Co-immunoprecipitation. 
Co-immunoprecipitation was performed using anti-FLAG M2 agarose beads 
(Invitrogen) according to the manufacturer instructions. Briefly, HEK 293 cells were split 
at 1:12 into 15-cm plates and transfected with 8 µg of plasmid encoding TNFR1 (pCMV6-
XL5-TNFR1) on day 1 by calcium phosphate transfection. On day 3, cells were lifted by 
shearing, washed once, and resuspended in ice-cold PBS at ~106/mL. LTα and TNF were 
added at 12 ng/mL and 25 ng/mL respectively, and the cells were incubated for 30 min at 
 
 78 
4 °C while rocking. Cells were then washed three times in ice-cold PBS and resuspended 
in RIPA lysis buffer, then analyzed by western blot. TNFR1 was detected using rabbit α-
TNFR1 (Abcam, ab19139, 1:1,000) and α-rabbit secondary, as described above. Full gels 
are shown in Figure 2.21. 
2.26  Quantum calculations. 
The interaction energy between model compounds was investigated with quantum 
mechanical calculations performed in the gas phase. The reduced and oxidized states of 
methionine were modeled by DMS and DMSO, respectively; the side chains of 
phenylalanine, tyrosine and tryptophan were modeled by benzene, phenol and indole. The 
interaction energy between compounds A and B was defined as: 
 
All energies were obtained from fully unrestrained structure optimizations carried 
out with Gaussian 09153 using the Møller-Plesset perturbation theory at the second order 
(MP2) method with the 6-311+G(d,p) basis set and corrected for basis set superposition 
error.154 Additional data computed using the M06-2X density functional theory155 are 
reported in Table 2.1. These two levels of calculation were chosen because we previously 
showed that they bracket the interaction energy calculated at the couple-cluster truncated 
at single and double excitations with triple excitations added perturbatively (CCSD(T)) 
level115 with the 6-311+G(d,p) basis set.115 Notice that for each complex several minima 
were characterized, and the data are reported only for the lowest energy one. 
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The dispersion energy contribution to the complex formation was calculated by 
taking the difference between the interaction energy (equation (1)) computed at the MP2 
and Hartree-Fock (HF) levels.115 In both cases the same basis set was used, and the HF 
energies were calculated as single point on the MP2 optimized structures. 
The effect that the variety of conformations adopted in solution has on the 
interaction energy was investigated by averaging the interaction energies of 128 structures 
randomly sampled from the minimum (sulfur-aromatic distance between 4 Å and 6 Å) of 
the ABF simulations in ethyl acetate described above. Hydrogen bonded structures were 
defined as having donor-acceptor distance of <2.5 Å and non-hydrogen-bonded structures 
had a donor-acceptor distance of >4 Å. Upon removal of the solvent, the instantaneous 
interaction energy was calculated at the MP2/aug-cc-pVDZ level using equation (1) 
without any additional structure optimization. 
A similar procedure was used to investigate the interaction energy between the side 
chains of Met120, Tyr96 and Tyr122 in LTα. From the MD simulations described below, 
128 structures were randomly selected and the average interaction energy calculated at the 
MP2/aug-cc-pVDZ level as: 
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The side chains were truncated at the Cβ-Cγ bond and the missing valence was 
saturated with a hydrogen atom. Upon removal of the rest of the protein and the solvent 
and without any further optimization, the interaction energy was calculated at the MP2/aug-
cc-pVDZ level and corrected for the basis set superposition error. 
For the calculations on the ethyl acetate simulations described above, the NBO156 
charges were calculated and averaged over all 128 structures. The NBO localization 
scheme was tested along Mulliken157 localization over a number of different basis sets of 
increasing size. Because the results showed a strong dependence of the Mulliken charges 
on the basis set size158 whereas NBO charges did not, the NBO localization scheme was 
preferred. 
2.27  Replica-exchange molecular dynamics of calmodulin. 
The REMD simulation was performed in NAMD 2.9 using the CHARMM22 
potential parameters.159 Eleven residues of the last helix (136−146) of CaM (PDB ID: 
3CLN)138 were used in the all-atom point-charge force field in vacuo to match conditions 
of the quantum calculations. Eight replicas with temperatures exponentially spaced from 
300K to 600K (300K, 331.23K, 365.7K, 403.77K, 445.8K, 492.2K, 543.43K, 600K) were 
used with the initial velocities of the atoms generated by the Maxwell-Boltzmann 
distribution and a timestep of 1 fs. The first 106 steps were performed without attempting 
exchanges to equilibrate, then exchanges were attempted every 1,000 steps (1 ps) with an 
acceptance rate ~20%. Coordinates were taken every 100,000 steps (100 ps). 78,810 frames 
were taken for the unoxidized peptide and 74,400 frames for the oxidized peptide, 
corresponding to a total simulation time per replica of 985 and 930 ns, respectively. Only 
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the replicas at 300 K were used in the analysis. Methionine-aromatic interactions were 
identified as having a distance of <7 Å and an angle less than 60°, consistent with previous 
definitions.115,116  Hydrogen bonds were cutoff at <2.5 Å from hydrogen to acceptor. 
2.28  Molecular dynamics simulations of LTα and TNFR1. 
We carried out molecular dynamics simulations of oxidized or unoxidized LTα in 
its unbound state and unoxidized in complex with TNFR1 using the structure, 1TNR as the 
starting configuration.160 Two additional systems, a Tyr122 interacting configuration and 
a Tyr96 interacting configuration, were constructed in which Met120 began bound to 
Tyr122 or Tyr96, respectively, whereas all other residues in the 1TNR crystal structure 
were left essentially unchanged (minor manipulation and steepest descent minimization 
was required to resolve overlap in the binding pocket). The starting configurations of 
Met120, Tyr96 and Tyr122 in these systems were taken from the oxidized ligand 
simulation. Each system was solvated in a box of at least 40,000 explicit water molecules 
modeled as TIP3P to fully capture solvation effects161 and the charge was neutralized by 
adding K+ and Cl- ions. The isothermal-isobaric (NPT) ensemble was used along with the 
CHARMM36 force field162–164 at a temperature of 303K and 1 atm pressure, which were 
maintained using the Langevin piston and Nosé-Hoover165 algorithms. Parameters for 
MetOx were provided by K. Kuczera166 and adapted for use in the CHARMM36 force field. 
Long-range electrostatics were calculated using the particle mesh Ewald method167 with a 
1.5 Å grid spacing and fourth order interpolation. Lennard-Jones interactions were 
switched off at a cutoff distance of 10 Å. Each system (except the Tyr96 and Tyr122 
interacting configurations) was minimized using NAMD 2.8159 for 1,000 steps, then 
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equilibrated with Cα harmonic constraints of 1, 0.1, and 0.01 kcal/mol Å2 for 2 ns at each 
stage. Dynamic trajectories were propagated with the r-RESPA algorithm168 with a 2 fs 
time step and the RATTLE algorithm169 was applied to all covalent bonds involving 
hydrogen. The ligand-receptor system was simulated for ~35 ns and distance and angle 
analyses were averaged over the entire trajectory. The ligand-only systems were simulated 
for a total of ~430 ns. The first 150 ns (including relaxation) were excluded from structural 
analyses to allow re-equilibration of the ligand after removal of the receptor chains. The 
Tyr96 and Tyr122 interacting systems were equilibrated with great care before running 
unrestrained dynamics. Each was minimized to resolve steric clashes, then equilibrated 
according to the scheme shown in Table 2.8.  Distances and angles were calculated from 
the thioether sulfur of Met120 to the centers and normal vectors of the aromatic groups of 
Tyr96, Tyr122 and Trp107. Methionine-aromatic interaction cutoffs were defined as in the 
CaM simulations. 
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Table 2.8 Relaxation schedule for the MOx120-receptor complex simulations. Restraint spring constants are 
given in kcal/mol/Å2. 
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Chapter	  3.  Thioether	  Cosslinked	  Macrocycles	  for	  Modulating	  Protein-­‐
Protein	  Interaction	  
 
Reproduced with permission from “Tuning Sulfur Oxidation States on Thioether-
Bridged Peptide Macrocycles for Modulation of Protein Interactions” Gabriella T. Perell, 
Rachel L. Staebell, Mehrdad Hairani, Alessandro Cembran, William C. K. Pomerantz, 
ChemBioChem 2017, Accepted Author Manuscript. Copyright 2017 Wiley. 
 
Motivation: 
Due to the prevalence as well as the increased stabilization energy of sulfoxide-p 
interactions we identified in Chapter 2, we were inspired to utilize sulfur oxidation states 
within thioether-bridged macrocycles to disrupt PPIs.  Through the incorporation of two 
thio-ethers, we were able to modify the polarity of peptides with sulfoxide and sulfone 
functional groups.  The thioether-bridged macrocycle mimics the active site of MLL, to 
disrupt the KIX:MLL interacting site.  
 
 
 
 
 
 85 
3.1  Introduction 
 
 
The role of sulfur within biological systems has been identified to be useful with 
respect to drug discovery.  Sulfur has been prominently used in small-molecule drugs, with 
24.8% of drugs containing a sulfur atom, Figure 3.1.143 One important contribution to this 
prevalence of sulfur-containing functional groups in drugs is the range of non-covalent 
interactions involving the various oxidation states of sulfur. These interactions range from 
ionic in character, to dipolar, and dispersive. For example, the sulfur atom of cysteine and 
methionine are found with increasing frequency near aromatic side-chains of 
proteins.106,115  Computationally, the methionine-aromatic interaction has an interaction 
energy of ~1–1.5 kcal/mol greater than the alkyl-aromatic-equivalent interaction.115  The 
sulfur-aromatic interaction has been experimentally investigated to have a stabilization 
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Figure 3.1 Suflur-containing drugs on the market including Crestor®, NexIUM®, and Singulair®. 
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effect of 2 kcal/mol120 for phenylalanine and cysteine.  For phenylalanine-methionine and 
tryptophan-methionine interactions, stabilization energies have been measured to be 0.3 
kcal/mol.106 Oxidation of methionine to a sulfoxide further enhances the phenylalanine-
methionine interaction by 0.5 - 0.6 kcal/mol (See Chapter 2).170  Dougherty and co-workers 
have also shown sulfonium ions to engage in cation-π interactions.110 Sulfur’s ability to 
access a variety of oxidation states including, thioethers, sulfoxides, sulfones, and 
sulfonium ions gives rise to sulfur’s chemical plasticity for molecular recognition.  A 
systematic analysis of these functional groups, which can be accessed under mild and 
chemoselective conditions, can inform how varied polarity states can affect the binding, 
stability, and physicochemical properties of sulfur-containing medicinal agents. 
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One emerging area of research in medicinal chemistry is the exploration of sulfur-
bridged-peptide macrocycles as protein-protein interaction (PPI) inhibitors.  Protein-
protein interactions are vital in all biological processes,30 and have been shown to be critical 
points for which manipulation may be possible.171 All-hydrocarbon ‘stapling’12,172,173 and  
lactam formation35,36,174 have received wide-spread use for stabilizing a-helices and 
increasing cellular uptake. Cysteine-mediated macrocycle formation has also been an 
effective conformational constraint due to the sulfhydryl reactivity profile and the 
encodability of this natural amino acid.63,175 Various methods have been employed for 
macrocyclization including S-alkylation with bis-electrophiles,68,176 SNAr,69 and thiol-ene64 
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Figure 3.2 A. Sulfur-containing a-helical macrocycles in various oxidation states and polarities. B. 
NMR solution structure of KIX (grey) binding to the a-helical peptide MLL (green), PDB ID: 2AGH. 
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reactions to form thioethers. Determining what factors affect cell penetration of crosslinked 
peptides has recently been assessed by Walensky et al. where they determine 
hydrophobicity, a-helicity, and pI are the driving factors of cellular uptake.177 Despite the 
increased approaches for macrocycle formation in both synthetic and genetically encodable 
libraries of stabilized a-helices, a systematic evaluation of the use of sulfur oxidation states 
of the nascent thioethers for tuning the physicochemical, biological, and molecular 
recognition properties of these peptides has yet to be explored. Here we use the a-helical 
region of the transcriptional activation domain of the mixed lineage leukemia protein 
(MLL), as a model system to evaluate how thioether oxidized states would affect secondary 
structure, stability, and affinity of stabilized a-helical peptides for future development of 
PPI inhibitors (Figure 3.2).    
The KIX domain of the coactivator CBP (cAMP-response element binding protein 
(CREB)-binding protein, Figure 3.2B) plays a versatile scaffolding role through 
interactions with over a dozen transcription factors, which engage two distinct binding 
sites.  Three notable transcription factors include the kinase inducible domain of CREB, 
and the transcriptional activation domains of c-Myb and MLL. While MLL is a necessary 
component of the transcriptional machinery that regulates normal blood cell growth, 
aberrant levels of MLL-mediated transcription leads to cancer cell growth.178 Recruitment 
of E2A to KIX –which binds to the same site as MLL—has been shown to induce acute 
lymphoblastic leukemia.100 MLL binding to KIX has also been shown to potentiate binding 
of c-Myb and CREB with KIX through an allosteric mechanism.179  
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     The MLL transcriptional activation domain folds into an a-helical secondary 
structure upon binding to KIX, which leads to formation of the activator-coactivator 
complex within the transcriptional machinery. This interaction is dictated by a dynamic, 
large hydrophobic region that has been difficult to target.  Few small molecule inhibitors 
have been discovered and none with sub-micromolar affinities.83,92 The difficult nature of 
this PPI motivated our study by using MLL as a model to explore KIX PPIs. 
3.2  Results and Discussion 
3.2.1  Polarity Assessment of Sulfur Oxidation at the Side-Chain, Amino Acid, and Peptide 
Level. 
Prior to evaluating effects of thioether oxidation on molecular recognition sites in 
proteins, we first sought to evaluate how modulations of the structure and oxidation state 
of the sulfur-bridged side chains can affect the physiochemical properties of peptides. By 
incorporating a bis-thioether constraint to enforce a-helicity in a sequence defined manner, 
helicity and polarity are evaluated (Figure	  3.1A).63 Oxidation of thioether groups into 
sulfones and sulfoxides provides a facile method of increasing polarity of otherwise 
hydrophobic peptides.180,181 Whereas lactam bridging is one method for increasing the 
polarity of the all-hydrocarbon-based cross-links, oxidized sulfur atoms may be less 
energetically costly for desolvation for eventual cellular uptake.  
To characterize the energy of solvation for the amide, thioether, sulfoxide, and 
sulfone moieties, we used the four model compounds shown in Figure	  3.3A. Solvation 
free energies in water were determined with density functional calculations using the SM12 
solvation model. The results in Figure	  3.3 show that N-methylacetamide has the largest 
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solvation energy (-9.1 kcal/mol) of the series, within 1 kcal/mol of the -10.0 kcal/mol 
experimental value.182 The large solvation energy is to be attributed to the hydrogen bonds 
formed both by the carbonyl oxygen and the amide hydrogen with water, accompanied by 
polarization of the wavefunction (the dipole moment increased from 3.6 D to 4.6 D in going 
from the gas phase to water). Much less favorable interactions with water were shown by 
the ethyl methyl thioether, which displayed a solvation energy of -0.7 kcal/mol, because of 
the inability of the thioether to form strong hydrogen bonds, and of its modest polarization 
by water (i.e., the dipole moments changed from 1.8 D in the gas phase to 2.0 D in water).  
Oxidation of sulfur from a thioether to either a sulfoxide or sulfone greatly 
increased the magnitude of the calculated solvation energy to -5.7 and -6.8 kcal/mol for the 
sulfoxide and sulfone containing molecules, respectively. Although the calculations 
showed that the free energy of solvation of the sulfone is 1.1 kcal/mol more negative than 
the sulfoxide, it is to be noted that only three oxidized sulfur compounds with available 
experimental data were included in the SM12 training set. Given the greater computational 
uncertainty associated with these moieties, the difference between solvation energies 
cannot be distinguished.  Both sulfoxides and sulfones can form hydrogen bonds with 
water, but density functional calculations showed that the sulfoxide forms a hydrogen bond 
that is approximately 3 kcal/mol stronger than the sulfone (see experimental for details). 
Such a capacity to hydrogen bond may in part explain the differences in partition 
coefficients and HPLC retention times described below. 
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We next compared our computational results of sulfur-containing side chains to 
experimental data from Schenck et al., where they evaluated the relative hydrophobicity of 
the amino acids glutamine, norleucine, methionine, methionine sulfoxide, and methionine 
sulfone via examination of partitioning coefficients between water and methylene chloride 
(Pm).181  Consistent with our solvation energy studies, significant differences in 
hydrophobicity were observed between methionine sulfoxide (Pm = 11± 3) and methionine 
(Pm = 0.046 ± 0.002).  Both sulfur-containing amino acids have increased hydrophilicity 
compared to the all-hydrocarbon norleucine, (Pm = 0.018 ± 0.002).  Methionine sulfone, 
while still hydrophilic, is somewhat less polar than the sulfoxide (Pm = 1.9 ± 0.2) which 
can form stronger hydrogen bonds with water as described above, and substantially less 
polar than glutamine (Pm = 78 ± 3) in this solvent system.181   
 
Figure 3.3 A. Computational analysis of the solvation energies in water in kcal/mol. Literature values 
from experimental measurements are in parentheses.  B.  HPLC retention time analysis of various 
MLL15 peptides with sulfur containing side-chains. A one percent per minute gradient of elution 
solvent acetonitrile was used in all cases. 
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Based on the results at the amino acid and side-chain level, and the discrepancy in 
partition coefficient and desolvation energy between sulfoxide- and sulfone-containing 
amino acid side chains, we next measured the ability of an individual amino acid for 
altering the polarity of a peptide in the context of a 15-residue peptide of MLL (WT 
MLL15), Figure	  3.3B. We based our analysis on the retention times through a C18 HPLC 
column as a relative comparative value for polarity. WT MLL15 contains one methionine 
residue and elutes at 41 minutes (51% acetonitrile). Chemical oxidation using H2O2 leads 
to a diastereomic mixture of two sulfoxides within the peptide and yields an average 
retention time of 36 minutes (46% acetonitrile).  When WT MLL15 is oxidized to a sulfone 
using H2O2 and performic acid, the less polar sulfone increases the retention time by 1 
minute relative to the sulfoxide (37% acetonitrile). Finally, when a regioisomer of 
methionine is used, penicillamine (Pn), the most hydrophobic peptide is produced eluting 
at 42 minutes (52% acetonitrile). We conclude from these findings that through the 
structural manipulation and/or oxidation of a single sulfur-containing amino acid within a 
short peptide, we can alter the retention time of the peptide by over six minutes leading to 
a large window of polarity and desolvation energy differences. Bis-thioether linkages 
discussed below, allow for an even greater range of tunability of the peptide polarity by 
chemical manipulation. 
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3.3  Secondary Structure Evaluation of Cross-linked Peptides 
     Incorporation of a side-chain crosslinking motif has been shown to increase the 
stability of a-helical peptides towards proteases, cellular uptake, and bioactivity.173 
Furthermore, crosslinking pre-organizes the peptide into the active secondary structure, 
thus reducing the entropic cost for folding which leads to significant increases in affinity 
towards a given target.22 More recently, the macrocycle hydrocarbon crosslinks or 
“staples” have also been shown to engage in favorable binding with hydrophobic sites on 
the protein surface.183  While this can increase affinity in some cases, such as the ATSP-
7041-HDMX49 and SAHBD-MCL-1,44 the hydrophobic nature can induce altered 
geometries, as seen in the ERa-SP6 interaction.184,185  Thus, perturbations of PPIs by the 
hydrophobic linker can affect affinity and be potentially detrimental to binding near polar 
residues on the protein surface. 
     To investigate the effect of sulfur-containing side-chain macrocycles on a-
helicity and subsequent binding affinity, we established a set of reaction conditions for 
peptide macrocyclization and subsequent oxidations at various positions within the helical 
region of the transcriptional activation domain of MLL.  Evaluation of the NMR solution 
structure of a complex of the KIX domain with MLL (PDB ID: 2AGH, Figure 3.2)85 shows 
MLL embedded on two faces of the a-helix which encompasses 11 amino acids. Therefore, 
we chose a 12-residue sequence of this peptide including a C-terminal tyrosine for a 
spectroscopic concentration determination handle.  We used this peptide sequence initial 
evaluation of helical propensity effects mediated by sulfur-containing cross-links referred 
to herein as MLL12. A single aspartate to lysine mutation at position 2848 of the native 
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sequence (which is equivalent to the second residue in our sequence), was made to increase 
solubility of this peptide construct. We further studied 15-residue peptides keeping the 
native aspartic acid and extending the sequence towards the N-terminus, as a leucine 
residue outside the a-helix has been shown to be important for binding to KIX.186  Of the 
available synthetic methods for peptide macrocyclization, we chose bis-thiol alkylation 
using dibromoalkanes of varying chain length using modified conditions from Hyunil et 
al.176  We increased the reaction temperature to 80 ºC in a microwave reactor for 20 min to 
afford crosslinked peptides, which were subsequently purified by RP-HPLC. 
 
      
We conformationally constrained the MLL peptides (12-15 residues) with alkyl 
crosslinkers, Figure 3.4. In an a-helix, there are 3.6 amino acids per turn, which makes 
amino acids that are 3, 4, or 7 residues apart ideal targets for crosslinking. We therefore 
H NH2N
O
H
H
N
O
N
O
H
N
O
OH
N
H O
H
N
O
H
N
H O
S
H
N
O
OH
O
N
H O
H
N
O
N
H O
H
N
O
NH2
N
H O
O
NH2
H
N
O
OH
H
N
H O
OH
H
NH2N
O
N
H O
H
N
O
H
N
H O
S
H
N
O
OH
O
N
H O
H
N
O
N
H O
H
N
O
NH2
N
H O
O
NH2
H
N
O
OH
H
N
H O
OH
O
O
OH
MLL12:
MLL15:
Ac-ILPSDIMDFVLKNTY
Ac-SDIMDFVLKNTY
HO
O
O
HO
Figure 3.4 MLL Sequences either 12 or 15 residues of the helical portion of the protein that interacts with 
KIX. 
 95 
incorporated two cysteine residues at an initial site (i) and at either position 3, 4, or 7 (Table 
3.1). Incorporation of D-cysteine at the i+3 position was used when an i,i+3 crosslink is 
synthesized. Previous reports have shown the most stereochemically favorable crosslink 
incorporates L- amino acids at the i site and D-amino acids at the i+3 position.187  For i, 
i+4 or 7, L-stereochemistry is used at both positions.16 We utilized a 10-carbon alkyl chain 
for the i,i+7 crosslink, and an 8-carbon chain for the i,i+3 or 4 crosslink, as this optimal 
length of the crosslinker has been reported.64 
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Helical stabilization has been shown to be beneficial for binding, cellular uptake, 
and proteolytic stability.  Therefore, we used circular dichroism in the far UV region to 
identify specific sequences that have increased helicity with the incorporation of a 
crosslinking constraint and for evaluating changes in sulfur oxidation to the overall peptide 
helicity.  We first investigated the effect of bis-thioether macrocylcization on a-helicity at 
Table 3.1 MLL peptide constructs showing primary sequence, incorporated linkage length and 
oxidation state (Sox) with corresponding % helicity. Amino acids with sulfhydryl groups indicated 
in bold, and crosslinked sequences indicated via X. 
No. Sequences* Linker   site 
 
Linker 
Length, 
Sox 
% 
Helicity 
WT MLL15 ILPSDIMDFVLKNTY -- -- 24 
1 SKICDFCdLKNTY i,i+3 -- 21 
1X SKICDFCdLKNTY i,i+3 8 25 
2 SKIMDFCLKNCY i,i+4 -- 34 
2X SKIMDFCLKNCY i,i+4 8 32 
3 SKICDFVLKNCY i,i+7 -- 26 
3X SKICDFVLKNCY i,i+7 10 43,44** 
3Xa SKICDFVLKNCY i,i+7 10, sulfone 33,34** 
3Xb SKICDFVLKNCY i,i+7 10, sulfoxide 39 
4 ILPCDIMDWICKNTY i,i+7 -- 9 
4X ILPCDIMDWICKNTY i,i+7 10 16 
5 ILPSDICDWILKNCY i,i+7 -- 53 
5X ILPSDICDWILKNCY i,i+7 10 43 
5Xa ILPSDICDWILKNCY i,i+7 10, sulfone 11 
5Xb ILPSDICDWILKNCY i,i+7 10, sulfoxide 8 
6 ILPCDICdDWILKNTY i,i+3 -- 7 
6X ILPCDICdDWILKNTY i,i+3 8 12 
7 SKICDFVLKNPnY i,i+7 -- 45 
7X SKICDFVLKNPnY i,i+7 10 10 
8 SKICDFVPnKNTY i,i+4 8 35 
8X SKICDFVPnKNTY i,i+4 8 21 
Cd abbreviated for D-Cysteiene; Pn abbreviated for Penicillamine 
*All peptides acetylated at N-terminus 
**CD experiment run at two concentrations (100 µM, and 25 µM, respectively)  
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various peptide positions within the MLL sequence. The uncrosslinked MLL12 peptides 
containing two cysteine mutants show moderate helical propensity without stabilization 
(21-34%, Peptides 1,2,3,Table 3.1).  For the cross-linked peptides we chose the eight and 
ten carbon alkyl cross-linker used by Wang et al. as they observed a slight increase in 
helicity in their crosslinked i,i+4 and i,i+7  peptides, respectively.64 We also investigated 
how the eight carbon alkyl crosslink at the i, i+3 position affects helicity as this linkage 
site was not evaluated previously. In the case of the i,i+4 crosslinked MLL12 peptide, 2X, 
we observed a small decrease in helicity (0.9 fold to 32%, Figure 3.7) whereas in peptide 
1X, containing the i, i+3 crosslink, a slight increase in helicity was observed (1.2 fold to 
25%, Figure 3.7).  In the case of the i,i+7  crosslink  we were able to observe a larger 1.7 
fold increase in helicity from 26% to 43% for the MLL12 peptide 3X. This latter 
crosslinking position is our most favorable site for macrocyclization.   
  
 
Figure 3.5 Far-UV CD spectra used to evaluate helicity of MLL constructs, taken in a 10 mM phosphate 
buffer, pH 7.4 with 30% TFE at 100 µM. A. 3X shows the highest helicity within the i,i+3,4,7 MLL12 
series.  B.  Oxidation of the i, i+7 MLL12 to the sulfoxide 3Xb and sulfone 3Xa.  
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Helicity can also be affected by peptide aggregation. This was recently observed in 
a report using an all-hydrocarbon stapled peptide.188 We tested if the a-helicity of 3X was 
affected by aggregation by carrying out the experiment for 3X at two different 
concentrations 25 µM and 100 µM. In this case the helicity remained similar, arguing 
against an artificially high CD concentration-dependent signature from aggregation (43% 
vs 44%, Figure 3.6). The more polar thioether may also be beneficial in this case for 
promoting solvation. 
 
  
We extended our investigation to look at longer peptides including a mutant of 
MLL which exchanges a phenylalanine and valine (residues 9 and 10) to tryptophan and 
isoleucine for increasing the potency of MLL15 against KIX.  In this case, we assessed 
both the i,i+7  and i,i+3 crosslinks. Peptides 4X and 5X contain an unstructured N-terminal 
ILP sequence, to include the a hotspot leucine residue for binding KIX75 and an i, i+7 
 
Figure 3.6. CD experiments showing the a-helical traces of MLL12 bisthioether 3X at 25 and 100 µM 
concentrations yield the similar % helicity (44.4% and 43.3%, respectively), indicating the helicity is 
concentration independent. B. a-helical traces of MLL12 bisthioether sulfone 3Xa at different concentrations 
also yields similar % helicities (34% and 33%). bisthioether sulfone 3Xa at different concentrations also 
yields similar % helicities (34% and 33%). 
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crosslink at two different positions. These peptides show a similar increase in helicity as 
3X upon macrocyclization (1.8- and 1.7-fold respectively) although the total helicity was 
lower for 4X (16%, Table 3.1). Peptide 6X with the i, i+3, crosslink also showed a 1.7-
fold enhancement of helicity to 12% from the uncrosslinked analog 6, Figure 3.7. 
Together, these results identify suitable sites for crosslinking to enhance structure within 
the thioether macrocycles, but indicate a significant sequence-dependent effect on helicity, 
consistent with prior studies.17  
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Once a favorable crosslink was identified for peptide 3X, sulfur oxidation was 
investigated for additional structural perturbation from this side-chain modification. First, 
peptide 3X was oxidized to contain two sulfones (3Xa) leading to a drop in helicity (1.3 
fold drop to 34%, Table 3.1), although the overall helicity is higher than the uncrosslinked 
peptide 3. This value was also concentration independent (Table 3.1, Figure 3.6B). 
Alternatively, when peptide 3X was oxidized to contain the sulfoxides in 3Xb, a smaller 
drop of helicity was observed (1.1-fold drop to 39%, Table 3.1). Although in two of the 
three cases oxidation resulted in a % helicity change of 10% or less, the peptide 5Xa 
containing two sulfones showed a more drastic loss in helicity (43% to 11%, Table 3.1), 
with respect to its reduced counterpart, 5X. The sulfoxide variant, 5Xb also had decreased 
helicity to 8%, Figure 3.8.  
 
Figure 3.7. CD traces of a-helical signatures show 6X with increased helicity, but low compared to 6 (7%-
12%). Peptide 4X also has enhanced helicity compared to the uncrosslinked analog (9%-16%). 
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Our findings on potential detrimental effects upon thioether oxidation from cysteine 
precursor amino acids, are consistent with a recent report by Zhang et al. using short single 
turn helical macrocycles. Using shorter hydrocarbon linkers, they also observe a reduction 
in helicity for singly oxidized thioether-crosslinked peptides to both a sulfoxide and a 
sulfone.189 Furthermore, it was observed that only one sulfoxide epimer enhances the 
helicity, whereas the other disrupts helicity. When the sulfoxide points away from the helix 
in the R-configuration, Zhang et al. calculated an N-C-C-S dihedral angle of  approximately 
-66o, whereas in the S-configuration the sulfoxide oxygen points towards the peptide 
causing a steric clash leading to an increase of the dihedral angle to -81°.189 As we are 
unable to separate the diasteromeric sulfoxide species, we may have enhanced helicity from 
only one diastereomer. These results support that although oxidation within the peptide 
macrocycle was tolerated in several cases, modest perturbation towards the a-helical 
conformation can occur and should be considered in future studies.     
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Figure 3.8 A. Penicillamine series with MLL12 i,i+4 and 7 compared to uncrosslinked analogs.  B.   
Full length 5 compared with the crosslinked peptide, 5X, oxidized variant, 5Xa and the WT MLL 15. 
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    In some cases, an increased hydrophobic crosslink may be important.  
Replacement of cysteine with penicillamine leads to a more hydrophobic side-chain 
modification and serves as a potential valine mimic. We evaluated how the 
conformationally constrained hydrophobic amino acid affected helicity.  Surprisingly, the 
i,i+7 series of the uncrosslinked peptide containing a single penicillamine near the C-
terminus 7, led to a high level of helicity 45%, versus 26% for having a cysteine at the 
same position in peptide 3.  However, the a-helicity was substantially reduced 4.6-fold to 
9.8% upon macrocylization to 7X (Table 3.1, Figure 3.8).  Crosslinking at i,i+4 positions 
is also destabilizing but led to a less substantial loss in helicity upon macrocylization from 
0.6 fold to 21% (8 to 8X, Table 3.1, Figure 3.8).   
We conclude for our initial studies of thioether macrocyclization that alkyl 
crosslinkers of appropriate length are both tolerated within the a-helix at positions i,i+3, i 
+4 and i+7, and can enhance a-helicity in certain peptide sequences. Sulfoxidation and 
sulfonation can be installed within the peptide side-chain macrocycles but at the expense 
of some degree of helicity. Oxidation can also dramatically affect the relative polarity of 
these peptides. In the case of peptide 5X, oxidation to a sulfone 5Xa, or sulfoxide, 5Xb, 
leads to over a fourteen minute difference in HPLC retention time (Figure 3.9).  Due to 
the potential for thioether oxidation of cysteine-macrocyclized peptides in cellular 
settings, intracellular functional effects should be interpreted with care. 
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Figure 3.9 Stacked HPLC traces of 5, 5X, 5Xa, and 5Xb with a 20_70 %B gradient run on the same C18 
RP-Column.  The sulfoxide shows the most polar retention time (29.8 min), followed by the sulfone (30.9 
min), the uncrosslinked (32.55 min) and the crosslinked variant (44.4 min).  Chromeleon Software v. 7.2 
Peak Pick analysis tool was used in determining retention times. 
 
3.3.1  Proteolytic Stability Upon Macrocylization and Oxidation    
An additional advantage of crosslinking peptides is the enhanced stability towards 
proteases due to reduced populations of the extended conformation necessary for protease-
mediated hydrolysis.  As an initial evaluation of the effects of conformational crosslinks 
and oxidation within the crosslinks, we tested four peptides containing the i+7 crosslink.  
We used the 15 residue MLL peptide, 5X, two oxidized versions: the dual sulfone, 5Xa, 
and the dual sulfoxide, 5Xb, as well as the uncrosslinked analog 5, and the native peptide 
sequence for MLL (WT MLL15).  
min
5-32.55 min
5X-44.4 min
5Xa-30.9 min
5Xb-29.8 min
20_70%B gradient
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     We chose trypsin as a model protease to measure relative stability as there was a 
single lysine recognition site within all peptide sequences. A significant stability for the 
crosslinked peptide 5X was seen (t1/2 = 50 min) whereas 5 (t1/2 = 10 min) had a similar 
degradation rate to the WT MLL15 (t1/2 = 5 min, Figure 3.10). These results are consistent 
with previous reports on stabilized a-helices. Surprisingly, despite the low helicity, 
oxidation of 5X to the sulfoxide variant, 5Xb showed enhanced proteolytic stability (T1/2 
= 100 min).  The peptide 5Xa, showed an even stronger resistance towards proteases (21% 
degraded at 200 min, Figure 3.10). The origin of these stabilizing effects upon oxidation 
are unknown. From our studies above, we could not attribute this increase in stability to 
helix stabilization. The dual sulfone- and dual sulfoxide-containing peptides in this case 
may afford additional resistance towards proteases caused by an inability to fit into the 
5
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Figure 3.10 Proteolytic stability assessesment of MLL and MLL-derived peptide macrocycles during 
a tryptic digest. WT MLL15 (pale purple) and acyclic peptide 5 (mauve) proteolyze rapidly compared 
to the crosslinked 5X (green T1/2 = 50 min), 5Xb (black T1/2 = 100 min)  and 5Xa (gold, 21% degraded 
at 200 min). Remaining peptide was quantified via RP-HPLC integration. 
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enzyme active site due to the increase in size of the side-chain, or non-productive molecular 
recognition effects. This stabilization will be further studied in future investigations.  
3.3.2  Molecular Recognition with KIX 
Having demonstrated a moderate increase in peptide helicity from i to i+7 crosslinks, 
a modest perturbation to structure upon oxidation, and an increase in proteolytic stability 
with both the constrained and oxidized peptides, we evaluated the effects of crosslinking 
and oxidation upon PPIs with KIX. We turned our attention to a protein-observed fluorine 
NMR method (PrOF NMR), which has recently been used to characterize binding of small 
molecules190 and the binding footprints of peptides to the KIX protein differentiating the 
MLL site from the CREB site.191 This method uses a protein that is sequence-selectively 
labeled with 3-fluorotyrosine (3FY). Y631 is a diagnostic amino acid found within the 
MLL binding site. Titration of 3FY-labeled KIX with WT MLL15 shows a concentration-
dependent decrease in the intensity of the Y631 resonance. Between one and two 
equivalents of WT MLL15 (i.e., 50 and 100 µM peptide), the resonance completely 
broadens into baseline, consistent with the intermediate chemical exchange regime, Figure 
3.11. Although potency cannot directly be obtained for high affinity peptides in a 
straightforward manner by this method, chemical exchange in the intermediate to slow 
exchange regimes are consistent with the expected mid to low micromolar affinity of MLL 
peptides for KIX.192  
 MLL engages KIX through more than a single helical face and through N-terminal 
residues outside of the a-helix in WT MLL15.75 Therefore,  appropriate crosslinking sites 
can be challenging to identify at positions that do not disrupt binding. To evaluate the 
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relative effects on binding affinity from various crosslinking motifs within the MLL 
sequence, we compared each binding titration to an uncrosslinked analog containing the 
two cysteine residues. In an attempt to increase affinity, we also mutated residues in 
position 9 and 10 from phenylalanine and valine to tryptophan and isoleucine respectively 
based on published data92 and frequency of tryptophan at protein hotspots9.  In the case of 
uncrosslinked peptide 5, Y631 has already broadened into baseline at one equivalent 
peptide. When the peptide 5 was crosslinked to 5X (i,i+7), binding was slightly attenuated 
at 1 eq, giving rise to resonance broadening of Y631 of KIX similar to WT MLL15 (Figure 
3.12A, B). The resonance further broadens into baseline with two equivalents of peptide 
(100 µM 5X, Figure 3.12C). However, oxidation of 5X to the dual sulfone 5Xa abolished 
binding (Figure 3.12C), indicating the thioether was the proper oxidation state in this case. 
More studies on the effect of oxidation will be necessary to harness its potential utility 
within crosslinked peptide inhibitors for affecting protein interactions.   
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Figure 3.11. 19F-NMR experiments were carried out with 3FY-labeled KIX protein (50 µM 3FY-KIX, 50 
mM HEPES and 100 mM NaCl, pH 7.2).  A.  Titration of WT MLL15 into 3FY-KIX shows perturbation 
of Y631 with significant broadening into baseline between 1 and 2 equivalents of WT MLL15.  B.  NMR 
solution structure of KIX (grey) binding to MLL (green) with the five tyrosine residues (blue) with side 
chains labeled (PDB ID: 2AGH, MLL-interacting residue Y631 shown in blue) C. 19F-NMR spectra with 
6/6X are overlaid with 3FY-KIX at 2 equivalents of peptide.  D. 19F-NMR spectra of 4/4X overlaid with 
3FY-KIX at 1 equivalents of peptide.  NMR spectra from full titrations can be found in the supporting 
information. 
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Figure 3.12 19F-NMR experiments were carried out with 3FY-labeled KIX protein (50 µM 3FY-KIX, 
50 mM HEPES and 100 mM NaCl, pH 7.2). A-C. Overlaid NMR plots of A. Complete loss of signal at 
1 equivalent of 5. B.  Less binding is observed for the crosslinked analog, 5X. C. Oxidized macrocycle 
5Xa disrupts binding relative to the uncrosslinked and crosslinked analog. 
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Figure 3.13 19F-NMR experiments were carried out with 3FY-labeled KIX protein (50 µM 3FY-KIX, 50 
mM HEPES and 100 mM NaCl, pH 7.2). A-D. Overlaid NMR plots of A) MLL derivative 4 with slight 
perturbations of Y631 at 2 equivalents of ligand. B. Crosslinked 4X shows little change in tyrosine 
resonances, indicating it does not bind well to KIX. C. i, i+3 cysteine incorporated peptide 6 shows small 
perturbations. D. Peptide 6X has increased perturbations of Y631 relative to the uncrosslinked analog, with 
significant broadening at 4 equivalents of ligand. 
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To evaluate a second cross-linking position, we tested a different MLL15 peptide, 
4X, with an i,i+7 crosslink replacing an important leucine residue at the binding interface. 
We compared the binding to uncrosslinked 4.  In these two cases, both peptides do not 
perturb Y631 resonance indicating no binding, Figure 3.13 A,B.  As a final series of 
peptides, we chose a shorter cross-linker with an i,i+3 relationship which are oriented away 
from the KIX interface in the NMR structure of KIX (PDB ID: 2AGH).  In this case, the 
side-chain crosslink is beneficial as peptide 6 in the i,i+3 series showed no appreciable 
binding interactions with KIX up to 200 µM peptide (Figure 3.13 D), whereas the 
crosslinked variant 6X broadened Y631 with four equivalents of ligand (Figure 3.13 C, 
D).  We interpret the lower degree of broadening at high concentrations to indicate overall 
weaker binding than 5X, Figure 3.12. Although none of the peptides surpasses the apparent 
affinity of MLL15, peptide 5X is an encouraging starting point based on its increased 
proteolytic stability and moderate binding to KIX for future designs targeting this 
challenging PPI.  
3.4  Conclusions 
In summary, we have evaluated the effects of modulating the polarity of sulfur-
containing peptide macrocycles by varying sulfur oxidation states through chemoselective 
reactions from thioethers to sulfoxides and sulfones. We first evaluated the relative effects 
of desolvation of sulfur containing side-chains relative to amide groups computationally 
and evaluated the polarity differences of short peptides containing either penicillamine, 
methionine, methionine sulfoxide, or methionine sulfone.  These peptides access a range 
of polarities, but all are less polar than an amide, but more polar than an all-hydrocarbon 
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side-chain. Such polarity tuning possibilities from a single sidechain may be a 
consideration for altering peptide aqueous solubility and modifying propensities for 
cellular uptake. For sulfur-containing peptide macrocycles, in some cases we were able to 
both enhance a-helicity as well as proteolytic stability. For the case of i to i +7 crosslinkers, 
dual sulfoxidation and sulfonation are also tolerated within the peptide macrocycle such as 
in 3X, 3Xa and 3Xb.  Finally, as a first step towards evaluating peptides as future PPI 
inhibitors of the MLL-KIX interactions, macrocycle 5X is able to maintain binding to KIX, 
and may serve as a starting point for developing cell permeable inhibitors of KIX function.  
In the future, additional sulfur-containing amino acids and helix promoting side-chain 
linkers such as bibenzyl193 and perfluorobiphenyl groups69 may be useful for studying the 
effects of sulfur oxidation on polarity tuning, conformation, and molecular recognition at 
PPI interfaces. 
3.5  Future Works 
3.5.1  Fluorescence Microscopy for Evaluating Cellular Uptake  
Constrained helical peptide constructs have large utility as pharmaceutical drug 
candidates for intracellular proteins due to their ability to penetrate through the cellular 
membrane. To evaluate the penetration capabilities of our thioether cross-linked peptides, 
we incubated fluorescently-labeled peptides, Fluor-5, and Fluor-5X with HeLa cells, 
washed the cells thoroughly, fixed on a plate, and used Hoescht nuclear dye for 
fluorescence microscope imagery. A known cell penetrating peptide with eight arginine 
residues is known to penetrate cells through an active cellular uptake process, Figure 
3.14A.194 The typical punctate pattern of fluorescence is observed throughout the cytosol 
for the octa-arginine peptide.194 An unalkylated MLL peptide Fluor-5 image surprisingly 
shows diffusion throughout the cytosol Figure 3.14B, whereas the crosslinked variant 
Fluor-5X, which should have increased permeability localizes around the outside of the 
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cellular membrane, but does not penetrate through, Figure 3.14D. With such a large 
amount of penetration observed for Fluor-5, we re-evaluated the peptide mass after it was 
dissolved in DMSO, and observed disulfide formation. The disulfide constrained peptide 
may allow the construct to penetrate cells. We are still investigating why the thioether 
cross-linked peptide does not penetrate the membrane. Other constrained peptides should 
be investigated in future studies to confirm if impermeability is due to a specific cross-
linked sequence, or if the thioether crosslink has a detrimental effect to cellular 
permeability. Further studies are necessary to evaluate optimal thio-ether crosslinked 
peptides, and their ability to be taken up into cells.  
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Figure 3.14 Merged fluorescence microscopy image of HeLa cells with Hoescht nuclear stain (blue) 
incubated with A) fluorescenated Octa-Arg (green), a control peptide known to penetrate through 
cellular membranes B) Fluor-5 (disulfide, green) 5 C) DMSO control, and D) Fluor-5X (green). 
Octa-Arg Fluor-5
DMSO Fluor-5X
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3.5.2  Extended MLL peptide sequences may enhance affinity and solubility (Mentored 
project with Rachel Staebell) 
 
Extending the MLL peptide at the C-terminus may add binding affinity.  This 
region is a flexible tail, but may provide ionic salt bridges or other non-covalent 
interactions that allow this 20-residue peptide to bind with higher affinity than the 15-
residue peptide. There is an arginine (R145) at the C-terminus of KIX which potentially 
could interact with aromatic rings, Figure 3.15. By mutating residues within the extended 
region to either alanine or aromatic residues, we can identify which residues contribute to 
the binding affinity, and where potential crosslinking motifs will be amenable.  
Fluorescence polarization was used to monitor these interactions. When alanine replaced 
proline (peptide B), a there is a slight decrease in affinity (constrained Ki = 4.14 vs. 2.13 
µM), indicating proline is a necessary residue. However, for the other alanine mutated 
residues, higher affinity was observed (peptides C,D,E, Table 3.2, Figure 3.16) with the 
greatest affinity for the serine mutation to alanine (peptide C,  constrained Ki = 0.77 µM). 
To identify possible non-covalent interactions with R145, we replaced Q86 with a glutamic 
acid (F), a phenylalanine (G), tryptophan (H), and tyrosine (I). The tryptophan mutation 
(H) showed the highest affinity, with a constrained Ki = 0.94 µM, Figure 3.17. This 
research is ongoing, and may prove to be higher affinity sequences to evaluate with thio-
ether bridged crosslinking motifs to disrupt PPIs. 
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R145Q861
MLL
KIX
Figure 3.15 Solution structure of MLL interacting with KIX (PDB ID: 1KDX).  Glutamine 86 on 
MLL (pink) is replaced with aromatic residues including tryptophan, which may lead to a cation-π 
interaction with arginine 145 on KIX (orange). 
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Table 3.2 Fluorescence polarization IC50 and Ki values, constrained and unconstrained for extended MLL 
peptides 
Letter Sequence IC50 (µM) 
Constrained 
IC50 (µM) 
Ki 
(µM) 
Ki 
Constrained 
(µM) 
MLL15 
WT ILPSDIMDFVLKNTY 11.3 ±	  	  0.85 15.7  ±	  0.96 1.42 1.97 
A ILPSDIMDFVLKNTPSMQAY 12.7 ±	  2.18 17.0 ±	  1.40 1.59 2.13 
B ILPSDIMDFVLKNTASMQAY 11.5 ±	  1.47 33.1 ±	  	  1.20 1.44 4.14 
C ILPSDIMDFVLKNTPAMQAY 5.73 ±	  0.57 6.13 ±	  0.42 0.72 0.77 
D ILPSDIMDFVLKNTPSAQAY 8.88 ±	  0.93 12.3 ±	  1.02 1.11 1.54 
E ILPSDIMDFVLKNTPSMAAY 12.7 ±	  1.15 15.1 ±	  0.85 1.59 1.89 
F ILPSDIMDFVLKNTPSMEAY 14.8 ±	  1.06 18.9 ±	  0	  .81 1.85 2.36 
G ILPSDIMDFVLKNTPSMFAY 10.6 ±	  	  0.48 10.7 ±	  0.32 1.32 1.34 
H ILPSDIMDFVLKNTPSMWAY 3.29 ±	  0.29 7.53 ±	  0.42 0.41 0.94 
I ILPSDIMDFVLKNTPSMYAY 9.52 ±	  0.63 8.50 ±	  0.40 1.19 1.06 
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Figure 3.16 Fluorescence polarization curves with 20-residue MLL peptides with a alanine mutations. 
Peptide A is the native 20-residue MLL sequence, (B) replaces proline, (C) replaces serine, (D) replaces 
methionine, (E) replaces glutamine with alanine. 
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3.5.3  b-hairpin motif examining the Met-Ox interactions with tyrosine and phenylalanine 
(NMR taken by Laura Hawk) 
To evaluate the interactions between the sulfoxide of methionine and aromatic 
residues, a b-hairpin motif, as previously described by Waters and colleagues106 was 
utilized with the sequence, RMOXVTVNGKTIXQ with X being either alanine, 
phenylalanine, tryptophan, or tyrosine. The hairpin motif allows one to evaluate 
interactions between discrete residues at positions two and 11. 1H NMR analysis shows the 
incorporation of the residue of interest at position 11 shifts the diastereomeric methyls next 
to the sulfoxide upfield with increasing electron-rich aromatic residues, Figure 3.18. When 
alanine is incorporated, the methyls resonances are at 2.695 and 2.687 ppm. Phenylalanine 
incorporation at position 11 shifts both methyl resonances upfield, 0.07-0.08 ppm, 
respectively. Tyrosine further shifts resonances to 2.601 and 2.593 ppm. Tryptophan shifts 
the resonances significantly upfield compared to the alanine control as well as the other 
aromatic residues, with resonances at 2.544 and 2.529, respectively. Each amino acid has 
a propensity to fold the b-sheet slightly differently, which potentially can affect the shift in 
the methyl resonances.  If amino acid propensity is the driving factor, then tyrosine would 
shift the resonances furthest upfield (propensity 1.29), followed by phenylalanine (1.28), 
tryptophan (1.19), and alanine (0.97); However, since we see tryptophan with the furthest 
Figure 3.17 Fluorescence polarization curves with 20-residue MLL peptides with a 
mutation of Q86 with glutamic acid (F), phenylalanine(G),  tryptophan (H), and 
tyrosine (I). 
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upfield methyl shift, b-sheet propensity is not the reason for the upfield shifts. The upfield 
shift is consistent with idea of a more electron-rich ring current within tryptophan shielding 
the methyl groups stronger than the other aromatic substituents, of which we previously 
evaluated in Chapter 2.   
 
 
 
3.6  Efforts Towards a Perfluorinated Aryl-Thioether-Bridged Macrocycle Monitored 
with 19F-NMR in Collaboration with Professor Ratmir Derda 
3.6.1  Introduction 
A novel macrocyclization strategy utilizing cysteine side chains in a nucleophilic 
aromatic substitution (SnAr) reaction has proven to be a suitable method to constrain 
helical peptides, Figure 3.19.  Derda and colleagues have used a highly reactive (up to 180 
M-1s-1) SNAr electrophile, decafluoro diphenylsulphone (DFS) to efficiently form a stable 
[ppm] 2.8  2.7  2.6  2.5 
RMOXVTVNGKTIYQ
RMOXVTVNGKTIWQ
N
H
S
H3C O
O
RMOXVTVNGKTIFQ
RMOXVTVNGKTIAQ
A
B
D
C
2.687 
2.609 
2.529 
2.593 
Figure 3.18 1H NMR overlay of four peptides in a hairpin motif. A. tryptophan incorporated within 
position 11 of the peptide shifts the resonances significantly upfield. B. tyrosine incorporated at 
postion 11 C. Phenylalanine methyls shifted upfield compared to the alanine control, D. 
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macrocycle.175  The reaction is completed within two hours by first adding a disulfide 
reducing agent, TCEP (1mM), diluting the reactants 10-fold with 0.5 mM Tris, pH 8.5, 5% 
DMF, and DFS to afford the final product.175 Two peptides were identified to bind to 
Human Serum Albumin (HSA) to improve their serum half-life through phage display, but 
specific affinity values had not been ascertained. Molecules that are able to bind to the 
plasma have a dramatic effect on the transport and distribution of the drug, and allows for 
a prolonged half-life.195 A major component within plasma that is frequently responsible 
for the binding of drugs is HSA.196 HSA has two subdomains that bind the majority of its 
ligands: Site IIa and Site IIIa.197 We evaluated two peptides for their affinity and site 
specificity towards HSA.   
 The peptides evaluated are identical except for the last three residues being either 
–KKK or –SSS (Figure 3.19), hence the naming scheme, DFS-KKK or DFS-SSS, 
respectively. To evaluate how the stabilized macrocycles affect affinity, we used a peptide 
observed fluorine NMR technique, analogous to prior PrOF NMR studies.192 The utility of 
19F-NMR to analyze binding affinity of fluorinated protein to ligand has been validated in 
the Pomerantz lab.190,198 A reverse experiment where the fluorine label on the ligand with 
increasing equivalents of protein titrated has been evaluated by others and shown to be an 
effective method to quantify peptide binding affinity.199  
 
Figure 3.19 Decafluoro-diphenyl sulfone crosslinked peptide sequences shown for both DFS-SSS and 
DFS-KKK. 
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3.6.2  Results and Discussion 
To assess conditions to monitor the fluorinated small molecule resonance shifts 
with increasing protein concentration, we used a known ligand of bovine serum albumin, 
Dexamethasone, which has one fluorine atom, a doublet at -165.4 ppm, Figure 3.22. It has 
been previously shown that dexamethasone binds to bovine serum albumin with ~ 30 µM 
affinity.200 Using bovine serum albumin at increasing concentrations, a shift in the 
dexamethasone fluorine doublet upfield was observed (Figure 3.22). The resonance shift 
was fit to a binding isotherm, and a dissociation constant of ~ 30 µM was estimated. Due 
to the broadening of the peaks at higher BSA concentrations, and the high standard 
deviation of the binding fit, we could only conclude an estimation of Kd, Figure 3.20. 
 
 122 
 
 
 
 
 
 
 
[ppm]- 130 - 135 - 140 
wpogtp-160819-14  21  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  21  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  31  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  41  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  51  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  61  1  C:\Users\pere0176\Desktop\NMR_Data
wpogtp-160819-14  71  1  C:\Users\pere0176\Desktop\NMR_Data
[ppm]- 130 - 135 - 140 
A        B
0 μM HSA 
20 μM HSA 
10 μM HSA 
160 μM HSA 
80 μM HSA 
40 μM HSA 
0 μM HSA 
20 μM HSA 
10 μM HSA 
160 μM HSA 
80 μM HSA 
40 μM HSA 
 
Figure 3.20 Binding Isotherm of Dexamethasone with Bovine Serum Albumin  A  Kd =  32 ± 59 µM was 
calculated from the binding fit.  Due to such large error, this value should be only taken as an estimate. 
 
Figure 3.21 Increasing concentrations of HSA was added to a 20 µM DFS-KKK peptide solution. 
B.  Added HSA was titrated into a constant 20 µM solution of DFS-SSS. 
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Figure 3.22. 19F-NMR spectrum overlay with increasing concentrations of BSA titrated into 
Dexamethasone.  The single fluorine doublet in dexamethasone shifts upfield and broadens into baseline.  
A binding isotherm fit to the resonance shift estimates the Kd to be around 30 µM. 
[ppm]- 163 - 164 - 165 - 166 - 167 
0 μM BSA + 20 μM Dexamethasone
20 μM BSA + 20 μM Dexamethasone
160 μM BSA + 20 μM Dexamethasone
80 μM BSA + 20 μM Dexamethasone
40 μM BSA + 20 μM Dexamethasone
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After determining the proper experimental conditions, an evaluation of HSA with 
DFS cross-linked peptides were carried out, Figure 3.21. At a fixed concentration of DFS-
peptide at 20 µM, HSA was titrated from 0-1.6 mM. No substantial change was observed 
for the aromatic fluorine residues of the DFS-SSS peptide, but with DFS-KKK peptide, a 
broadening of the fluorine resonances into baseline was seen. The broadening effect would 
be characterized as intermediate chemical exchange kinetics. Due to the broadening, a 
binding isotherm cannot be fit to a resonance shift; however, intermediate chemical 
exchange binding behavior is consistent with ligands binding with low to mid-micromolar 
affinity.  
To parse out the binding site on HSA, competition NMR assays were used with 
previously reported HSA ligands: L-Tryptophan and Ibuprofen. Both L-
Tryptophan and Ibuprofen bind the IIIa site of HSA, albeit with varying affinity. 196 
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Ibuprofen is a tight binder of the site, with 370 nM, Figure 3.23. L-Tryptophan however 
has a lower affinity towards the same site, Kd = 100 µM.196 To better understand the binding 
site of the DFS-KKK ligand, we competed it off with both the high and low affinity 
competitors. By adding 20 µM of DFS-KKK to 40 µM HSA, a broadening of resonances 
is observed. If the competitor binds at the same site with higher affinity than the peptide, 
the resonances will return. Such a result could also be due to an allosteric effect.  We were 
unable to compete off 20 µM DFS-KKK with either 100 µM or 1 mM of L-Tryptophan, 
most likely due to the weaker affinity. With Ibuprofen, however, we did see competition 
with 1 mM, where the resonances were able to return fully.     
 
Figure 3.23 Competition with Ibuprofen at 0, 100 uM, and 1 mM.  Resonances come back out of 
baseline at 1 mM competitor, indicating binding at the same site.  Ibuprofen has previously been 
observed to bind site IIIa. 
No Inhibitor
100 uM Ibuprofen
1 mM Ibuprofen
[ppm]- 130 - 135 - 140 
40 μM HSA + 20 μM DFS-KKK
40 μM HSA + 20 μM DFS-KKK +
40 μM HSA + 20 μM DFS-KKK +
 126 
 
 
3.6.3  Conclusion 
Two peptides with a DFS-crosslink were evaluated for affinity towards the HSA 
protein. The peptide, DFS-KKK showed a significant enhancement of affinity towards 
HSA, with broadening of the resonances seen at 20-40 µM. This type of broadening of the 
fluorine resonances is due to intermediate exchange, consistent with a mid-micromolar 
affinity.  HSA displays specificity towards DFS-KKK; however, the DFS-SSS peptide 
displays only modest broadening of fluorinated aryl resonances near 80-160 µM HSA. The 
charged lysine residues may fit within the binding site more readily. The binding site IIIa 
may be less amenable to the serine residues, Figure 3.24. More structural and binding 
studies may elucidate the specificity seen towards DFS-KKK. Crystal structures of HSA 
with DFS-peptides are currently being explored. This is a first step in identifying DFS-
 
Figure 3.24 Solution structure of Human Serum Albumin (gray) binding to Ibuprofen (blue) in the 
IIIa binding site with 370 nM affinity (PDB ID: 2BXG)201 
Site IIIa
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peptide interactions with proteins such as HSA. Furthermore, the utility of using 
fluorinated ligands to identify protein interactions is far reaching due to the ubiquitous use 
of fluorine within drug candidates (20% in 2014).143 This work highlights the utility of 19F-
NMR to monitor fluorinated ligands binding to the protein of interest. 
3.7  Experimental Section 
3.7.1  Computational Methods  
Geometry optimizations of the compounds listed in Figure 3.3A were carried out 
in the gas phase with Q-Chem 4.1202 at the B3LYP/6-31G(d) level by Alessandro Cembran. 
203–206  Free energies of solvation in water were then carried out as single point calculations 
on the gas phase minima with the same functional, basis set, and program using the 
continuum solvation model SM12.182 Charge analysis was performed using the CM5 
model.207  
3.7.2  Density Functional Theory Calculations of Hydrogen Bond Interactions 
We investigated the strength of hydrogen bonds with water of both sulfone and 
sulfoxide using density functional theory calculations on dimethyl sulfoxide (DMSO) and 
methylsulfonylmethane (MSM). The smaller models with respect the main text were 
chosen in order to rule out any possibility of different energy values arising from different 
conformational states of the ethyl moiety with respect to the water molecule. By using this 
approach, any energy difference between the sulfoxide and sulfone is to be attributed only 
to the different hydrogen bonding strength. 
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We employed the same level of theory and program as for the calculations 
described in the main text. Calculations were performed with Q-Chem 4.1 at the B3LYP/6-
31G(d) level, and solvation effects were taken into account using the SM12 continuum 
solvation model.  In one set of calculations, the difference in the hydrogen bond energy of 
the complex 𝐷𝑀𝑆𝑂 ∙ 𝑊𝑎𝑡𝑒𝑟 and the complex 𝑀𝑆𝑀 ∙ 𝑊𝑎𝑡𝑒𝑟 was calculated from the gas-
phase optimized geometries (see Figure 3.25) using the following scheme: 
Δ Δ𝐸-./0123/-4. = 𝐸 𝐷𝑀𝑆𝑂 ∙ 𝑊𝑎𝑡𝑒𝑟 − 𝐸 𝐷𝑀𝑆𝑂 − 𝐸 𝑀𝑆𝑀 ∙ 𝑊𝑎𝑡𝑒𝑟 −𝐸 𝑀𝑆𝑀 	   (1) 
To take into account the solvation effects on the calculated energies, single point 
energy calculations on all the gas-phase optimized geometries were performed using the 
SM12 continuum solvation models in water solution. Using the same scheme, in a second 
set of calculations we investigated the effects of adding a second water molecule to the 
complex. As shown in Figure 3.25, for MSM each oxygen is hydrogen bonded to one 
water. The results in Table 3.3 show that in the gas phase the hydrogen bond formed by 
DMSO is 2.6 kcal/mol stronger than for MSM. Inclusion of solvation effects further 
increases the strength of the interaction difference to 3.3 kcal/mol. Addition of a second 
water molecule confirms this trend, showing a stronger interaction energy for DMSO both 
in the gas phase (3.1 kcal/mol) and including solvation effects (5.6 kcal/mol).  
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Table 3.3 Interaction energy differences from Eq. 1 calculated at the B3LYP/6-31G(d) in the gas 
phase and using the SM12 solvation model. Results are reported in kcal/mol for the complexes with 
one water and two water molecules. 
Molecule Gas Phase Water Solution 
1 Water 
Complex -2.6 -3.3 
2 Waters 
Complex -3.1 -5.6 
Figure 3.25 Gas-phase optimized geometries of the water complexes 
of DMSO and MSM.  
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3.7.3  Alkylation of peptides 
Prior to purification of the acyclic peptide, the peptide was dissolved (~5 mg/mL) 
in 1:5 CH3CN:NH4HCO3 (20 mM, pH 8.3) to which 1.5 eq TCEP was added and stirred at 
RT for ~ 1h.193  The solution pH is maintained at pH 8 with 1N NaOH.  Dibromoalkane 
(10 eq) is added, and heated in a microwave reactor for 25 min at 80 ºC.  The crude mixture 
is diluted 2X with a 60:40 0.1% TFA water: CH3CN solution followed by RP-HPLC 
purification.   
3.7.4  Oxidation of thioether crosslinked peptides 
3.7.4.1   Sulfone formation 
A solution of 30% (v/v) hydrogen peroxide (49 µL) was added to a chilled formic 
acid solution (1.95 µL) and stirred on ice for 2 h to form performic acid.  The MLL peptide 
(~1 mg) was separately dissolved into 80 µL formic acid, 20 µL methanol; solution and 
chilled to 4 ºC.  Performic acid (50 eq) was added and stirred for 1.5 h.  The reaction was 
quenched with β-mercaptoethanol and purified on HPLC.181  
3.7.4.2   Sulfoxide formation 
The MLL peptide (~1 mg) was dissolved in 600 µL methanol and 20 µL of 30% 
(v/v) hydrogen peroxide solution (450 eq).  The reaction was stirred for 2 h, and then 
quenched with β-mercaptoethanol and purified by RP-HPLC.208  
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3.7.5  Circular Dichroism Methods 
Peptides were run on a Jasco J-815 Spectropolarimeter at room temperature using 
standard measurement parameters: wavelength, 190-260 nm; step resolution, 1.0 nm; 
accumulations, 4; path length, 0.1 cm; bandwidth, 1 nm; scanning speed, 50 nm/min.  
Compounds were dissolved in 10 mM phosphate buffer, pH 7.4 with 30% TFE to 
concentrations of 100 µM.  A baseline of 30% TFE in buffer was subtracted from each run.  
Data was converted from mdeg into ellipticity ([θ], deg cm2 dmol-1) using equation 1. 
below: [𝜃] = ;	  <===.>3 (Eq. 1) 
 
where  y is the signal in degrees, n is the number of amides, l is the path length in 
cm, and c is the concentration in dmol/cm3.  The percent helicity is the ratio of 
[q]222/max[q]222 where 
max[q]222 = (−40 000 X [1 − k/n]), k = 2.5, n = number of residues.18 
 
3.7.6  Proteolysis 
Peptides were dissolved in 100 mM NH4HCO3, pH 8.1 to a final concentration of 
200 µM.  A 1 mg/mL stock concentration of trypsin was prepared, and using a 100: 1 
substrate: enzyme ratio, trypsin was added to a stirring peptide solution.  Time points were 
quenched with 10 µL of trifluoroacetic acid, and injected onto a Dionex 3000 RP-HPLC. 
Peak area degradation was analyzed and plotted against time. 
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3.7.7  Protein Observed Fluorine NMR (PrOF) 
Protein observed 1D 19F NMR samples were obtained as previously described192 
using a frequency window of -131 to -141 ppm, a D1 of 0.6 sec and an acquisition time of 
0.1 sec.  Peptide stock solutions were prepared in DMSO at 1-10 mM. Peptides were 
titrated into KIX (protein solutions at 55 µM in 50 mM HEPES, 100 mM NaCl, 5% D2O, 
pH 7.4) at 0, 0.5, 1.0, and 2.0 equivalents of protein with a final concentration of 0.5% 
(v/v) DMSO.  
3.7.8  Protein Expression Experimental 
3FY-labeled KIX was expressed using E. coli/Bl21(DE3) co-transformed with the 
pRARE plasmid expressing tRNAs for rare codons. 3FY-labeled protein was expressed 
with LB media grown until an O.D. at 600 nm of 0.7 was reached, as verified on a Varian 
Cary 50 Bio UV/Vis spectrophotometer.  Cells were harvested and resuspended in defined 
media of Muchmore et al.209 which contained 3-fluorotyrosine (60 mg/L) in place of 
tyrosine. Resuspended bacteria were incubated at 37 oC while shaking for 1.5 h.  The 
bacterial culture was cooled to 20 oC for 30 min. then induced with 1 mM IPTG for 18-20 
h at 20 °C.  Cells were pelleted and stored at -20 °C.  Pellets were thawed to room 
temperature, and lysis buffer (50 mM Phsophate pH 7.4, 300 mM NaCl), PMSF (5 mM), 
and Egg White Lysozyme (1 mg/mL) were added followed by sonication and purified via 
FPLC using NTA-resin (Qiagen) and an imidazole gradient (0 to 400 mM). Concentration 
of KIX was evaluated via absorbance at 280 nm.210  
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3.7.9  Solid Phase Peptide Synthesis 
Peptides were made on a 25 µmol scale on NovaSyn TGR® resin in a CEM MARS 
microwave reactor.  The resin was weighed into a fritted 6 mL syringe, swelled in 
methylene chloride (DCM) for 5 min, and washed with N,N’-dimethylformamide (DMF) 
three times.  In a separate vial containing 25 µmols of Fmoc-amino acid, 1000 µL of DMF, 
1-hydroxybenzotriazole monohydrate (HOBT, 200 µL, 0.5 M solution in DMF), O-
benzotriazol-1-yl-N, N, N’, N’-tetramethyluronium hexafluorophosphate (HBTU 200 µL, 
0.5 M solution in DMF), and diisopropylethylamine (DIEA 200 µL, 1.0 M solution in 
DMF) activated the amino acid. The mixture stirred at 70 °C (400 W power, ramp 2 min, 
hold 4 min) for the coupling reaction.  The resin was washed 3 x with DMF, DCM, and 3X 
with DMF).  To remove the Fmoc group, 2 mL of 20% piperidine in DMF (solution v/v) 
was added to the resin and the solution was irradiated at 80 °C (400 W power, ramp 2 min, 
hold 2 min).  The resin was subsequently washed and the coupling/deprotection reactions 
were repeated until the complete peptide was synthesized and the final residue deprotected.  
Acetylation of the N-terminus was accomplished by adding 500 µL acetic anhydride, 100 
µL triethylamine (TEA), and 1.4 mL DCM to the resin and stirring for 1.5 h.  For 
fluorescent peptides, a b-alanine spacer was added to the N-terminus.  With the final Fmoc- 
deprotected from b-alanine, NHS-fluorescein ester (2 eq) was stirred with the peptide on 
resin (12.5 µmols) in 1000 µL DMF and 200 µL DIEA, stirred at R.T. overnight. Cleavage 
from the resin was carried out by stirring the resing for 2 h in a mixture 95:3:2 TFA: 
thioanisole: ethanedithiol at room temperature.  The cleavage solution was separated from 
the resin, and concentrated under a stream of N2.  The peptide was precipitated out in ether, 
cooled to -20 °C for at least 15 min, and pelleted out by centrifugation at 3000 x g for 5 
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min at 4 °C.  The pellet was dissolved into a 60:40 0.1% TFA in H2O: acetonitrile mixture 
with added DMF to ensure dissolution.  Dissolved peptides were injected into a Dionex 
Ultimate 3000 RP-HPLC using a C-18 column on a 10-60% acetonitrile gradient over 60 
min.  Purified peptides were analyzed via Ab-Sciex 5800 MALDI-TOF/TOF Mass 
Spectrometer.  Peptides theoretical and actual masses are shown in Table 3.5. 
3.7.10  Fluorescence Microscopy 
HeLa cells were seeded 100,000 on 35 mM glass-bottomed plates and incubated in 
2 mL media (DMEM with 1% penicillin-streptomycin cocktail) supplemented with 10% 
FBS for 24 h at 37 °C. Checked for confluency (~ 40%), aspirated the media, rinsed 2x2 
mL PBS.  We added 1.5 mL PBS and incubated with 2.7 µM fluorescently-labeled peptide 
for 60 min at 37 °C. The cells were aspirated and washed 2X 2 mL PBS. 1 mL of 
paraformaldehyde was added, agitated on shaker for 10 min., aspirated, and rinsed 2X 2 
mL PBS.  1 mL of Hoescht stain 34560 (1 µg/mL in H2O) was added to stain nucleus.  
Shake for 10 min., and were aspirated and washed 2X 2 mL PBS. A final 2 mL of PBS was 
added and images were taken on a were taken on an Olympus FV1000 IX2 Inverted 
Confocal Microscope. Images were analyzed with Olympus Fluoview, v. 4.0 software. 
[Hoescht: λ(ex) = 358 nm, fluorescein: λ(ex) = 492 nm].  
3.7.11  DFS-peptide titrations with serum albumin 
Peptide observed 1D 19F NMR samples were obtained as previously described 
using a frequency window of -160 to -170 ppm, a D1 of 0.7 sec and an acquisition time of 
0.05 sec.  Dexamethasone and BSA stock solutions were prepared at 2 mM.  BSA was 
titrated into DexMeth (20 µM), or HSA was titrated into DFS-SSS or DFS-KKK at 0, 10, 
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20, 40, 80, and 160 µM.  Competition studies were done with 0, 100 µM, or 1 mM of L-
Trp or Ibuprofen, 40 µM of HSA, and 20 µM of DFS-KKK peptide.  A frequency window 
of -125-145 ppm was used.  See Table 3.4 below for competition experimental conditions. 
 
 
 
 
 
 
 
	  
  
 
 
 
 
 
 
Table 3.4 Competitive 19F-NMR experiments with added Ibuprofen or L-Tryptophan 
Competition 
Expt 
Inhibitor 
Ibuprofen 
(100 mM) 
µL 
Inhibitor L-
Tryptophan 
(5 mM) uL 
DMSO 
Protein 
(40 µM) 
Volume 
KKK-
DFS (20 
µM) 
Volume 
TFE 
(µL) 
 
D2O 
(µL) 
Water 
(µL) 
No Inhibitor 
L-Trp Blank 0 0 0 10 15.4 2 25 447.6 
No Inhibitor 
Ibuprofen 
Blank 
0 0 5 10 15.4 2 25 442.6 
100 uM 
Ibuprofen 0.5 0 4.5 10 15.4 2 25 442.6 
100 uM 
L=Trp 0 10 0 10 15.4 2 25 437.6 
1 mM 
Ibuprofen 5 0 0 10 15.4 2 25 442.6 
1 mM L-Trp 0 100 0 10 15.4 2 25 347.6 
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Name Peptide sequences 
Theoretical 
[M + Na] 
Observed 
[M + Na] 
WT MLL15 Ac-ILPSDIMDFVLKNTY 1831.94 1832.3 
MLL15-Sulfone Ac-ILPSDIMDFVLKNTY + 2Oxygen 1863.93 1864.1 
MLL15-Suloxide Ac-ILPSDIMDFVLKNTY + Oxygen 1825.9* 1825.8** 
1X Ac-SKICDFCdLKNTY + 8 Carbon Chain 1607.8 1607.7 
1 Ac-SKICDFCdLKNTY 1497.69 1497.5 
2X Ac-SKIMDFCLKNCY + 8 Carbon Chain 1637.8 1637.5 
2 Ac-SKIMDFCLKNCY 1483.7 1483.45 
3X Ac-SKICDFVLKNCY + 10 Carbon Chain 1633.86 1634.06 
3 Ac-SKICDFVLKNCY 1472.7* 1473.5** 
3Xa Ac- SKICDFVLKNCY + 10C + 4Oxygen 
(sulfone) 1697.84 1697.75 
3Xb Ac- SKICDFVLKNCY + 10C + 2Oxygen 
(sulfoxide) 1665.85 1665.76 
4X Ac-ILPCDIMDWICKNTY+ 10 Carbon 
Chain 2030.0 2029.2 
4 Ac-ILPCDIMDWICKNTY 1890.8 1891.0 
5 Ac-ILPSDICDWILKNCY 1835.9* 1836.97** 
5X Ac-ILPSDICDWILKNCY + 10 Carbon 
Chain 1998.04 1997.39 
5Xa Ac-ILPSDICDWILKNCY+ 10 Carbon 
Chain + 4 Oxygen 2062.02 2063.11 
5Xb Ac-ILPSDICDWILKNCY+ 10 Carbon 
Chain + 2 Oxygen 2008.03* 2007.95** 
6X ILPCDICdDWILKNTY+ 8 Carbon Chain 1984.0 1983.2 
6 ILPCDICdDWILKNTY 1872.9 1873.0 
7X Ac-SKICDFVLKNPnY + 10 Carbon Chain 1661.89 1662.2 
7 Ac-SKICDFVLKNPnY 1523.75 1524.1 
8X Ac-SKICDFVPnKNTY + 8 Carbon Chain 1621.82 1622.1 
8 Ac-SKICDFVPnKNTY 1511.71 1511.9 
Fluor-5X Kfluor-bAILPSDICDWILKNCY +10 
Carbon Chain 2513.95 2513.2 
Fluor-5  Kfluor-bAILPSDICDWILKNCY 2373.06 2373.3 
 
Octa-Arg-Fluor Fluor-
bARRRRRRRR 1695.94* 1696.26** 
GP4097A Ac-SKIMDCILKCTY + m-xylene 1582.78* 1582.88** 
GP4097B Ac-SKICDWICKNTY + m-xylene 1638.77 1638.63 
 ** Denotes [M+H] observed mass   
 * Denotes [M+H] theoretical mass   
    
    
Table 3.5 Peptide sequences with corresponding theoretical mass, and observed mass, taken on a MALDI-
TOF/TOF mass spectrometer. 
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Table 3.6 Peptide sequences with corresponding %B elution from HPLC trace 
No. Sequences Linker site 
 
HPLC %B 
Elution 
WT 
MLL15 ILPSDIMDFVLKNTY n/a 
51 
1 SKICDFCdLKNTY i,i+3 33 
1X SKICDFCdLKNTY i,i+3 44 
2 SKIMDFCLKNCY i,i+4 33 
2X SKIMDFCLKNCY i,i+4 47 
3 SKICDFVLKNCY i,i+7 39 
3X SKICDFVLKNCY i,i+7 51 
3Xa SKICDFVLKNCY i,i+7 37 
3Xb SKICDFVLKNCY i,i+7 36 
4 ILPCDIMDWICKNTY i,i+7 54 
4X ILPCDIMDWICKNTY i,i+7 66 
5 ILPSDICDWILKNCY i,i+7 55 
5X ILPSDICDWILKNCY i,i+7 66 
5Xa ILPSDICDWILKNCY i,i+7 51 
5Xb ILPSDICDWILKNCY i,i+7 50 
6 ILPCDICdDWILKNTY i,i+3 54 
6X ILPCDICdDWILKNTY i,i+3 68 
7 SKICDFVLKNPnY i,i+7 41 
7X SKICDFVLKNPnY i,i+7 56 
8 SKICDFVPnKNTY i,i+4 32 
*Pn stands for Penicillamine 
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3.7.12  HPLC Quality Control  
Quality control HPLC traces below were run on two Dionex-3000 HPLC 
instruments with three different C-18 columns, which lead to slight deviations of retention 
times.  Varied gradients of acetonitrile: 0.1%TFA water were run based on the 
hydrophobicity of peptide.  The gradient used as well as the %acetonitrile (B solvent) at 
which the peptide elutes is shown on each Quality Control trace. 
 
 
Table 3.7 Extended MLL peptides sequences with corresponding mass spectrometry data, , taken on a 
MALDI-TOF/TOF mass spectrometer. 
Peptide 
Name Sequence Theoretical [M + Na] Observed [M + Na] 
MLL15 WT ILPSDIMDFVLKNTY 1831.94 1833.06 
A ILPSDIMDFVLKNTPSMQAY 2347.16 2347.59 
B ILPSDIMDFVLKNTASMQAY 2321.70 2321.47 
C ILPSDIMDFVLKNTPAMQAY 2331.17 2331.40 
D ILPSDIMDFVLKNTPSAQAY 2286.16 2286.51 
E ILPSDIMDFVLKNTPSMAAY 2290.14 2290.42 
F ILPSDIMDFVLKNTPSMEAY 2348.15 2348.49 
G ILPSDIMDFVLKNTPSMFAY 2366.17 2366.29 
H ILPSDIMDFVLKNTPSMWAY 2405.18 2405.49 
I ILPSDIMDFVLKNTPSMYAY 2382.17 2382.43 
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8X,47%B elution
8,32%B elution
7X,56%B elution
7,41%B elution
2X,47%B elution
2,33%B elution
1X, 44%B elution
1, 33%B elution
3,39%B elution
3X,51%B elution
4X, 66%B elution
4, 54%B elution
6X, 68%B elution
6, 54%B elution
3Xa, 37%B elution
3Xb, 36%B elution
5, 55%B elution
5X, 66%B elution
5Xa, 51%B elution
MLL15, 51%B elution
20_70%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
20_70%B gradient
20_70%B gradient
30_80_%B gradient
30_80%B gradient
20_70_%B gradient
20_70_%B gradient
10_60%B gradient
20_70%B gradient
10_60%B gradient
10_60%B gradient
5Xb, 50%B elution20_70%B gradient
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8X,47%B elution
8,32%B elution
7X,56%B elution
7,41%B elution
2X,47%B elution
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1X, 44%B elution
1, 33%B elution
3,39%B elution
3X,51%B elution
4X, 66%B elution
4, 54%B elution
6X, 68%B elution
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3Xb, 36%B elution
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5X, 66%B elution
5Xa, 51%B elution
MLL15, 51%B elution
20_70%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
20_70%B gradient
20_70%B gradient
30_80_%B gradient
30_80%B gradient
20_70_%B gradient
20_70_%B gradient
10_60%B gradient
20_70%B gradient
10_60%B gradient
10_60%B gradient
5Xb, 50%B elution20_70%B gradient
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3Xb, 36%B elution
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5Xa, 51%B elution
MLL15, 1%B elution
20_70%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
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30_80_%B gradient
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10_60%B gradient
5Xb, 50%B elution20_70%B gradient
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1X, 44%B elution
1, 33%B elution
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3 ,51 B elution
4X, 66%B elution
4, 54%B elution
6X, 68%B elution
6, 54%B elution
3Xa, 37%B elution
3Xb, 36%B elution
5, 55%B elution
5X, 66%B elution
5Xa, 51%B elution
MLL15, 51%B elution
20_70%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
 r i t
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30_80_%B gradient
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10_60%B gradient
5Xb, 50%B elution20_70%B gradient
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3X,51%B elution
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5Xa, 51%B elution
, 51 B elution
20_70%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
10_60%B gradient
20_70%B gradient
20_70%B gradient
30_80_%B gradient
30_80%B gradient
20_70_%B gradient
20_70_%B gradient
10_60%B gradient
20_70%B gradient
10_60%B gradient
 
5Xb, 50%B elution20_70%B gradient
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10_60%B gradient
5Xb, 50%B elution20_70%B gradient
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20_70%B gradient
20_70%B gradient
30_80_%B gradient
30_80%B gradient
20_70_%B gradient
20_70_%B gradient
10_60%B gradient
20_70%B gradient
10_60%B gradient
10_60%B gradient
5Xb, 50%B elution20_70%B gradient
30_80%B 61.6 %B
20_70%B 52.5 %B
10_60%B
19 %B
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Chapter	  4.  Efforts	  Towards	  Intramolecular	  Thiol-­‐Ene	  Reaction	  
Motivation 
 
Researchers have utilized a variety of novel methods for the synthesis of 
macrocyclized peptides, including SN2 reactions, ring closing metathesis reactions, and 
SNAr, as discussed in Chapter 1.  One reaction that we were particularly interested in was 
the thiol-ene reaction.64,68  Unlike our previous method which oxidizes both thioethers, this 
strategy allows for specific tunable oxidation states at specific cysteines in the peptide 
backbone.  
4.1.1  Introduction  
 
The thiol-ene reaction has garnered much interest recently to cyclize peptides.  A 
few labs have used a variety of thiol-ene reactions to afford thio-ether bridged peptides.  
Chou and colleagues have utilized a di-alkene to make the bis-thioether bond and have 
identified carbon linkages of 8-9 having robust yields (90-91%).64  A recent study by Li 
and co-workers invoked a thiol-ene reaction to afford an intramolecular crosslink between 
a free thiol on cysteine seven residues away from a non-natural alkenyl glycine residue.211  
A tether of 10-11 atoms proved to be the most efficient, where longer tethers (12-13 atoms) 
lead to a lower percent conversion.  Furthermore, they were able to oxidize the one sulfur 
atom within the tether to a sulfoxide using hydrogen peroxide.  Analysis of the secondary 
structure using CD revealed that differing epimers of the sulfoxide influence helical 
content.  One epimer led to a random coil whereas the other induced helicity.189,211 This 
highlights the modular capability sulfoxides can have on secondary structure and the 
potential to further utilize specific sulfoxide epimers in distinct regions of the peptide.   
 160 
Our research efforts were motivated by the lack of peptidomimetics which can 
incorporate a range polar functional groups.  It has been observed that the hydrophobic 
linkage found in most macrocycles, i.e. stapled peptides can direct interactions with the 
binding site.173,185  While some binding sites are more amenable to hydrophobic crosslinks, 
other sites have a more hydrophilic nature.  We worked to develop a strategy that adds a 
range of potential polarities to identify optimal peptidomimetics for specific PPIs.  Our 
interest with the thiol-ene reaction was due to the capability of incorporating various 
oxidation states to a specific thioether within the peptide macrocycle, of which we are 
unable to achieve with our previously reported strategy utilizing dibromoalkanes (Chapter 
3).  Tuning one or two thio-ethers into a variety of oxidation states would further add 
opportunities for optimized macrocyclic ligands that have not been previously utilized.   
 
S S
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DMPA, 365 nm λν
n
*
* Sulfur Functionality
S
O
S
O
S
O
*
Sulfoxide
Sulfone
Sulfonium ion
Figure 4.1 Thiol-ene approach to incorporating one oxidizable thiol into thioether crosslinked 
peptides. Thiol-ene reaction initiated with 2,2-dimethoxy-2-phenylacetephenone (DMPA) and 365 
nm light to form a bisthioether linkage. 
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4.2  Results and Discussion 
Using 365 nm light to initiate an –ene radical reaction, thiols could selectively react 
to form a thioether-bridged macrocycle, Figure 4.1.212 This reaction could potentially be 
done either on resin or in solution, and can be monitored through HPLC.  A number of 
applications of the thiol-ene reaction has been employed, including 
glycopolypeptides213,214 and polymerization reactions.215   While the reaction proceeds 
robustly with excess –ene, our method will not allow for more than a 1:1 ratio of thiol to –
ene, as the reaction will proceed intramolecularly, Figure 4.1. 
In order to incorporate the non-natural alkenyl substituent for crosslinked peptides, 
we developed a three step synthetic route for the synthesis of Fmoc-S-alkenyl cysteine 
(Figure 4.2).  An initial esterification reaction with chlorotrimethylsilane in methanol 
generates a methyl ester 1 in a 78% yield.216 Alkylation driven by the base, cesium 
carbonate, affords the N-Fmoc-S-butenyl-L-cysteine methyl ester 2 in 87% yield using the 
modified protocol of Salvatore et al.217 The final product, N-Fmoc-S-butenyl-L-cysteine 3, 
is obtained in 40% yield after a carboxylated displacement reaction with lithium iodide in 
refluxing ethyl acetate.218,219 This amino acid can be incorporated into solid phase peptide 
synthesis in preparation for the thiol-ene reaction, and varying alkenyl linker lengths can 
be utilized to identify optimal lengths for the helical construct.  This synthesis simplifies 
the on-resin chemistry by removing the multiple steps of incorporating orthogonal cysteine 
protecting groups resulting in subsequent deprotection of one group, alkylation, and 
deprotection of the second cysteine.  Furthermore, the synthesis of the non-natural cysteine 
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amino acid allows for oxidation before incorporation into the peptide.  This allows for two 
different oxidation states to be incorporated at two different sites. 
 
 
To test the reactivity of the Fmoc-S-alkenyl-cysteine, we first investigated how the 
Fmoc-S-butenyl-cysteine, 3, could react with an exogenous thiol, b-mercaptoethanol, 
Fmoc
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O
SH
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N
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H
N
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O
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H
N
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O
S
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78%
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1
1
2
2 3
Figure 4.2 Three step synthetic Scheme for Fmoc-S-butenyl Cysteine with initial methyl-ester formation, 
alkylation of the thiolate, and final deprotection to afford the acid. 
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Figure 4.3.  Over one hour with 10 mol% DMPA photoinitiator, and 3 equivalents of thiol, 
the reaction afforded product, as observed through the diminishing alkene protons at 5.05 
ppm, Figure 4.4. Alkene protons were compared to the Fmoc aryl proton 2H doublet 
resonance at 7.75 ppm.  Due to Fmoc-protecting group susceptibility to weak bases, only 
1.75 eq. of the alkenyl protons are observed. After one hour, a substantial reduction (83%) 
of the alkenyl protons was observed, indicating product, 4, has formed.  ESI-MS confirmed 
the final product mass, [M+H] = 442.4.  
 
 
 
 
 
Figure 4.3 Synthetic Scheme thiol-ene reaction with exogenous thiol on Fmoc-S-butenyl-Cysteine. 
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To evaluate racemization of the a-carbon on cysteine, we synthesized a tripeptide 
(Gly-Cysbutenyl-Phe). Monitoring racemization using RP-HPLC, we identified 95% of 
peptide stays in the L-configuration, with 5% conversion to the D-Cysteine, Figure 4.5. 
We compared the retention times of a Gly-Cys-Phe peptide with either L-Cys or D-Cys 
incorporated.  We again see the retention time to be about 2 minutes different with the Gly-
Cys(L)-Phe eluting earlier than Gly-Cys(D)-Phe, Figure 4.5. 
 8.0  7.5  7.0  6.5  6.0  5.5  5.0 [ppm]
1.75
0.304
2.00
Fmoc
H
N
S
OH
O
Fmoc
H
N
S
OH
O
S
OH
Starting material 1H-NMR
Product 1H-NMR
2.00
Figure 4.4 Thiol-ene reaction monitored with 1H-NMR. 
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 Since we observed the thiol-ene reaction to proceed with exogenous thiol, we then 
evaluated the reactivity of an intramolecular thiol-ene reaction between residues on the 
same face of an a-helical peptide.  We tested our method on a short 12-residue peptide, 
MLL, which binds to the KIX protein. Replacement of the methionine residue for Fmoc-
S-butenyl-Cysteine or Fmoc-S-pentenyl-Cysteine using solid phase peptide synthesis. A 
cysteine residue was placed 7 residues away, which could then react with the alkene. The 
thiol-ene reaction was carried out off-resin using 365 nm UV light and a catalytic photo-
initiator.17,18 The reaction was tested with a number of variables, including the linker 
length, the distance between the linkage (3,4, or 7 residues), the photoinitiator, the amount 
G-Cd-F
G-CL-F
H2N
O
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N
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L D
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Figure 4.5 Racemization of tripeptide with 5% racemization to D-Cysteine. 
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of photoinitiator, the solvent, and the light source, Table 4.1. Even with all these varied 
methods, we were still unable to achieve product. A competing product, where the thiols 
form intermolecular disulfide bonds was observed. If this side-reaction can be prevented, 
we may be able to obtain product; therefore, further investigation into reducing disulfide 
formation is on-going.   
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4.3  Conclusion 
The strategy to utilize a thiol-ene reaction may prove to be of benefit in identifying 
high affinity, cell permeable peptidomimetics. Incorporating non-natural S-alkenyl 
cysteine derivatives will allow for varying oxidation states at only one cysteine position 
within the peptide construct. We have observed reactivity with exogenous thiol and a non-
natural cysteine, but have been unsuccessful towards an intramolecular reaction within a 
peptide. A few factors may be disrupting the formation of the macrocycle including 
disulfide formation, type of initiator, solvent, and UV source. The suppression of the 
disulfide formation by purging the vial with nitrogen prior to irradiation may prove to be 
     Table 4.1 Thiol-ene reaction variables evaluated 
Sample Solvent Conc. (mM) 
DMPA 
mol% 
DMPA 
addition 
(min) 
Time 
(min
) 
Light 
Source 
Ac-SKICDFVC(S-butenyl)KNTY-NH2 
DMSO 
+ DTT 6.5 10% 0, 20 60 
UV 
Lamp 
Ac-SKICDFVC(S-butenyl)KNTY-NH2 DSMO 6.5 10% 0, 20 60 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 
1:1 
DMF:D
MSO 3.2 90% 0 120 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 DMSO 3.2 45% 
0, 30, 60 
90 120 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 DMSO 6.4 45% 
0, 30, 60 
90 120 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 
1:1 
DMF:D
MSO 3.2 45% 0 10 
Rayonett 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 
1:1 
DMF:D
MSO 3.2 10% 
0, 20, 40, 
60, 80, 
100 120 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 DMSO 3.725 45% 0, 20 30 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 
1:1 
DMF:D
MSO 3.725 45% 0, 20 30 
Ac-SKIC(S-butenyl)DFVCKNTY-NH2 DMSO 7.45 45% 0 10 
Ac-SKICDFVC(S-pentenyl)KNTY-NH2 
DMSO 
+ DTT 6.5 10% 0, 20 60 
UV 
Lamp 
Ac-SKICDFVC(S-pentenyl))KNTY-
NH2 DSMO 6.5 10% 0, 20 60 
Ac-SKIC(S-pentenyl))DFVCKNTY-
NH2 
1:1 
DMF:D
MSO 3.2 90% 0 120 
Ac-SKIC(S-pentenyl)DFVCKNTY-NH2 DMSO 3.2 45% 
0, 30, 60 
90 120 
Ac-SKIC(S-pentenyl)DFVCKNTY-NH2 DMSO 6.4 45% 
0, 30, 60 
90 120 
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of benefit, and we are currently investigating this avenue, as well as an increase in UV 
power.  
4.4  Future Works 
4.4.1  Oxidation states used to tune polarity 
The ability to modify cysteine residues (Figure 4.6) into sulfones 5 or sulfoxides 7 
allows for various polarities to be analyzed. With hydrocarbon staples, the hydrophobic 
chain is well suited to interact with the hydrophobic binding surface and increase its 
affinity, as seen with Bim-SAHB stabled peptides.22 In other cases, an increase in polarity 
of the linker allowed for greater affinity. This shows the importance and variability of 
polarity within the targeted binding interaction. Expanding the options with tunable 
oxidation states allows for optimization of an inhibitor. Researchers have noticed the 
difficulty of negatively charged peptides on cellular uptake.51 By converting thiols into 
sulfonium ions 6, the net charge of a peptide can be increased.211 Exploiting oxidation 
states may allow researchers to find suitable macrocyclic peptides that can successfully 
target and inhibit a range of PPIs. 
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In determining the optimal polarity, synthesis of Fmoc-S-butenyl-L-cysteine amino 
acids that can be oxidized to sulfones (5), sulfonium ions (6), or sulfoxides (7) prior to 
peptide synthesis would allow for a simplistic route to various oxidative peptide derivatives 
(Figure 4.6). Following a previously described protocol, we can use hydrogen peroxide 
and formic acid to form the sulfones or performic acid for sulfoxide formation.181  
Subsequent thioethers can further be alkylated at low pH to form sulfonium ions.211  
Additionally, the alkylation is orthogonal to all other amino acids under these acidic 
conditions.220,221 
 
 
 
 
Figure 4.6 Oxidation of thiol groups for incorporation into solid phase peptide synthesis (SPPS) 
allowing for optimal polarity of stabilized peptides. 
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4.5  Experimental 
4.5.1  Small molecule synthesis 
 
N-Fmoc-L-cysteine methyl ester (1) 
 
Chlorotrimethylsilane (0.55 mL, 3.645 mmol) was diluted to MeOH (5 mL) and 
stirred.  N-Fmoc-L-cysteine (250 mg, 0.729 mmol) was then added, and the reaction 
mixture was stirred at ambient temperature for 2 h.  The formed precipitate was then 
separated via vacuum filtration, washed with hexanes (2 × 3 mL), and dried under high 
vacuum yielding 1 as a white powder (203 mg, 0.568 mmols, 78% yield). Optical Rotation 
 [a]D23  + 8.813 (c 1.112, DCM),  1H NMR (300 MHz, CDCl3) δ 2.98-3.02 (dd, 2 H, J=2.4, 
7.5), 3.81 (s, 3 H), 4.24-4.26 (t, 2 H, J=6.9), 4.45 (dd, 2 H, J=2.4, 7.2), 4.65-4.69 (dt, 1 H, 
J=4.2, 7.8), 5.68 (d, 1 H, J=7.5), 7.33-7.44 (cm, 4 H), 7.60-7.63 (d, 2 H, J=7.2), 7.76-7.79 
(d, 2 H, J= 6.9). 
N-Fmoc-S-butenyl-L-cysteine methyl ester (2) 
 
N-Fmoc-L-cysteine methyl ester (168.0 mg, 0.470 mmol) was diluted in 10 mL of 
anhydrous N,N dimethylformamide (DMF) and stirred.  Cesium carbonate (270. mg, 0.564 
Fmoc
H
N
SH
OCH3
O
Fmoc
H
N
S
OCH3
O
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mmol) and 4-bromo 1-butene (318. mg, 2.35 mmol) were added, and the reaction mixture 
was stirred at ambient temperature for 1.5 h.  Reaction was quenched with ammonium 
chloride and extracted ethyl acetate (EtOAc, 3×).  The organic layers were combined and 
washed with water (3×), brine (1×), dried over magnesium sulfate (MgSO4), and 
concentrated under high vacuum. The residue was purified via flash column 
chromatography (4:1 hexanes: EtOAc) to yield a yellowish powder (167 mg, 0.406 mmols,  
87% yield). ESI-MS confirmed the final product mass, [M+Na] = 434.138, theoretical 
[M+Na] = 434.14. Optical Rotation  [a]D23 + 7.22 (c 0.96, DCM). 1H NMR (300 MHz, 
CDCl3) δ 2.316 (dt, 2 H, J = 7.5, 14.4), 2.60 (t, 2 H, J = 7.2), 3.016 (d, 2 H, J = 5.1), 3.77 
(s, 3 H), 4.243 (t, 1 H, J = 6.9), 4.392 (d, 2 H, J = 7.2), 4.615 (dt, 1 H, J=4.2, 7.8), 5.05 (dd, 
1 H, J=1.2, 3), 5.110 (dd, 1 H, J=3, 4.5), 5.63 (d, 1 H, J = 7.5), 5.78 (ddt, 1 H, J=6.9, 10.2, 
13.5), 7.33-7.44 (cm, 4 H), 7.60-7.63 (d, 2 H, J=7.2), 7.76-7.79 (d, 2 H, J= 6.9). 
N-Fmoc-S-pentenyl-L-cysteine methyl ester 
 
N-Fmoc-L-cysteine methyl ester (500 mg, 1.39 mmols) was dissolved in 10 mL of 
anhydrous N,N dimethylformamide (DMF) and stirred.  Cesium carbonate (798 mg, 2.43 
mmols) and 5- bromo 1-pentene (1.04 g, 0.825 mL) were added, and the reaction mixture 
was stirred at ambient temperature for 1.5 h.  Reaction was quenched with ammonium 
Fmoc
H
N
S
OCH3
O
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chloride and extracted ethyl acetate (EtOAc, 3×).  The organic layers were combined and 
washed with water (3×), brine (1×), dried over magnesium sulfate (MgSO4), and 
concentrated under high vacuum. The residue was purified via flash column 
chromatography (4:1 hexanes: EtOAc) to yield a yellowish powder (0.417 mmols, 0.177 
g, 30% yield).  ESI-MS confirmed the final product mass, [M+Na] = 448.155, theoretical 
[M+Na] = 448.16. Optical Rotation  [a]D23 + 6.568 (c 1.00, DCM). 1H NMR (300 MHz, 
CDCl3) δ 1.6927 (dt, 2H, J = 7.85, 14.49), 2.1645 (tt, 2H 8.19, 14.04), 2.5588 (t, 2H, J = 
7.39), 3.029 (d, 2H, J = 3.08),  3.81 (s, 3 H), 4.268 (t, 1 H, J = 7.17), 4.433 (d, 2 H, J = 
7.17), 4.615 (dt, 1 H, J=4.2, 7.8), 5.05 (dd, 1 H, J=1.2, 3), 5.110 (dd, 1 H, J=3, 4.5), 5.63 
(d, 1 H, J = 7.5), 5.78 (ddt, 1 H, J=6.9, 10.2, 13.5), 7.33-7.44 (cm, 4 H), 7.60-7.63 (d, 2 H, 
J=7.2), 7.76-7.79 (d, 2 H, J= 6.9). 
N-Fmoc-S-butenyl-L-cysteine (3) 
 
N-Fmoc-L-cysteine methyl ester (155 mg, 0.377 mmol) was dissolved in 1.9 mL 
ethyl acetate (0.2 M) and lithium iodide (252 mg, 5 eq), and stirred at reflux for 16 h. Upon 
completion, the reaction was acidified with 0.1 M HCl and extracted (1×) into EtOAc.  The 
organic layers were combined and washed with water and brine, and extracted into 0.1 M 
NaOH (3×), washed with DCM (1×), acidified with 0.1 M HCl and extracted into EtOAc 
(3×).  The organic layer was washed with sodium thiosulfate (1×), brine (1×), and dried 
Fmoc
H
N
S
OH
O
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under high vacuum.  The residue was purified via flash column chromatography (97:2:1 
dichloromethane: isopropanol: acetic acid) to yield a white powder (39.0 mg, 40%). ESI 
theoretical [M+Na] = 420.12, observed [M+Na] = 420.4. Optical Rotation  [a]D23 - 1.81 (c 
1.29, DCM),  (10 replicate measurements in DCM).   1H NMR (300 MHz, CDCl3) δ 2.316 
(dt, 2 H, J = 7.5, 14.4), 2.60 (t, 2 H, J = 7.2), 3.016 (d, 2 H, J = 5.1), 4.243 (t, 1 H, J = 6.9), 
4.392 (d, 2 H, J = 7.2), 4.615 (dt, 1 H, J=4.2, 7.8), 5.05 (dd, 1 H, J=1.2, 3), 5.110 (dd, 1 H, 
J=3, 4.5), 5.63 (d, 1 H, J = 7.5), 5.78 (ddt, 1 H, J=6.9, 10.2, 13.5), 7.33-7.44 (cm, 4 H), 
7.60-7.63 (d, 2 H, J=7.2), 7.76-7.79 (d, 2 H, J= 6.9). 
N-Fmoc-S-pentenyl-L-cysteine  
 
N-Fmoc-L-cysteine methyl ester (89 mg, 0.209 mmol) was dissolved in 1.9 mL 
ethyl acetate (0.2 M) and lithium iodide (139.9 mg, 5 eq), and stirred at reflux for 16 h. 
Upon completion, the reaction was acidified with 0.1 M HCl and extracted (1×) into 
EtOAc.  The organic layers were combined and washed with water and brine, and extracted 
into 0.1 M NaOH (3×), washed with DCM (1×), acidified with 0.1 M HCl and extracted 
into EtOAc (3×).  The organic layer was washed with sodium thiosulfate (1×), brine (1×), 
and dried under high vacuum.  The residue was purified via flash column chromatography 
(97:2:1 dichloromethane: isopropanol: acetic acid) to yield a white powder (80.3% yield) 
ESI-MS confirmed the final product mass, [M+Na] = 448.155, theoretical [M+Na] = 
Fmoc
H
N
S
OH
O
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448.16. Optical Rotation [a]D23 = - 1.206 (c 0.995, DCM),  (10 replicate measurements in 
DCM).   1H NMR (300 MHz, CDCl3) δ 1.6927 (dt, 2H, J = 7.85, 14.49), 2.1645 (tt, 2H 
8.19, 14.04), 2.5588 (t, 2H, J = 7.39), 3.029 (d, 2H, J = 3.08), 4.268 (t, 1 H, J = 7.17), 4.433 
(d, 2 H, J = 7.17), 4.615 (dt, 1 H, J=4.2, 7.8), 5.05 (dd, 1 H, J=1.2, 3), 5.110 (dd, 1 H, J=3, 
4.5), 5.63 (d, 1 H, J = 7.5), 5.78 (ddt, 1 H, J=6.9, 10.2, 13.5), 7.33-7.44 (cm, 4 H), 7.60-
7.63 (d, 2 H, J=7.2), 7.76-7.79 (d, 2 H, J= 6.9). 
 (4) 
 
N-Fmoc-S-butenyl-L-cysteine (0.0378 mmols) was dissolved in DMF (0.5 M).  b-
mercaptoethanol (3 eq., 0.113 mmols) was added along with 10 mol % DMPA.  A 365 nm 
UV lamp irradiated the sample for 1 h.  A microscale pipette column was used to purify 
the sample.  ESI-MS confirmed the final product mass, [M+H] = 442.4, theoretical [M+H] 
= 442.18. 
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N-Fmoc-L-cysteine methyl ester 
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N-Fmoc-S-pentenyl-L-cysteine methyl ester  
 
Acetone
[ppm] 8  6  4  2  0 
[re
l]
 0
 
 2
 
 4
 
 6
 
 8
 
 1
0 
 1
2 
 1
4 
MJH_Fmoc-Cys-But-OCH3  10  1  C:\Users\pere0176\Desktop\NMR_Data
Fmoc
H
N
S
OCH3
O
 177 
 
N-Fmoc-S-butenyl-L-cysteine 
 
[ppm] 8  6  4  2 
[ r
e l
]
 0
 
 1
0  
 2
0  
 3
0  
GTP_penetene  10  1  C:\Users\pere0176\Desktop\NMR_Data
Fmoc
H
N
S
OH
O
 178 
 
N-Fmoc-S-pentenyl-L-cysteine 
 
[ppm] 10  8  6  4  2 
[ r
e l
]
 0
 
 2
 
 4
 
 6
 
 8
 
 1
0  
 1
2  
 1
4  
wpogtp-141117-4  10  1  C:\Users\pere0176\Desktop\NMR_Data
Fmoc
H
N
S
OH
O
 179 
 
 
 (4) 
 
[ppm] 8  6  4  2 
[ r
e l
]
 0
 
 1
0  
 2
0  
 3
0  
GTP_penetene  10  1  C:\Users\pere0176\Desktop\NMR_Data
H
NO
O
S
S
OH
OHO
 180 
 
 
 
 
 
 
 
 
 
 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
-20
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
131015v3_3102
GTP_thiolene
University of Minnesota
Department of Chemistry
VAC-300
 181 
Chapter	  5.  Specific	  Acetylation	  Patterns	  of	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5.1  Introduction  
5.1.1  Epigenetics 
Epigenetics is the study of the alterations in phenotype due to a change in gene 
expression without modification of the genetic code. Much of the genome function is 
enoded by the DNA sequence and regulating transcriptional factors; however, depending 
on external stimuli, identical genomes can lead to varied levels and gene expressions. This 
variated interpretation is driven by the changes within packaged DNA. Epigenetics plays 
an important role in regulating gene transcription as well as the alterations within 
chromatin which lead to different patterns of expression. These chemical variations, termed 
post translational modifications (PTMs), can include lysine acetylation, methylation, 
ubiquitinylation, and serine or threonine phosphorylation can associate with DNA, or can 
occur on the DNA template itself, such as cytosine methylation. Researchers are 
discovering the scope and effect these dynamic, reversible processes can play within both 
healthy and diseased states.  
PTMs occur within the chromatin, which is created through the packaging of DNA into 
tightly wound bundles. There are ~ 147 base pairs of DNA wrapped around eight of four 
highly conserved histone proteins (H3, H4, H2A, and H2B) that comprise chromatin. The 
organization of DNA into compact structures greatly influences the activation, or silencing 
of genes. When tightly bound, DNA is inaccessible, leading to the heterochromatin state, 
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Figure 5.1.  When loosely packed with an appearance of ‘beads on a string’, the DNA is 
more accessible, which can lead to active transcription.222 The histone proteins used to 
wrap DNA were initially thought to be static proteins acting as templates only necessary 
as a physical constraint on DNA. Researchers are now understanding the active role histone 
proteins play in gene expression, and recognizing the utility of these key regulators of 
cancer progression, previously thought to have been only implicated with genetic 
mutations.   
 
 
 
Figure 5.1 Varied states of DNA bundles wrapped around histone proteins.  Tightly bundled histones 
lead to an inactive state, heterochomatin, whereas loosely wrapped DNA from an active state is 
termed the Euchromatin state. 
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Modifications of chromatin can directly change DNA through methylation, or chemical 
change histones that interact with DNA through covalent histone modifications.223  This 
chapter will focus specifically on covalent histone modifications.  Many histone alterations 
take place on the tail of the histone, the only unstructured portion of the protein that 
protrudes from the histone bundle (Figure 5.1). These extrusions can interact with other 
proteins, which leads to alterations of the tails through modifications such as acetylation, 
ubiquitination, and methylation. The vast influence histones have on biological diversity 
has led to the idea of a histone language where the encodability of histones are defined 
through the ‘histone code’. There are three distinct roles that define the histone code: 
readers, writers, and erasers.   
5.1.2  Histone Code Writers 
Enzymes that add modifications are histone acetyltransferases and histone 
methyltransferases (HATs and HMTs)—the writers of the histone code that covalently 
crosslinks methyl or acetyl groups. Post-translational modifications of lysine residues on 
the histone tails has been extensively studied. Persuasive evidence has identified 
acetylation or methylation of specific lysine residues on the amino termini of a histone tail 
to regulate transcription.224 One highly studied histone modification is on lysine 27 of H3 
(H3K27). The histone methyltransferase, polycomb repressor complex 2 (PRC2) acts as a 
‘writer’ of the histone code, where the catalytic subunit EZH2 of PRC2 methylates Lys27 
of H3. Lysine methylation has a role in a variety of biological functions including 
heterochromatin formation, X-chromosome inactivation, and transcriptional regulation.225  
Interestingly, lysine has been found to be mutated to a methionine in disease states.226  The 
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methionine mutation is able to diminish methylation of H3K27 through binding to PRC2, 
rendering it unable to methylate Lys27, which ultimately leads to detrimental downstream 
effects such as pediatric glioblastomas.226 Researchers are realizing these modifications are 
central to vast changes in gene expression, and potential manipulation to these such sites 
may provide therapeutic strategies.   
5.1.3  Bromodomains—Readers of the Histone Code 
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A class of ‘reader’ proteins that recognizes acetylated lysine residues on histone 
tails are termed bromodomains. The protein was first identified in 1992 by Tamkun et al. 
when studying the Brahma gene in drosophila.228 They discovered it was necessary for 
activation of a variety of developmental genes, and without brahma function, 
developmental defects would arise. There are currently 61 human bromodomains 
identified, and categorized into 9 groups, based on sequence similarity (>35%) and 
sequence length, Figure 5.2.227,229  The majority of bromodomains have a left-handed four-
helix bundle (az, aA, aB, aC), called the ‘BRD fold’.230  Between the helices Z-A and B-
C is a hydrophobic pocket that binds to acetylated lysine residues. While significant work 
had been done on both ‘writers’ and ‘erasers’, less was done on ‘reader’ proteins such as 
bromodomains.  Not until 2010 was there a submicromolar inhibitor of the histone binding 
modules. Two groups published inhibitors of BRD4, within the bromodomain extra-
terminal (BET) bromodomain family—Bradner and colleagues identified the small 
molecule inhibitor (JQ1),231 and Tarakhovsky and colleagues determined I-BET to be a 
competitive inhibitor.232 Since then, an emergence of research on BET bromodomains 
ensued, which led to the discovery of a variety of small molecule inhibitors.233 Limited 
research has focused on the other 53 bromodomain proteins that do not fit into the BET 
class. The need to probe and understand other classes will be necessary for progression of 
novel bromodomain inhibitors within the field of epigenetics. 
5.1.4  Histone Deacetylases 
The erasers of the histone code, termed histone deacetylases (HDACs), are proteins 
which remove acetyl groups from the N-terminal tail of histones. By removing acetyl 
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groups, a positive lysine residue is revealed. This positive character is hypothesized to 
tighten the histone core into the heterochromatin state, thereby inactivating the histone, and 
down-regulating gene transcription.234  The acetylation state of histones is a key component 
of active gene expression, and an elevated level of HDACs lead to diseased states, such as 
ovarian cancer, and T-cell lymphoma.235 Since HDACs have been identified to associate 
with tumor-suppressor genes, they have been a key target in regards to cancer. 235 The first 
FDA approved HDAC inhibitor, vorinostat was approved for treatment in 2006.236 Since 
then, a flurry of research on HDAC inhibitors has ensued, which may lead to more potent 
inhibitors of oncotargets. 
5.1.5  Histone variants 
Varied isoforms of all four main histone proteins have been identified.237  These slight 
variations in amino acid sequence can lead to significant changes in expression.237 An 
interesting variant of the H2A histone is the H2A.Z variant, which has 60% sequence 
similarity to H2A, and is highly conserved (90%) from yeast S. cerevisiae to humans.238  
H2A.Z has been involved in numerous biological processes including gene activation, 
chromosome segregation, heterochromatin silencing, and cell cycle progression.239 One 
interesting regulatory effect involves the deletion of glycine at position 98 found within 
H2A.Z, which causes significant changes to the secondary structure. The mutation causes 
an extended  a-helical structure on H2A.Z, which doubles the length of the helix.240 The 
extension leads to an interaction with an H2A.Z chaperone, acidic nuclear phosphoprotein 
32 kilodalton e(ANP32E). The chaperone preferentially interacts with the H2A.Z/H2B 
dimer, but not H2A/H2B dimer.241 The extended a-helix is also incompatible with 
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nucleosome binding, and aids in the eviction of the H2A.Z histone.240 This highlights the 
dramatic impact small changes in primary sequence can have on histone dynamics.   
5.1.6  Malarial H2A.Z  
Plasmodium falciparum is a deadly parasite to humans that causes malaria in more than 
800,000 individuals per year.242 This parasite has vast detrimental effects on both the 
economics and health of the human population. The parasitic virulence (var) gene 
expression dictates the pathogenicity by being turned on.  There are 60 var genes within 
P. falciparum that have mutually exclusive expression to another, where only one gene 
will be active at a time, whereas the rest will be repressed.  Epigenetics plays a key role in 
var expression by activating and silencing them based on the chromatin structure dictated 
through posttranslational modifications of the histones.      
The lysine acetyltransferase domain of PfGCN5 is known to acetylate H3K9 and 
H3K14.243  Researchers have identified histone acetyltransferases as a potential target to 
turn off var gene expression levels, which leads to a decrease in the levels of parasitic 
growth.244  Understanding the role histones play within epigenetic systems of P. falciparum 
may lead to anti-malarial therapeutics.    
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5.2  Specific Acetylation Patterns of H2A.Z Form Transient Interactions with the 
BPTF Bromodomain   
Reproduced with permission from “Specific Acetylation Patterns of H2A.Z Form 
Transient Interactions with the BPTF Bromodomain” Gabriella T Perell, Neeraj K. Mishra, 
Babu Sudhamalla, Peter D. Ycas, Kabirul Islam, William C. K. Pomerantz, Biochemistry 
2017, Accepted Author Manuscript. Copyright 2017 ACS. 
 
Motivation: 
While acetylation states have been shown to be necessary with the four canonical 
histones to be read by bromodomains, it has been less extensively evaluated with a highly 
conserved H2A variant, H2A.Z.  We sought to understand which, if any, acetylation pattern 
on H2A.Z binds to specific bromodomains, since no direct interaction had been observed 
previously.  
5.2.1  Introduction  
Chromatin structure is dynamically regulated via post-translational modifications 
to both DNA and bound histone proteins. The nucleosome particle comprises 
approximately 147 base pairs of DNA surrounding an octameric bundle of four conserved 
histones: H2A, H2B, H3, and H4. This assembly provides a scaffold for recruiting 
transcription factors to accessible genomic regions for modulating transcription.245  
Histone acetylation is one such modification recognized by bromodomain effector modules 
and subsequently results in the recruitment of the transcriptional machinery. In addition to 
conserved histones, histone variants can be exchanged into nucleosomes dramatically 
affecting chromatin stability,246 and provide an additional mechanism for transcriptional 
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control.247  Here, we evaluate interactions of the histone variant H2A.Z with a select set of 
bromodomains.  
      H2A.Z is a non-conserved histone variant commonly found at transcription start 
sites,248,249 leading to a destabilized nucleosome.250  H2A.Z levels positively correlate with 
the activating histone mark, H3K4me3 and negatively correlate with the repressive 
modification,  H3K27me3.251–253 H2A.Z histones are spread throughout the promoter of 
inactive genes in the un-acetylated state, but they are acetylated near highly localized 
transcription start sites (TSS).254 In yeast, the acetyltransferase, GCN5 acetylates N-
terminal lysines of H2A.Z with a preference towards acetylation of K14.255 Accumulation 
of hyperacetylated levels of H2A.Z at the TSS have been correlated with high levels of 
proliferative gene expression in bladder cancer,256 melanoma,257 and liver cancer.258  
However, the role and mechanisms employed by H2A.Z for regulating disease states are 
still being uncovered.  
Histone chaperones also play a key role in the removal and addition of the H2A 
variant.259,260 Recently, the histone chaperone ANP32e was identified to selectively remove 
H2A.Z from the nucleosome240 and the SWR1 complex has been identified to catalyze the 
exchange of H2A with H2A.Z. The recruitment of SWR1 is partly directed through 
bromodomain subunit of SWR1, Bdf1, which identifies acetylated histone tails on H3 and 
H4.261,262 While the acetylation state of H2A.Z correlates with disease states254 and 
epigenetic control.263 To date, direct bromodomain interactions with acetylated H2A.Z 
histones have not been systematically evaluated. An understanding as to which, if any, 
acetylation states on H2A.Z are necessary to bind bromodomains would further elucidate 
the role H2A.Z plays in gene regulation.  
 190 
The bromodomain and PHD finger-containing transcription factor BPTF, has 
recently been described to serve an important regulatory role in cell cycle progression, 
proliferation, development, and the immune response;264,265 furthermore, high levels of 
BPTF correlate with poor patient prognoses in various cancers.266–268  One role of BPTF as 
a potential oncoprotein has been supported via identification of a c-Myc protein-protein 
interaction at low affinity interaction sites on chromatin, thus leading to BPTF’s association 
with various Myc-dependent cancers.269,270 Recently, it has been shown that BPTF 
selectively immunoprecipitated H2A.Z-containing nucleosomes over H2A-containing 
nucleosomes.271,272  Further, knockdown of either BPTF or H2A.Z decreased the mRNA 
levels of ten elevated genes in bladder cancer that have H2A.Z enrichment near their 
TSS.271  Based on these results, we sought to test if these effects were regulated via a direct 
interaction of the BPTF bromodomain with the acetylated H2A.Z histone as a potential 
mechanism for regulating transcription.  
5.2.2  Results 
 
5.2.2.1   Evaluation of Acetylation Patterns on H2A.Z with 5FW-BPTF Using PrOF 
NMR      
Bromodomain-histone interactions are characteristically weak interactions with 
measured affinities at mid-micromolar to millimolar levels.273 For example, the BPTF 
bromodomain has been characterized to recognize acetylated lysine 16 of histone H4 
(H4acK16) with Kd = 99-210 µM affinity by ITC and fluorescence polarization, 
respectively, whereas the adjacent PHD domain of BPTF binds H3K4Me3 with a Kd = 1.6-
2.7 µM, Figure 5.3.274 Therefore, to characterize weak binding interactions with the BPTF 
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bromodomain, we turned to NMR spectroscopy which is capable of accurate quantitation 
of micromolar and millimolar dissociation constants.  
 
Figure 5.3 Proteins and ligands characterized in this study (A) BPTF sequence with varying domains 
including the DNA binding homeobox and Different Transcription factors (DDT), two plant homeodomain 
(PHD) fingers, and bromodomain (BRD). W2824 which is modified in this study is indicated for clarity. (B) 
BPTF bromodomain with W2824 highlighted (orange) in complex with H4AcK16 (purple) (PDB ID: 3QZS). 
(C) BPTF small molecule ligands NH2-AU1 and bromosporine and peptide ligands H2A.Z and H4AcK16. 
Acetylatable lysines shown in purple. 
 
Protein-observed 19F NMR (PrOF NMR) has become a useful method for 
characterizing protein-ligand interaction binding sites and quantifying affinity, particularly 
for weakly binding ligands.275,276 In the case of several bromodomains, there is a tryptophan 
that is part of a three-residue hydrophobic region called the WPF shelf.  This tryptophan is 
near the histone binding site and has been used for detecting binding events by PrOF NMR, 
including with BPTF.198 For studies presented here, a single fluorinated BPTF 
bromodomain was expressed with W2824 fluorine-labeled as 5-fluorotryptophan using 
previously reported methods, and defined as 5FW-BPTF for this report.192 This protein 
construct was used to characterize the affinity of all peptides described in this report.  
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Figure 5.4 PrOF NMR experiments with H4AcK16 binding to 5FW-BPTF. (A) binding isotherm of 
H4AcK16 binding to 5FW-BPTF with Kd = 300 µM. (B) Overlaid 19F NMR spectra with increasing 
concentration of H4AcK16 peptide with 47 µM BPTF.   
 
    To benchmark our method, we first characterized the interaction between the 
BPTF bromodomain and a 20-residue peptide of the N-terminal region of H4acK16. 
Titration of this peptide with the fluorinated bromodomain and measurement of the change 
in chemical shift of W2824 of BPTF yielded a Kd of 300 µM (Figure 5.4A), comparable 
to the reported affinity determined by fluorescence polarization of 210 µM.274 The slight 
difference may correspond to experimental conditions, or a small perturbation from 
fluorine incorporation. We next turned our attention to H2A.Z. H2A.Z is found in two 
isoforms, I and II. We elected to study a 20-residue peptide of H2A.Z I with an N-terminal 
tyrosine residue as a chromophore for accurate concentration determination, as isoform I 
has been researched more extensively than isoform II. This peptide will be called H2A.Z 
for the rest of the manuscript. There are five lysine residues in the active portion of H2A.Z 
that can potentially be acetylated and ‘read’ by BPTF (K4, K7, K11, K13, and K15). To 
identify which, if any, acetylation state was necessary to bind BPTF, we acetylated the 
lysine residues in various mono-, di-, tri-, tetra-, and penta-acetylated patterns. Using 19F 
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NMR we followed the shift of a single fluorine resonance from the 5-fluorotryptophan 
incorporated in BPTF (Figure 5.5A). An initial study of singly-acetylated lysine residues 
showed H2A.Z AcK4, -AcK7, and -AcK11 to have the greatest affinities (~ 1.2-1.3 mM, 
Figure 3B, C), whereas H2A.Z AcK15 and the un-acetylated histone displayed either non-
saturating binding or no binding behavior.  
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Figure 5.5 H2A.Z fluorine NMR binding experiments with BPTF. (A) PrOF NMR titration overlay with 
increasing concentrations of H2A.Z AcK4,11 shifting the 5-fluorotryptophan resonance on BPTF (50 µM 
protein). (B) H2A.Z histone peptide binding isotherms with various mono-acetylated states. (C) Dissociation 
constants determined using PrOF NMR on H2A.Z acetylated histone variants binding to 5FW-BPTF (N.B. 
= non-binding, N.S. = non-saturating). (D) An array of di-, tri-, tetra-, and penta-acetylated H2A.Z peptide 
PrOF NMR binding isotherms with BPTF. Dissociation constants are indicated with corresponding fitting 
error from nonlinear regression analysis. 
 
Based on the singly-acetylated histone results and the known effects of 
hyperacetylated histones at TSS,277 we then tested an array of di-, tri-, tetra-, and penta-
acetylated histone peptides (Figure 5.5D). From these titrations, di-acetylated histone 
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H2A.Z AcK 4, 11 showed the highest affinity towards 5FW-BPTF with Kd = 780 µM and 
modest selectivity over the other acetylation patterns. H2A.Z AcK 4,7 also had increased 
affinity compared to other acetylation patterns, with a Kd = 990 µM. Higher acetylation 
states which included AcK4 and 11 led to attenuated binding, indicating avidity effects 
from hyperacetylation also do not promote this interaction. We conclude from these 
studies, that the BPTF bromodomain is capable of binding acetylated H2A.Z histones, 
albeit weaker than conserved histone H4AcK16.  
5.2.2.2   Various Bromodomains Evaluated for Affinity Towards H2A.Z AcK4, 11 
 We selected four additional bromodomains as an initial evaluation if H2A.Z AcK4, 
11 was a preferred acetylation pattern for BPTF over other bromodomains. Two 
bromodomains we selected from the bromodomain and extraterminal (BET) family, Brd4 
and BrdT contain a WPF shelf similar to BPTF. We selected another bromodomain, GCN5 
from plasmodium falciparum (PfGCN5), which also contains a WPF shelf, and is predicted 
to be structurally related to BPTF based on the phylogenetic tree analysis with human 
GCN5L2 and BPTF. A fourth unrelated malarial bromodomain which does not contain a 
WPF shelf, PFA0510w was also evaluated. Malarial bromodomains were selected because 
within P. falciparum, the multi-gene var has shown to enrich both H2A.Z nucleosomes 
and H2B.Z, indicating these variants may have a specific functionality in regards to P. 
falciparum virulence.242  
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Figure 5.6 PrOF NMR titrations with various bromodomains and ligands.  Stacked spectra with increasing 
concentration of H2A.Z AcK4,11 titrated into A. PfGCN5 B. PFA0510w C. BrDT D. BrD4. In the case of 
BrdT, the only the non-WPF shelf resonance for W44 moves, consistent with binding somewhere outside the 
histone binding site.  E. Bromosporine titrated into PfGCN5 F. The Intermediate-slow exchange exhibited 
by bromosporine binding is consistent with a high affinity interaction.  Based on this perturbation, the 
downfield resonance is tentatively assigned as the WPF-shelf tryptophan, W1379.  F)  Bromosporine titrated 
into BPTF exhibits intermediate to fast exchange binding kinetics, consistent with a weaker affinity 
interaction than with PfGCN5. 
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  A PrOF NMR titration indicated that H2A.Z AcK4, 11 exhibited weaker affinity 
towards the BET bromodomains (Figure 5.7 A, B) with Kd =1.5 and 4.2 mM for the N-
terminal bromodomains of Brd4 and BrdT respectively. In the case of the Brd4 
bromodomain, only the resonance for W81 was perturbed consistent with binding near the 
histone recognition site.  However, in the case of BrdT, the WPF shelf resonance W50, was 
not affected, and only the resonance for W44 was perturbed.  This latter interaction with 
BrdT may thus be a weak nonspecific binding event. Alternatively, PfGCN5 showed a 
significant perturbation of the downfield fluorinated tryptophan resonance at -125.5 ppm 
resulting in an affinity of 0.65 mM, similar to our results with BPTF (Figure 5.7 C, D). 
We tentatively assign this resonance to the tryptophan in the WPF shelf, based on similar 
perturbations of this resonance from PrOF NMR experiments with pan-bromodomain 
inhibitor, bromosporine (Figure 5.6A, Figure 5.8). Finally, because the second PFA0510w 
bromodomain lacks a WPF shelf, we labeled this protein with 3-fluorotyrosine, due to the 
presence of a conserved tyrosine (Y1235) within the binding site, Figure 5.8. This final 
titration experiment with H2A.Z AcK4, 11 exhibited little chemical shift perturbation, with 
only slight broadening of the upfield resonance at high concentrations, which we attribute 
to a non-specific effect and did not pursue further (Figure 5.6 B). Although the affinity is 
modest, these studies with H2A.Z AcK4, 11 support a preference for the BPTF 
bromodomain and the structurally related PfGCN5 bromodomain, although a larger panel 
of bromodomains would need to be evaluated to define a selectivity profile. 
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Figure 5.7 H2A.Z AcK4,11 histone peptide PrOF NMR binding isotherms with bromodomains (A) Brd4 
(B) BrdT (C) BPTF and (D) malarial bromodomain PfGCN5. Dissociation constants are indicated with 
corresponding fitting error from nonlinear regression analysis.  
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Brd4
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Figure 5.8 Five bromodomain-containing proteins shown in gray, with either tryptophan or tyrosine 
residues shown as sticks (red). (A) Brd4 with three tryptophan residues where W81 is part of the WPF-
shelf (PDBID: 5HLS). (B) BrdT with two tryptophans, W50 part of the WPF-shelf (PDBID: 4FLP). 
(C) PfGCN5 with two tryptophan residues, W1379 part of the WPF-shelf (PDBID: 4QNS). (D) 
PFA0510w with five tyrosine residues (PDBID: 4PY6). (E) BPTF with one tryptophan residue within 
the WPF-shelf (PDBID: 3UV2). 
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5.2.2.3   Ligand-Observed 1H NMR Competition Experiments 
    Having established an acetylation pattern and preference for the PfGCN5 and 
BPTF bromodomains, we further tested bromodomain binding site engagement versus a 
less specific binding mode using a ligand-observed 1H NMR method, the Carr-Purcell-
Meiboom-Gill (CPMG) competition experiment. The 1H CPMG NMR experiment utilizes 
the transfer in the transverse relaxation time (T2) of the protein to the ligand in the bound 
state which is subsequently filtered out. This transfer is observed as a drop in resonance 
signal intensity when a ligand binds to the protein of interest. Recovery of signal can be 
induced with addition of a high affinity competitor.278 An initial experiment with only 
H2A.Z AcK4,11 shows the two acetyl singlet resonances near 1.88 ppm. When either 
PfGCN5 or the BPTF bromodomain was added, a significant drop in the resonance 
intensity is observed, as expected if the ligand were binding to the bromodomain.  In a 
separate experiment, we validated pan-bromodomain inhibitor bromosporine, binding to 
the PfGCN5 bromodomain by PrOF NMR with high affinity (Figure 5.6). When we added 
bromosporine to PfGCN5, a full recovery of resonance intensity was observed for PfGCN5 
with 400 µM bromosporine (Figure 5.10A). However, in the case of BPTF, only partial 
recovery (34%) was seen upon addition of 400 µM bromosporine. Titration of 
bromosporine with BPTF using PrOF NMR yielded a Kd of 37 µM (Figure 5.9) which 
may be too weak for full displacement of H2A.Z from BPTF, or the compound may 
become aggregated and not soluble at high concentrations. We recently reported on a BPTF 
bromodomain inhibitor AU1 with a Kd of 2.8 µM.198 However, this compound is also not 
soluble at high concentrations.  We therefore used an analog capable of binding to the 
BPTF bromodomain, but with a protonatable benzylic amine for solubility, NH2-AU1. In 
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this case, addition of the inhibitor was able to dose dependently return the resonance 
intensity (75% at 800 µM). The CPMG experiment corroborates our initial assessment in 
that H2A.Z AcK4,11 binds to both BPTF and PfGCN5 and can be competitively displaced 
with small molecule inhibitors which engage the histone binding pocket.  
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Figure 5.9 PrOF NMR binding isotherm with bromosporine binding to BPTF.  Data fit from spectra 
obtained in Figure 5.6 F. 
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Figure 5.10 Ligand-observed 1H NMR CPMG competition experiments for evaluating H2A.Z AcK4,11 
histone binding site occupancy (A) Pf GCN5 and (B, C) BPTF. Experimental spectra are shown for the 
histone alone (black), the histone plus bromodomain (red), and the histone plus bromodomain and increasing 
concentration of inhibitor (blue, green in B) for bromosporine and (blue, green, magenta and gold in (C) for 
BPTF inhibitor NH2-AU1. 
 
5.2.2.4   Photo-crosslinking Captures a Transient Bromodomain Interaction  
Sudhamalla et al. recently showed that photo-crosslinking experiments were 
capable of capturing transient bromodomain histone interactions using a BPTF 
bromodomain analog where the tryptophan in the WPF shelf was replaced with a para-
azidophenylalanine (BPTF-pAzF).279  Without higher resolution structural biology data, 
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we sought to capture the transient bromodomain histone interaction demonstrating 
bromodomain engagement near the WPF shelf. In this final set of experiments, we 
incubated three biotinylated H2A.Z peptide constructs with BPTF-pAzF—unacetylated 
H2A.Z, mono-acetylated AcK15, and di-acetylated AcK4, 11. Using 0.5 and 1.0 mM 
peptide, each solution with BPTF was irradiated with 365 nm light. Photo-crosslinked 
protein-peptide adducts were resolved via gel electrophoresis and detected via western blot 
with an anti-biotin antibody (Figure 5.11). In the case of the un-acetylated H2A.Z, no 
crosslinking was observed. For H2A.Z AcK15, low levels of crosslinking were observed 
consistent with the previously detected weak interactions from PrOF NMR titrations 
(Figure 5.5 B, C). However, for di-acetylated H2A.Z AcK 4, 11 increased crosslinking in 
a dose-dependent fashion was observed. Control experiments showed no crosslinking was 
detected in the absence of photo-irradiation in all cases. We conclude from these studies 
that di-acetylated H2A.Z AcK4, 11 engages the BPTF bromodomain in a manner 
consistent with previously characterized histone interactions.  
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Figure 5.11  (A) pAzido-phenylalanine mutant replaces W2824 in BPTF for photo-crosslinking experiments. 
This residue is part of the acetylated lysine recognition site within the WPF Shelf of BPTF. (B) Photo-
crosslinking anti-biotin western blot analysis of biotinylated H2A.Z variant peptides irradiated with BPTF-
pAzF. Un-acetylated, mono-acetylated, and di-acetylated H2A.Z peptides: unAcK, AcK15, and AcK4,11, 
respectively were tested at 0.5 and 1.0 mM in the presence and absence of UV light.  
 
5.2.3  Discussion  
 
Nucleosomes with histone variant H2A.Z can alter chromatin accessibility, 
particularly near transcriptional start sites, leading to altered transcriptional 
programming.280 Acetylation of H2A.Z was identified to play a fundamental role in 
changing chromatin states. The SWR-1-Com, NuA4, and GCN5 have been identified to 
acetylate H2A.Z,260,281 and ANP32e is able to evict H2A.Z from the nucleosome.240 
However, to date no direct interaction of H2A.Z with a bromodomain had been 
characterized.  Here, we identified specific acetylation states of the H2A.Z histone variant 
that can form transient interactions with the bromodomain of BPTF. All five lysine residues 
within the H2A.Z N-terminal tail were modified in a variety of mono- and multi-acetylated 
patterns. PrOF NMR identified H2A.Z AcK4,11 to have high micromolar affinity towards 
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BPTF (Kd = 780 µM). Acetylation of lysine 15 did not exhibit saturating binding behavior, 
arguing against a promiscuous acetyl-lysine recognition motif. 
      We compare our results with proteomics studies which have characterized 
abundant acetylation states of H2A.Z. In chicken erythrocytes, Dryhurst et al. found a tri-
acetylated version of H2A.Z to be the most abundant where it was specifically acetylated 
at lysine 4, 7, and 11.282 The second most abundant peptides found in their proteomic 
studies were di-acetylated histones acetylated at lysine 4, and 7, lysine 7 and 11, and lysine 
4 and 11. Proteomic analysis of H2A.Z from mouse embryonic stem cells revealed the 
mono-acetylated lysine residues to be the most highly abundant with preference for lysine 
4, 7, and 11, while di-acetylated lysines were the next highest in abundance. However, the 
di-acetylation pattern for lysine 4 and 11 was only detected at significant levels when 
H2A.Z was ubiquitinated.253 These results demonstrate that di-acetylation patterns on 
H2A.Z can be found under physiological conditions and that additional acetylation patterns 
in addition to Lys 4 and 11 may be relevant.  
 
Figure 5.12 Cartoon depicting two domains on the BPTF PHD domain and bromodomain that bind post-
translational modifications on histone tails. The PHD domain binds H3K4me3 with low micromolar affinity, 
while the bromodomain, BRD binds H2A.Z AcK 4, 11 with high-micromolar affinity. These two interactions 
may facilitate a bivalent intra-nucleosomal interaction as proposed by Ruthenburg et al.274 
 
H2A.Z  
acK State 
Ac
Ac
High Aﬃnity
Ac
Ac
Ac
me3
H3K4  
Low Aﬃnity
BRD
BPTF PHD
 
 206 
    In our experiments, we attain only modest affinity for H2A.Z AcK4,11 towards 
BPTF. This affinity should not be sufficient to facilitate H2A.Z nucleosome enrichment on 
its own as observed by Kim et al.271 However, enhancement of H2A.Z deposition near TSS 
correlates strongly with H3K4me3, a known recognition site for the BPTF PHD domain.253 
We believe the added affinity may strengthen a bivalent interaction (Figure 5.12), similar 
to how BPTF was demonstrated to interact with H4AcK16 and H3K4me3.274  Ruthenburg 
et al. identified bivalent interactions of H4Ack16 interacting with the bromodomain, and 
H3K4me3 with the PHD domain of BPTF lead to a greater increase in total affinity than 
just one modification alone (2-3 fold enhancement of nucleosomal binding with both 
H4AcK16 and H3K4me3 over mononucleosomal binding with H3K4me3 alone).274    
While only modest increases were observed, the H3K4me3 interaction lead to specificity 
towards only H4AcK16, even though H4AcK12 has similar affinity alone.  The interaction 
between H2A.Z AcK4,11 and BPTF may induce a similar bivalency with the PHD domain. 
This is a starting point in understanding the role acetylated H2A.Z plays in recognizing 
BPTF. Investigation into the bivalent interactions between the PHD and the bromodomain 
of BPTF with H2A.Z nucleosomes would be necessary to further understand their 
interactions in a more native-like environment.  
Four other bromodomains were also evaluated for affinity towards H2A.Z 
AcK4,11—Brd4, BrdT, PfGCN5, and PFA0510w. Of these proteins, only the PfGCN5 
bromodomain showed comparable affinity (Kd = 650 µM) to BPTF. The human GCN5L2 
bromodomain is structurally similar to BPTF, and both proteins bind H4AcK16.  In 
Saccharomyces cerevisiae, GCN5 promotes acetylation and binds acetylated nucleosomes 
via its bromodomain.283,284 The human GCN5L2 bromodomain contains a deep 
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hydrophobic cavity that binds Ne-acetylated lysines with modest affinity (Kd ~ 900 µM), 
with no affinity towards unacetylated peptides.285 The PfGCN5 bromodomain binds to 
H2A.Z AcK4,11 with a similar level as the affinity of human GCN5L2 for H4AcK16. 
Although the human and P. falciparum H2A.Z sequences are not identical, these 
biochemical results for characterization of H2A.Z represent an interesting starting point for 
understanding the role of acetylated H2A.Z in regulating virulence of the parasite.  
5.2.4  Conclusion 
We have studied the effects of N-terminal acetylation of histone variant H2A.Z on 
the direct interaction with bromodomains. Of the peptides tested, we identified a di-
acetylated lysine versus single or higher acetylation states of the H2A.Z histone that is 
responsible for recognition of the BPTF bromodomain. Both BPTF and H2A.Z play a 
significant role in cancer disease progression, and recent findings show a dependent 
functional activity of both proteins in bladder cancer. Our findings offer a potential link for 
modulating function through a direct interaction with H2A.Z in chromatin, but posit that a 
higher affinity multivalent interaction through a neighboring PHD domain may be 
necessary. Similar bromodomain interactions between H2A.Z and the PfGCN5 protein 
may also be present in P. falciparum. Synthetic nucleosomes incorporating particular 
acetylation patterns have been useful for characterizing effector domain interactions using 
single and multi-domain protein constructs. These constructs will be useful for further 
testing this molecular recognition event. 
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5.2.5  Material and Methods 
 
For E. coli growth, LB agar, LB media, defined media components including 
unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin and buffer components 
were purchased from RPI corp. 3-Fluorotyrosine, thymine, cytosine, guanosine were 
purchased from Alfa Aesar. Magnesium chloride, manganese sulfate, succinic acid, 
calcium chloride and 5-fluoroindole were purchased from Sigma-Aldrich.  
5.2.5.1   Peptide Synthesis 
Solid-phase peptide synthesis was performed using the procedure outlined below. 
1-hydroxybenzotriazole monohydrate (HOBT, Chem-Impex Int’l), O-benzotriazol-1-yl-
N, N, N’, N’-Tetramethyluronium hexafluorophosphate (HBTU, Novabiochem), and N,N-
Diisopropylethylamine (DIEA, Sigma Aldrich) were used as received without further 
purification and dissolved into reagent-grade DMF (Fisher Scientific).  N-α-Fmoc-N-ε-
Boc-L-lysine and N-α-Fmoc-N-ε-trifluoroacetyllysine were received from Chem-
Impex.  N-α-Fmoc-O-tBu-tyrosine, N-α-Fmoc-glycine, and N-α-Fmoc-N-ε-Boc-D-lysine 
were received from Novabiochem.  Piperidine, trifluoroacetic acid, dichloromethane 
(Sigma Aldrich), Triisopropylsilane (TCI America), acetic anhydride (Fisher Scientific), 
3-maleimidopropionic acid NHS (Chem impex), and triethylamine (Mallinckrodt) were all 
used as received. Peptides were made on a 25 µmol scale on NovaSyn TGR® resin in a 
CEM MARS microwave reactor. All peptides were synthesized using HOBT and HBTU 
coupling reagents according to published methods.286  Following Fmoc deprotection of the 
final residue, the peptides were cleaved from the resin using a mixture 95:2.5:2.5 
TFA:TIPS:H2O,  and stirring for 2 h.  The peptide cleavage solution was separated from 
 209 
the resin, and the solution was concentrated under a stream of N2.  The crude peptide was 
precipitated with ether, cooled to -20 °C for at least 15 min, and pelleted out by 
centrifugation at 3000xg for 5 min at 4 °C.  The pellet was dissolved into a 60:40 0.1% 
TFA in H2O: acetonitrile mixture and sufficient DMF to aid solubility.  Dissolved peptides 
were purified on a Dionex Ultimate 3000 RP-HPLC using a C-18 column on a 10-60% 
acetonitrile gradient over 60 min.  Purified peptides were analyzed via Ab-Sciex 5800 
MALDI- TOF/TOF Mass Spectrometer.  Peptide theoretical and actual masses are shown 
in Table 5.2. 
5.2.5.2   Protein Expression Conditions for Unlabeled or Fluorine-labeled 
Bromodomains Brd4(1), BrdT(1), BPTF, PfGCN5 and PFA0510w  
The pNIC28-BSA4 plasmid containing the Brd4(1) and BPTF genes were kind 
gifts from the laboratory of Stefan Knapp whereas plasmid containing gene of PfGCN5 
and PFA0510w were kind gifts from Raymond Hui lab at SGC Toranto.  
5.2.5.3   Unlabeled Bromodomains 
 For unlabeled protein expression of BPTF and pfGCN5 bromodomains, the E. coli 
Rosetta (DE3) strain (Novagen) was first transformed with the pRARE (Novagen) plasmid. 
The transformed cells were selected using chloramphenicol. Calcium competent pRARE-
containing E. coli cells were transformed with the respective plasmids. Co-transformed 
cells were selected by using 35 mg/L of chloramphenicol and 100 mg/L of kanamycin to 
select for the pRARE plasmid and bromodomain respectively. Following overnight 
incubation at 37 °C, a single colony was selected from the agar plate and inoculated in 50 
mL of LB media containing kanamycin (100 mg/L) and chloramphenicol (35 mg/L). The 
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primary culture was grown overnight at 37 °C while shaking at 250 rpm. For secondary 
culture growth, 1 L of LB media containing kanamycin (100 mg/L) was inoculated with 
the primary culture and incubated at 37 °C while shaking at 250 rpm. When the O.D. of 
culture at 600 nm reached 0.6, the shaker temperature was reduced to 20 °C. After 30 
minutes, the expression was induced with 1 mM IPTG overnight for 12-16 h. Cells were 
harvested by centrifugation and stored at -80 °C.  
5.2.5.4   Fluorine-labeled Bromodomains 
  The expression of 3-fluorotyrosine and 5-fluoro-tryptophan labeled proteins were 
performed by using previously published methods192,287 and briefly described here.  To 
express the labeled protein, the secondary culture in LB media was grown until an O.D. at 
600 nm of 0.6 was reached followed by harvesting the cells at 3000g for 10 minutes. Cells 
were resuspended in defined media of Muchmore et al.209 containing 3F-tyrosine (10 
mg/tyrosine residue in the respective protein/L defined medium) in place of tyrosine or 5-
fluoroindole (60 mg/L) in place of   tryptophan. The resuspended E. coli were incubated at 
37 °C while shaking for 1 h followed by the cooling to 20 °C and media temperature 
equilibration for 30 min. Protein expression was induced by 1 mM IPTG overnight (14−16 
h) at 20 °C. The cells were harvested and stored at −80 °C.  
5.2.5.5   Protein-Observed Fluorine NMR 
Protein-observed 1D 19F NMR samples were obtained as previously described192,198 
using a frequency window of -120 to -130 ppm, a D1 of 0.7 sec and an acquisition time of 
0.05 sec, SW of 30 ppm, NS = 1000, and a 90° pulse width.  Peptide stock solutions were 
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prepared in MilliQ water at ~20 mM. Peptides were titrated into bromodomain protein 
(protein solutions at 40-50 µM in 50 mM TRIS, 100 mM NaCl, 5% D2O, pH 7.4).   
5.2.5.6   1H CPMG NMR Spectroscopy 
1H CPMG NMR experiments were carried out on a Bruker HD-500 NMR.  A series 
of 1H CPMG NMR spectra were recorded and carried out in a single NMR tube with the 
initial run of 100 µM peptide. 2) peptide plus 10 µM protein, and 3) peptide + protein + 
100-800 µM competitor bromosporine or NH2-AU1(with a filter length of 1.2 s, interpulse 
delay of 2.5 ms, and D20 of 25 ms, loop counter at 160).   
5.2.5.7   Photo-crosslinking with H2A.Z (unAcK, AcK15, and AcK4, 11) Peptides 
This work was done by our collaborators Babu Sudhamalla and Kabirul Islam from 
the University of Pittsburgh. The procedure for protein expression and phototo-
crosslinking of BPTF-W2950AzF has been described previously.279  W2950 reported 
previously, corresponds to W2824 used in this current study.  In brief, for photo-
crosslinking experiments, 0.5-1 mM biotin-labeled histone H2A.Z peptides (unAcK, 
AcK15, and AcK4, 11) were preincubated with 30 µM of BPTF-W2950AzF in a buffer 
containing 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20, and 0.5 mM TCEP. 
After 30 min of incubation at room temperature, samples were subjected to UV irradiation 
at 365 nm for 15 min at 4 °C. Negative controls were not subjected to UV irradiation. 
Samples were then bound to Ni-NTA agarose resin and incubated for 1 h at room 
temperature with gentle agitation. To remove uncrosslinked peptide, samples were washed 
10 times each with 1 mL of washing buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1% 
Triton X-100). Finally, cross-linked proteins were eluted with a buffer containing 50 mM 
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Tris-HCl pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, and 400 mM imidazole. The 
eluted proteins were separated on a 4-12% Criterion XT precast SDS-PAGE gel (Bio-Rad 
Laboratories) and analyzed by Western blotting as described below. 
5.2.5.8   Western Blotting 
This work was done by our collaborators Babu Sudhamalla and Kabirul Islam from 
the University of Pittsburgh. Equal volumes of the pulled-down samples (both UV 
irradiated and non-irradiated) were separated on SDS-PAGE and transferred onto a 0.2 µm 
supported nitrocellulose membrane (Bio-Rad Laboratories) at a constant current 67 mA for 
16 h at 4 °C. Membranes were blocked with 20 mL of TBST buffer (50 mM Tris HCl pH 
7.4, 150 mM NaCl, 0.01% Tween-20) with 5% nonfat dry milk for 1 h at room temperature 
with gentle shaking. The blocking buffer was then removed and membranes were washed 
with 20 mL of TBST buffer. Immunoblotting was performed with 1:500 diluted primary 
antibody (Biotin pAb, cat# PA1-26792, Invitrogen) for 16 h at 4 °C. The antibody solutions 
were removed and membranes were washed three times with TBST buffer at room 
temperature. The blots were then incubated with HRP-conjugated secondary antibody 
Donkey anti-Goat IgG (H+L) pAb (cat# NBP1-74815, Novus) with 5% nonfat dry milk 
(1:500 dilution) in TBST for 1 h at room temperature. After similar washing, protein bands 
were visualized by chemiluminescence using VISIGLO HRP Chemiluminescent substrates 
A and B (cat# N252-120ML and N253-120ML, aMReSCO) following manufacturer’s 
protocol. 
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5.2.5.9   Synthesis of NH2-AU1.   
Synthesis and characterization of AU1 analogs were done by Peter Ycas at the 
University of Minnesota, and will be reported in a subsequent thesis. 
 
Materials. All solvents were commercial grade and used without further 
purification.  Silica gel for flash chromatography was 60 Å, 70-230 mesh.  TLC was 
performed using ALUGRAM® SIL G/UV254 aluminum backed plates.  All reagents were 
commercially available and used as received.  4-(aminomethyl)aniline, 33% HBr in acetic 
acid,  methyl 3-isocyanatobenzoate,  and trifluoroacetic acid was purchased from Sigma 
Aldrich. Benzyl carbonochloridate was purchased from Acros Organics, (S)-3-(Boc-
amino)pyrrolidine was purchased from Combi-Blocks 
2,4-dichloropyrimidine was purchased from Chem Impex, Triethylamine was 
purchased from Mallinckrodt Chemicals 
 
Figure 5.13 Reaction scheme for the synthesis of NH2-AU1 
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Synthesis of S1 
(S1)   
Compound S1 was prepared according to published methods Angewandte Chemie, 
International Edition, 52(39), 10261-10264; 2013 1H NMR (500 MHz, Chloroform-d) δ 
7.43 – 7.32 (m, 5H), 7.10 (d, J = 7.9 Hz, 2H), 6.66 (d, J = 8.4 Hz, 2H), 5.15 (s, 2H), 4.97 
(s, 1H), 4.28 (d, J = 5.8 Hz, 2H). 
 
Synthesis of S2 
 (S2)   
 (S)-3-(Boc-amino)pyrrolidine (500 mg, 2.69 mmol)) was suspended in 5 mL of 
ethanol followed by dissolution upon stirring with triethylamine (370 µL, 5.04 mmol). 2,4-
dichloropyrimidine (400 mg, 2.68 mmol) was then added to the solution and the mixture 
was stirred for 12 h at room temperature. Upon consumption of the starting material, the 
mixture was then treated with 5 mL of 1 M NaOH and extracted with 10 ml of ethyl acetate 
3 times. The product was isolated by silica gel chromatography (2:1, hexanes ethyl acetate) 
and obtained as clear oil which solidified to a white solid upon resting at room temperature 
(57% yield, 578 mg). 1H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J = 6.0 Hz, 1H), 6.19 
(d, J = 5.9 Hz, 1H), 4.70 (s, 1H), 4.33 (s, 1H), 3.93-3.18 (bm, 4H), 2.31 (s, 1H), 2.17 – 1.66 
(bm, 1H), 1.44 (s, 9H). 13C NMR (125 MHz, Chloroform-d) δ 161.12, 160.60, 156.46, 
155.25, 102.09, 80.19, 52.91-51.93 (two resolved populations), 50.69-49.41 (two resolved 
populations), 44.74, 31.81-30.46 (two resolved populations), 28.35. ESI-MS Calculated 
mass: 298.12 Observed mass M+H: 299.13. 
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Synthesis of S3 
(S3)  
Compound S2 (300 mg, 1.00 mmol) and (S1) (265 mg,1.03 mmol) were dissolved 
by stirring in 10 mL of dioxane at room temperature. The mixture was then heated to 100 
°C for 12 h. The solvent was removed and the product was purified by silica gel 
chromatography (100% ethyl acetate) (43% yield, 198 mg). The product was obtained as a 
pale yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.90 (d, J = 5.8 Hz, 1H), 
7.72 (d, J = 7.7 Hz, 3H), 7.40 – 7.21 (m, 6H), 7.11 (d, J = 8.1 Hz, 2H), 5.91 (d, J = 6.0 Hz, 
1H), 5.04 (s, 2H), 4.13 (d, J = 6.3 Hz, 2H), 3.76 – 3.08 (m, 5H), 2.13 (s, 1H), 1.89 (s, 1H), 
1.40 (s, 9H) 13C NMR (125 MHz, DMSO-d6) δ 160.56, 159.86, 156.77, 156.05, 155.74, 
140.63, 137.71, 131.96, 128.80 (2C), 128.22, 128.18(2C), 127.65 (2C), 118.67 (2C), 95.93, 
78.37, 65.75, 52.05, 44.80, 43.99, 28.69 (3C), two resonances are not resolvable or 
obscured by the DMSO-d6 resonance. ESI-MS Calculated mass: 518.26 Observed mass 
M+H: 519.27. 
Synthesis of S4 
(S4)  
Compound S3 (100 mg, 0.193 mmol) was dissolved in 2 mL of dichloromethane 
followed by room temperature dropwise addition of 0.5 mL of trifluoroacetic acid. After 
10 min the reaction was complete as judged by ESI-MS. The mixture was quenched by 
addition of 2 mL of 6 N NaOH and the product was extracted with ethyl acetate. Solvent 
evaporation of the crude material yielded a reddish brown solid. The resulting crude 
product (S4) was used without further purification. 
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Synthesis of S5 
(S5)   
(65 mg, 0.15 mmol) was dissolved by stirring in 2 mL of dichloromethane, methyl 
3-isocyanatobenzoate (33 mg, 0.18 mmol) was dissolved in 1 mL of dichloromethane and 
added dropwise. The reaction was stirred at 25 °C for 12 h and purified by silica gel 
chromatography (0-10% dichloromethane-methanol). The final product was obtained as a 
tan solid (63% yield over two steps, 73 mg). 1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 
1H), 8.62 (s, 1H), 8.15 (s, 1H), 7.93 (d, J = 5.9 Hz, 1H), 7.72 (d, J = 7.8 Hz, 3H), 7.56 (d, 
J = 8.1 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.42 – 7.24 (m, 6H), 7.13 (d, J = 8.2 Hz, 2H), 
6.63 (d, J = 6.7 Hz, 1H), 5.99 (d, J = 5.9 Hz, 1H), 5.04 (s, 2H), 4.35 (s, 1H), 4.13 (d, J = 
6.1 Hz, 2H), 3.84 (s, 3H), 3.56 (bm, 4H), 2.23 (s, 1H), 1.98 (s, 1H). 13C NMR (125 MHz, 
DMSO-d6) δ 166.75, 160.64, 159.52, 156.78, 155.61, 155.27, 141.14, 140.41, 137.70, 
132.21, 130.54, 129.52, 128.85, 128.79 (2C), 128.22, 128.18 (2C), 127.70 (2C), 122.69, 
122.35, 118.85 (2C), 118.59, 96.02, 65.76, 52.56, 52.44, 44.83, 43.99. One carbon is not 
resolvable or is obscured by the DMSO- d6 resonance ESI-MS Calculated mass: 595.25 
Observed mass M+1: 596.26 
 
Synthesis of NH2-AU1 
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NH2-AU1  
Compound S4 (90 mg, 0.15 mmol) was dissolved in 1 mL of 33% HBr in acetic 
acid and the compound was stirred for 4 h at room temperature. The solvent was removed 
and the product was precipitated in diethyl ether followed by addition of 1 mL of 1 M 
NaOH and extraction with 1 mL of ethyl acetate 3 times. The product was isolated by silica 
gel chromatography (0-20% dicholoromethane-methanol). The product was obtained as a 
white-yellow powder (65%, 45 mg) The product used in this study was used as an HBr 
salt. 1H NMR (400 MHz, DMSO-d6) δ 11.81 (s, 1H), 10.26 (s, 1H), 8.92 (d, J = 10.6 Hz, 
1H), 8.16 (d, J = 18.0 Hz, 3H), 8.00 (d, J = 11.0, 7.2 Hz, 1H), 7.72 – 7.63 (m, 2H), 7.57 (d, 
J = 6.4 Hz, 1H), 7.54 – 7.46 (m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 6.97 (d, J = 5.8 Hz, 1H), 
6.43 (d, J = 7.2 Hz, 1H), 4.02 (d, J = 6.2 Hz, 2H), 3.84 (s, 3H), 3.70 (d, J = 8.3 Hz, 1H), 
3.58 – 3.34 (m, 4H), 2.36 – 2.20 (s, 1H), 2.12 – 1.95 (s, 1H). 13C NMR (125 MHz, DMSO-
d6) δ 166.82, 160.62, 159.79, 156.12, 155.55, 141.73, 141.46, 130.47, 129.43, 129.27 (2C), 
128.88, 128.56, 128.46, 127.92, 122.61, 122.12, 118.61 (2C), 118.47, 96.19, 52.54, 44.84, 
43.07. ESI-MS Calculated mass: 461.22 Observed mass M+1: 462.22. 
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Figure 5.14 1H NMR of S2 acquired at 400 MHz in chloroform-d. 
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Figure 5.15 13C NMR spectra of S2 acquired at 125 MHz in chloroform-d. 
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Figure 5.16 1H NMR of S3 acquired at 500 MHz in DMSO-d6. 
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Figure 5.17 13C NMR spectra of S3 acquired at 125 MHz in DMSO-d6. 
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Figure 5.18 1H NMR of S5 acquired at 400 MHz in DMSO-d6. 
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Figure 5.19 13C NMR spectra of S5 acquired at 125 MHz in DMSO-d6. 
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Figure 5.20 1H NMR of NH2-AU1 acquired at 400 MHz in DMSO-d6. 
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Figure 5.21 13C NMR spectra of NH2-AU1 acquired at 125 MHz in DMSO-d6. 
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Figure 5.22 Inhibition curve of NH2-AU1 with BPTF and a tetraacetylated histone determined by 
Alphascreen. The inhibitory constant was determined to be 6.78*10-5 M. The assay was performed by 
Reaction Biology Corp.  The conditions of the experiment included 0.1% DMSO. 
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5.2.6  HPLC Quality Controls  
Quality control HPLC traces below were run on Dionex-3000 HPLC instruments 
fit with a C-18 column. A gradient of 10-60% acetonitrile over 50 minutes was run, 
followed by a five min. flush (95% ACN) and five min. equilibration (10% ACN: 90% 
0.1% TFA water). 
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5.2.7  Ongoing work evaluating histone peptide affinity towards BPTF 
 
To further investigate high affinity histone ligands towards BPTF, we evaluated an H4 
peptide. Using an AlphaScreen displacement assay, it has previously been reported that the 
H4 tetra-acetylated peptide (H4 AcK4) binds BPTF with an IC50 = 14.4 µM.288 A 
fluorescence polarization assay with TAMRA-H4AcK4 identified a Kd = 126 µM.279 We 
utilized the 19F NMR platform to identify the binding affinity of H4 AcK4 towards BPTF 
to be Kd = 69 ± 10 µM, Figure 5.23. Unlike H2A.Z, hyperacetylated H4 peptides appear 
to bind with higher affinity to BPTF. 
 
 
The variant of H2A.Z has two isoforms similar in sequence, with only a single 
amino acid difference within the N-terminal region, isoform II replaces a threonine with 
an alanine (H2A.Z I: AGGKAGKDSGKAKTKAVSR and H2A.Z II: 
AGGKAGKDSGKAKAKAVSR).282,289,290  Two H2A.Z isoforms have been identified in 
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1280 μM H4AcK4
W81
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A      B
Figure 5.23 Using 19F NMR to monitor H4 AcK4 binding the 5FW-BPTF.  A) Stacked NMR spectra with 
W81 fluorinated resonance on BPTF shifting with added ligand.  B) Corresponding binding isotherm of the 
shift in W81 resonance with increasing H4 AcK4 concentration, with a Kd = 69 ± 10 µM.  
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chicken DT40 cells to have similar function, as both are deposited by the SRCAP 
chromatin-remodeling complex.291  However, differences in growth and gene expression 
were observed, indicating the isoforms have varying effects on chromatin structure. 291  
While much of the literature focuses on isoform I, we wanted to further investigate if 
isoform II with the acetylation states at positions 4 and 11, binds BPTF as well.  Following 
the same methods as indicated in Section 5.2, we used 19F NMR to monitor the change in 
fluorinated W81 resonance with increasing equivalence of H2A.Z II. We observed a shift 
in the resonance to be within the fast exchange regime, and fit the data to a binding isotherm 
equation to afford a Kd = 252 ± 117 µM, Figure 5.24. Compared to the isoform I variant, 
this binds significantly tighter. The slight change in sequence has a sizable effect on affinity 
for the H2A.Z variant. This is an initial step in further identifying how H2A.Z variants 
interact with bromodomains. Further evaluation on other acetylation sites as well as other 
bromodomains with H2A.Z may further elucidate the role histone variants play within 
epigenetics.  
 
 
[ppm]- 123 - 124 - 125 - 126 - 127 
W81
5FW-BPTF
160 μM H2A.Z II AcK4,11
240 μM H2A.Z II AcK4,11
640 μM H2A.Z II AcK4,11
1280 μM H2A.Z II AcK4,11
A          B
Figure 5.24 Using 19F NMR to monitor H2A.Z II AcK4,11 binding the 5FW-BPTF.  A) W81 
fluorinated resonance on BPTF shifting with added H2A.Z II AcK4,11 ligand. B) Binding Isotherm of 
the shift in W81 resonance with increasing H2A.Z II AcK4,11 concentration, with a Kd = 252 ± 117 
µM. 
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Table 5.1 Peptides evaluated for binding towards BPTF 
Peptide Theoretical [M+H] 
Observed 
[M+H] 
H2A.ZAcK4,11 Iso II: 
YAGGKacAGKDSGKacAKAKAVSR 
 
2034.15 2034.4 
H4AcK4: 
YSGRGKacGGKacGLGKacGGAKacRHRK 
2323.36 2323.28 
Table 5.2 H2A.Z peptides with varying acetylation sites and H4AcK16 were synthesized and 
characterized with an Ab-Sciex 5800 MALDI-MS. 
Peptide Theoretical [M/z] 
Observed 
[M+H] 
YAGGKacAGKacDSGKacAKTKAVSR 2104.2 2105.16 
YAGGKAGKacDSGKacAKTKAVSR 2062.2 2063.14 
YAGGKacAGKacDSGKAKTKAVSR 2062.2 2063.38 
YAGGKacAGKDSGKacAKTKAVSR 2062.2 2063.4 
YAGGKacAGKacDSGKacAKacTKAVSR 2146.2 2147.17 
YAGGKAGKDSGKAKTKAVSR 1978.11 1979.17 
YAGGKacAGKDSGKAKTKAVSR 2020.1 2021.16 
YAGGKAGKacDSGKAKTKAVSR 2020.1 2021.14 
YAGGKacAGKacDSGKacAKacTKacAVSR 2189.2 2189.13 
YAGGKAGKDSGKacAKTKAVSR 2020.1 2021.28 
YAGGKAGKDSGKAKacTKAVSR 2020.1 2021.14 
YAGGKAGKDSGKAKTKacAVSR 2020.1 2021.12 
YSGRGKGGKGLGKGGAKRHR 2196.3 2196.7 
Biotin-bA-bA-
YAGGKAGKDSGKAKTKacAVSR 
 
2389.3 2390.3 
Biotin-bA-bA-
YAGGKacAGKDSGKacAKTKAVSR 
 
2431.3 2432.6 
Biotin-bA-bA-
YAGGKAGKDSGKAKTKAVSR 
 
2347.3 2348.6 
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5.3  Efforts Towards Small Molecule Effects of Fluorinated CREB-Binding Protein in 
Collaboration with Professor Stuart Conway 
5.3.1  Introduction  
Bromodomain containing proteins (BCPs) have a specific domain that bind post-
translationally modified amino acids such as acetylated lysine and phosphorylated serine.  
Complex formation leads to altered chromosomal states which regulate gene expression.  
These adverse alterations lead to a variety of problems including neurodevelopmental 
disorders,292 heart disease,293 and cancer overexpression.294  Cyclic AMP response element 
(CREB) binding protein (CBP) is an important transcriptional coactivator found to interact 
with several proteins including CREB, MLL, p300.  Protein Kinase A (PKA) regulates the 
phosphorylation of Ser133 on CREB, which leads to the recruitment of KIX that activates 
cellular expression.  Furthermore, acetylation of Lys136 on CREB stimulates interactions 
of the BRD of CBP, which leads to recruitment to the promotor.292 CBP histone acetyl 
transferase is the main, if not the only protein that acetylates Lys136.292 With both 
acetylated Lys136 and phosphorylated Ser133, a ternary complex with KIX, CREB, and 
CBP BRD has been observed. Disruption of the CREB:BRD complex have led to 
suppressed targeted cell expression. CBP-BRD interacts with acetylated lysine tails of 
histones. Targeting of only the CBP-BRD is a key challenge to suppress the specific 
transcriptional activity, as BRDs have similar homology. The lack of potent, selective 
bromodomain inhibitors is a key driving factor in the search for CBP BRD ligands. Several 
inhibitors have been evaluated including both small molecules and peptides with mid to 
low micromolar affinity, until recently Conway and colleagues identified a small molecule 
ligand with nanomolar affinity (MIB 411 with Kd = 390 nM, Figure 5.25).295–298  
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BET bromodomains are the most investigated bromodomains to date, and have 
attracted attention due to their role in a variety of disease states. Both Brd4 and BrdT are 
part of the BET subclass of bromodomains. Brd4 regulates the transcription of c-Myc, an 
oncogenic protein, and has also been implicated in NUT midline carcinoma.227  BrdT is a 
testis specific bromodomain involved in spermatogenesis; Suppression of BrdT is a 
promising avenue towards a male contraceptive. A few small molecule inhibitors have been 
identified to target BET bromodomains, including (+)-JQ-1231 and I-BET762.232 Both 
molecules contain a triazoloazepine scaffold able to engage with the Kac binding pocket by 
mimicking both the hydrophobic and hydrophilic interactions of a native Kac peptide. The 
inhibitor (+)-JQ-1 binds Brd4 and BrdT with mid-nanomolar affinity (Kd= 49 nM and 190 
nM with ITC, respectively).231 I-BET binds to Brd4 with 55 nM affinity, determined via 
 
Figure 5.25 CBP-BRD (PDB: 3P1C) shown with acetylated lysine in the binding groove. N1168 and 
Y1125 stabilizes Kac with hydrogen bonding. B. previously observed inhibitors of the CBP-BRD .297,298 
Inhibitors of CBP-BRDA      B
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 244 
ITC.232  While potent inhibitors, drug resistance has been observed for the triazoloazapine 
moiety in both small molecules.299 To this end, a virtual screen has recently been carried 
out to identify dihydropyridopyridine scaffolds that have submicromolar affinity for both 
BrdT and BrD4, as identified by the Pomerantz and Georg labs.300 The need to identify 
potent, selective bromodomain inhibitors is necessary. We therefore sought to help 
evaluate ligands of the CBP bromodomain using 19F-NMR assay in collaboration with the 
Conway lab, based on their previous inhibitor MIB 411, Figure 5.25.  
5.3.2  Results and Discussion 
The research lab of Stuart Conway began their search for a more potent inhibitor 
with a non-selective BRD inhibitor, dimethylisoxazole.298 Utilizing a fragment screen, they 
identified a variety of highly potent inhibitors of the CBP-BRD. Previous studies have 
identified MIB 411 to have a high binding affinity towards CBP, with Kd = 390 nM, as 
determined with ITC.  This compound, identified through an AlphaScreen, can interact 
with R1173 on CBP through a cation-p interaction that is believed to stabilize the ligand 
with 3.2-4.7 kcal/mol, determined with DFT calculations, Figure 5.26.298 In collaboration 
with the Conway lab, we evaluated a series of dihydroquinoxalinone compounds including 
MIB 411 that bind bromodomains CBP, Brd4 and BrdT with 19F NMR and fluorescence 
polarization for both specificity and affinity. By incorporating fluorinated tryptophan 
resonances into the bromodomains, we are able to monitor the change in resonance with 
added ligand, as previously described.190,191  
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There are three tryptophan residues in CBP, leading to three fluorine resonances in 
the 19F NMR spectrum. Perturbations were observed for the most downfield resonance at 
-123 ppm. Increasing concentration of ligand (0, 12.5, 25, and 50 µM) was titrated into 
5FW-CBP to observe resonance perturbations. Slow (MIB310 and MIB197) to 
intermediate (MIB374 and MIB411) exchange was observed for four of the ligands, with 
the fifth ligand (MIB432) showing aggregation (Figure 5.35). To test the specificity, we 
analyzed how the ligands bind to the BET bromdomain, Brd4. Fluorination of the three 
tryptophan residues was incorporated using 5-Fluoroindole during the expression of the 
protein.  19F NMR was again carried out with ligand titrations. In all cases, Trp-81 is 
perturbed the greatest, which is part of the WPF shelf within Brd4, Figure 5.28.  
MIB 411
R1173
3.5 Å
 
Figure 5.26 Solution structure of the CBP bromodomain interacting with MIB 411 (blue).  The cation-π 
interaction is shown with the positive charge on R1173 (orange) and the tetrahydroquinoline of MIB 411 
with a distance of 3.5-4.6 Å (PDB ID: 4NYX). 
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Intermediate to fast exchange was observed, consistent with low to mid-micromolar 
binders, but a specific Kd could not be extracted; therefore, a fluorescence polarization 
assay was utilized on Brd4, as well as another BET bromdomain, BrdT. Ligands were 
competed off with BI-BODIPY, a known binder of both BET bromodomains. A Kd value 
was obtained for Brd4 and BrdT to be 62.5 nM, and 380.9 nM, respectively, Figure 5.29 
and Figure 5.37. All ligands but the MIB 432, which again had aggregating issues Figure 
5.35, had low micromolar affinity for both BET bromodomains. MIB 197 has the highest 
affinity towards Brd4 with a Ki value of 1.52 µM, with slightly higher affinity for BrdT, Ki 
= 6.11 µM, Figure 5.28F, Figure 5.38, and Figure 5.32. 
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Figure 5.27 5FW-CBP 19F-NMR spectra overlays with increasing equivalence of 5 varied small 
molecule inhibitors, with 50 µM CBP.  MIB 197 and MIB 310 show intermediate exchange, MIB 374 
and MIB 411 show slow exchange; thus, MIB 411 and MIB 374 bind CBP with tighter affinity. MIB 
432 displayed aggregation, leading to an unclear affinity. 
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W75 W120 W81
Compound Brd4 Ki (μM) BrdT Ki (μM)
MIB 197 1.52 6.11
MIB 310 5.1 4.21
MIB 374 5.9 6.38
MIB 432 N/D N/D
MIB411 4.72 3.07
A       B
C       D
E       F
Figure 5.28 A-E. 19F-NMR of 5FW-Brd4 with increasing concentrations of 5 MIB compounds.  F. 
Table of Ki values from fluorescence polarization assays with Brd4 and BrdT binding to 5 small 
molecule CBP-BRD inhibitors.  Due to the aggregation, MIB 432 Ki values could not be determined 
(N/D). 
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5.3.3  Conclusion 
 
The bromodomain of CBP is a targetable site for the suppression of a variety of 
diseased states. The few inhibitors available currently do not have high specificity or 
potency within BET bromodomains. Five small molecules were evaluated against three 
bromodomains: CBP, Brd4, and BrdT. 5FW-CBP has three resonant peaks that can be 
monitored for movement with added ligand. With little discovery towards CBP 
brodomodmain inhibitors, there is great utility of 19F NMR assay for identifying ligands of 
the CBP bromodomain. Two molecules—MIB 197 and MIB 310 perturbed a fluorine 
resonance of 5FW-CBP within the intermediate exchange regime, but a binding curve 
could not be fit to the resonance move. We further evaluated these compounds with two 
BET bromdomains. MIB 197 has slight preference towards Brd4 with 1.52 µM, and MIB 
411 has affinity towards the BrdT domain with 3.07 µM. This is a first step in 
understanding selective inhibitors against the CBP bromodomain to target diseases 
including heart disease as well as a variety of cancers. 
5.4  Materials and Methods 
5.4.1  Protein Expression Experimental 
 
5FW-labeled CBP was expressed using E. coli/Bl21(DE3) cotransformed with the 
pRARE plasmid expressing tRNAs for rare codons. 5FW-labeled protein was expressed 
with LB media grown until an O.D. at 600 nm of 0.7 was reached. Cells were harvested 
and resuspended in defined media1 which contained 5-fluoroindole (60 mg/L) in place of 
tryptophan2.  Resuspended bacteria were incubated at 37 oC while shaking for 1.5 h. The 
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bacterial culture was cooled to 20 oC for 30 min. then induced with 1 mM IPTG for 18-20 
h at 20 oC. Cells were pelleted and stored at -20 oC. Pellets were thawed to room 
temperature, and lysis buffer (50 mM Phsophate pH 7.4, 300 mM NaCl), PMSF (5 mM), 
and Egg White Lysozyme (1 mg/ml) were added followed by sonication and purified via 
FPLC using NTA-resin (Qiagen) and an imidazole gradient (0 to 400 mM). The yield 
following purification was 11 mg/L for 5FW-labeled CBP. Concentration of CBP was 
evaluated via absorbance at 280 nm.3 5FW-lableled was expressed as previously 
described.4 
5.4.2  Protein Observed Fluorine NMR 
 
Protein observed 1D 19F NMR samples were obtained as previously described using 
a frequency window of -120 to -130 ppm, a D1 of 0.7 sec and an acquisition time of 0.05 
sec.  Small molecules stock solutions were prepared in DMSO at 20 mM. Small molecules 
were titrated into CBP or Brd4 (protein solutions at 50 µM in 50 mM TRIS, 100 mM NaCl, 
5% D2O, pH 7.4) at 0.25, 0.5, 1.0, and 2.0 equivalents of protein with a final concentration 
of 0.5% DMSO.  
5.4.3  Fluorescence Anisotropy Direct Binding and Competition Experiments 
 
Competitive inhibition experiments were carried with Brd4 and BrdT as previously 
described.4 Serial dilutions were run in triplicate on a Tecan Infinite 500 plate reader using 
384-well plates (Corning 3676). In competition experiments, Brd4 was held constant at 
496 nM, and BrdT at 1.516 µM, equivalent to 80% bound tracer, BI-BODIPY (25 nM), as 
determined via direct binding experiments.  The fluorescently tagged BI-BODIPY was 
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synthesized according to published methods.5 Ki values were determined according to 
equation 1.  A competition curve with known inhibitor BI25366 was used to estimate the 
baseline in cases where 100% inhibition could not be achieved with small molecule 
inhibitors. 
 
 𝑦 = 𝑐 + 𝑏 − 𝑐 	  ×	   DEF2FG H DEF2FG IHJ2GK2   Eq. 1 
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5.5  Fluorescence Polarization binding curves 
Binding curves were constrained to the baseline of the self-competition anisotropy 
values, and used in determining the Ki values. 
 
 
 
 
 
 
Figure 5.29 Direct Binding of Brd4 with BI-BOPIPY with Kd of 62.5 nM. 
 
Figure 5.30 Self-competition of BI2536 with BI-BODIPY on Brd4. 
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Figure 5.31 Competition of BI2536 with MIB 374 on Brd4 giving a constrained Ki of 5.90 µM. 
Figure 5.32 Competition of BI2536 with MIB 197 on Brd4 giving a constrained Ki of 1.52 µM 
at three different times.  Longer equilibration times did not affect the Ki. 
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Figure 5.33 Competition of BI2536 with MIB 310 on Brd4 giving a constrained Ki of 5.10 µM. 
 
Figure 5.34 Competition of BI2536 with MIB 411 on Brd4 giving a constrained Ki of 4.72 µM. 
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Figure 5.35 Competition of BI2536 with MIB 432 on Brd4.  Aggregation led to an unclear competition 
curve. 
 
Figure 5.36 Self-competition of BI2536 with BI-BODIPY on BrdT. 
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Figure 5.37 BI-BODIPY ligand FP binding assay with BrdT.  A Kd of 380 nM was obtained for the 
previously identified high affinity ligand. 
 
Figure 5.38 Competition of BI2536 with MIB 197 on BrdT. 
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Figure 5.39 Competition of BI2536 with MIB 310 on BrdT. 
 
Figure 5.40 Competition of BI2536 with MIB 411 on BrdT. 
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Figure 5.41 Competition of BI2536 with MIB 411 on Brd4. 
 
Figure 5.42 Competition of BI2536 with MIB 432 on Brd4.  Aggregation led to poor  
-­2 0 2
8 0
9 0
1 0 0
1 1 0
lo g [M IB 37 4 ]  µM
A
n
is
o
tr
o
p
y
    
(m
A
)
M IB 3 7 4 _ B rd T
 260 
Chapter	  6.  References	  
(1)  Stumpf, M. P. H.; Thorne, T.; Silva, E. De; Stewart, R.; An, H. J.; Lappe, M. 
Estimating the Size of the Human Interactome. Proc. Natl. Acad. Sci. U. S. A. 2008, 
105, 6959–6964. 
(2)  Verdine, G. L.; Walensky, L. D. The Challenge of Drugging Undruggable Targets 
in Cancer: Lessons Learned from Targeting BCL-2 Family Members. Clin. Cancer 
Res. 2007, 13, 7264–7270. 
(3)  Jochim, A. L.; Arora, P. S. Assessment of Helical Interfaces in Protein-Protein 
Interactions. Mol. Biosyst. 2009, 5, 924–926. 
(4)  Smith, M. C.; Gestwicki, J. E. Features of Protein-Protein Interactions That 
Translate into Potent Inhibitors: Topology, Surface Area and Affinity. Expert Rev. 
Mol. Med. 2012, 14, e16. 
(5)  Clackson, T.; Wells, J. A. A Hot Spot of Binding Energy in a Hormone-Receptor 
Interface. Science (80-. ). 1995, 267, 383–386. 
(6)  Babine, R. E.; Bender, S. L. Molecular Recognition of Protein−Ligand Complexes: 
Applications to Drug Design. Chem. Rev. 1997, 97, 1359–1472. 
(7)  Hopkins, A. L.; Groom, C. R. The Druggable Genome. Nat. Rev. Drug Discov. 
2002, 1, 727–730. 
(8)  Russ, A. P.; Lampel, S. The Druggable Genome  : An Update. Drug Discov. Today 
2005, 10, 1607–1610. 
(9)  Bullock, B. N.; Jochim, A. L.; Arora, P. S. Assessing Helical Protein Interfaces for 
Inhibitor Design. J. Am. Chem. Soc. 2011, 133, 14220–14223. 
(10)  Kabsch, W.; Sander, C. Protein Secondary Structure: Pattern Recognition of 
Hydrogen-Bonded and Geometrical Features. Biopolymers 1983, 22, 2577–2637. 
(11)  Karle, I. L.; Flippen-Anderson, J. L.; Uma, K.; Balaram, P. Apolar Peptide Models 
for Conformational Heterogeneity, Hydration, and Packing of Polypeptide Helices: 
Crystal Structure of Hepta- and Octapeptides Containing α-Aminoisobutyric Acid. 
Proteins Struct. Funct. Bioinforma. 1990, 7, 62–73. 
(12)  Schafmeister, C. E.; Po, J.; Verdine, G. L. An All-Hydrocarbon Cross-Linking 
System for Enhancing the Helicity and Metabolic Stability of Peptides. J. Am. Chem. 
Soc. 2000, 122, 5891–5892. 
(13)  Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. Application of Ring-Closing 
Metathesis to the Synthesis of Rigidified Amino Acids and Peptides. J. Am. Chem. 
Soc. 1996, 118, 9606–9614. 
(14)  Pace, C. N.; Scholtz, J. M. A Helix Propensity Scale Based on Experimental Studies 
of Peptides and Proteins. Biophys. J. 1998, 75, 422–427. 
(15)  Hilinski, G. J.; Kim, Y.-W.; Hong, J.; Kutchukian, P. S.; Crenshaw, C. M.; 
Berkovitch, S. S.; Chang, A.; Ham, S.; Verdine, G. L. Stitched α-Helical Peptides 
via Bis Ring-Closing Metathesis. J. Am. Chem. Soc. 2014, 136, 12314–12322. 
(16)  Kim, Y.-W.; Verdine, G. L. Stereochemical Effects of All-Hydrocarbon Tethers in 
i,i+4 Stapled Peptides. Bioorganic Med. Chem. Lett. 2009, 19, 2533–2536. 
(17)  Bernal, F.; Tyler, A. F.; Korsmeyer, S. J.; Walensky, L. D.; Verdine, G. L. 
Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide. J. Am. 
Chem. Soc. 2007, 129, 2456–2457. 
 261 
(18)  Bird, G. H.; Bernal, F.; Pitter, K.; Walensky, L. D. Chapter 22 Synthesis and 
Biophysical Characterization of Stabilized α-­‐Helices of BCL-­‐2 Domains. In 
Programmed Cell Death, The Biology and Therapeutic Implications of Cell Death, 
Part B; Enzymology, B. T.-M. in, Ed.; Academic Press, 2008; Vol. Volume 446, pp. 
369–386. 
(19)  Walensky, L. D.; Bird, G. H. Hydrocarbon-Stapled Peptides: Principles, Practice, 
and Progress. J. Med. Chem. 2014, 57, 6275–6288. 
(20)  Cromm, P. M.; Spiegel, J.; Grossmann, T. N. Hydrocarbon Stapled Peptides as 
Modulators of Biological Function. ACS Chem. Biol. 2015, 10, 1362–1375. 
(21)  Li, Y.-C.; Rodewald, L. W.; Hoppmann, C.; Wong, E. T.; Lebreton, S.; Safar, P.; 
Patek, M.; Wang, L.; Wertman, K. F.; Wahl, G. M. A Versatile Platform to Analyze 
Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real 
Time. Cell Rep. 2014, 9, 1946–1958. 
(22)  Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; 
Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of Apoptosis in Vivo by a 
Hydrocarbon-Stapled BH3 Helix. Science (80-. ). 2004, 305, 1466–1470. 
(23)  Chu, Q.; Moellering, R. E.; Hilinski, G. J.; Kim, Y.-W.; Grossmann, T. N.; Yeh, J. 
T.-H.; Verdine, G. L. Towards Understanding Cell Penetration by Stapled Peptides. 
Med. Chem. Commun. 2015, 6, 111–119. 
(24)  Labelle, J. L.; Katz, S. G.; Bird, G. H.; Walensky, L. D. A Stapled BIM Peptide 
Overcomes Apoptotic Resistance in Hematologic Cancers. J. Clin. Invest. 2012, 
122. 
(25)  Okamoto, T.; Zobel, K.; Fedorova, A.; Quan, C.; Yang, H.; Fairbrother, W. J.; 
Huang, D. C. S.; Smith, B. J.; Deshayes, K.; Czabotar, P. E. Stabilizing the pro-
Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or 
Biological Activity. ACS Chem. Biol. 2013, 8, 297–302. 
(26)  Bird, G. H.; Gavathiotis, E.; LaBelle, J. L.; Katz, S. G.; Walensky, L. D. Distinct 
BimBH3 (BimSAHB) Stapled Peptides for Structural and Cellular Studies. ACS 
Chem. Biol. 2014, 9, 831–837. 
(27)  van den Berg, A.; Dowdy, S. F. Protein Transduction Domain Delivery of 
Therapeutic Macromolecules. Curr. Opin. Biotechnol. 2011, 22, 888–893. 
(28)  Cantel, S.; Isaad, A. L. C.; Scrima, M.; Levy, J. J.; DiMarchi, R. D.; Rovero, P.; 
Halperin, J. a; D’Ursi, A. M.; Papini, A. M.; Chorev, M. Synthesis and 
Conformational Analysis of a Cyclic Peptide Obtained via I to i+4 Intramolecular 
Side-Chain to Side-Chain Azide-Alkyne 1,3-Dipolar Cycloaddition. J. Org. Chem. 
2008, 73, 5663–5674. 
(29)  Bird, G. H.; Christian Crannell, W.; Walensky, L. D. Chemical Synthesis of 
Hydrocarbon-Stapled Peptides for Protein Interaction Research and Therapeutic 
Targeting. In Current Protocols in Chemical Biology; John Wiley & Sons, Inc., 
2009. 
(30)  Azzarito, V.; Long, K.; Murphy, N. S.; Wilson, A. J. Inhibition of α-Helix-Mediated 
Protein–protein Interactions Using Designed Molecules. Nat. Chem. 2013, 5, 161–
173. 
(31)  Galande, A. K.; Bramlett, K. S.; Burris, T. P.; Wittliff, J. L.; Spatola, A. F. Thioether 
Side Chain Cyclization for Helical Peptide Formation: Inhibitors of Estrogen 
 262 
Receptor-Coactivator Interactions. J. Pept. Res. 2004, 63, 297–302. 
(32)  Jackson, D. Y.; King, D. S.; Chmielewski, J.; Singh, S.; Schultz, P. G. General 
Approach to the Synthesis of Short Alpha-Helical Peptides. J. Am. Chem. Soc. 1991, 
113, 9391–9392. 
(33)  Dekan, Z.; Vetter, I.; Daly, N. L.; Craik, D. J.; Lewis, R. J.; Alewood, P. F. α-
Conotoxin ImI Incorporating Stable Cystathionine Bridges Maintains Full Potency 
and Identical Three-Dimensional Structure. J. Am. Chem. Soc. 2011, 133, 15866–
15869. 
(34)  Knerr, P. J.; Tzekou, A.; Ricklin, D.; Qu, H.; Chen, H.; van der Donk, W. A.; 
Lambris, J. D. Synthesis and Activity of Thioether-Containing Analogues of the 
Complement Inhibitor Compstatin. ACS Chem. Biol. 2011, 6, 753–760. 
(35)  Harrison, R. S.; Shepherd, N. E.; Hoang, H. N.; Ruiz-gómez, G.; Hill, T. A.; Driver, 
R. W.; Desai, V. S.; Young, P. R.; Abbenante, G.; Fairlie, D. P. Downsizing Human, 
Bacterial, and Viral Proteins to Short Water-Stable Alpha Helices That Maintain 
Biological Potency. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 11686–11691. 
(36)  Osapay, G.; Taylor, J. W. Multicyclic Polypeptide Model Compounds. 2. Synthesis 
and Conformational Properties of a Highly .alpha.-Helical Uncosapeptide 
Constrained by Three Side-Chain to Side-Chain Lactam Bridges. J. Am. Chem. Soc. 
1992, 114, 6966–6973. 
(37)  Osapay, G.; Taylor, J. W. Multicyclic Polypeptide Model Compounds. 1. Synthesis 
of a Tricyclic Amphiphilic .alpha.-Helical Peptide Using an Oxime Resin, Segment-
Condensation Approach. J. Am. Chem. Soc. 1990, 112, 6046–6051. 
(38)  Taylor, J. W. The Synthesis and Study of Side-Chain Lactam-Bridged Peptides. 
Biopolymers 2002, 66, 49–75. 
(39)  Chang, Y. S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K.; To, K.-H.; Olson, 
K. A.; Kesavan, K.; Gangurde, P.; Mukherjee, A.; et al. Stapled Α−helical Peptide 
Drug Development: A Potent Dual Inhibitor of MDM2 and MDMX for p53-
Dependent Cancer Therapy. Proc. Natl. Acad. Sci.  2013, 110, E3445–E3454. 
(40)  Moldoveanu, T.; Grace, C. R.; Llambi, F.; Nourse, A.; Fitzgerald, P.; Gehring, K.; 
Kriwacki, R. W.; Green, D. R. BID-Induced Structural Changes in BAK Promote 
Apoptosis. Nat. Struct. Biol. 2013, 20, 589–597. 
(41)  Leshchiner, E. S.; Braun, C. R.; Bird, G. H.; Walensky, L. D. Direct Activation of 
Full-Length Proapoptotic BAK. Proc. Natl. Acad. Sci. U. S. A. 2013, 110. 
(42)  Walensky, L. D. Direct BAKtivation. Nat. Struct. Mol. Biol. 2013, 20, 536–538. 
(43)  Cohen, N. a; Stewart, M. L.; Gavathiotis, E.; Tepper, J. L.; Bruekner, S. R.; 
Walensky, L. D. A Competitive Stapled Peptide Screen Identifies a Selective Small 
Molecule That Overcomes MCL-1-Dependent Leukemia Cell Survival. Chem. Biol. 
2012, 19, 1175–1186. 
(44)  Stewart, M. L.; Fire, E.; Keating, A. E.; Walensky, L. D. The MCL-1 BH3 Helix Is 
an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer. Nat Chem Biol 2010, 6, 
595–601. 
(45)  Moellering, R. E.; Cornejo, M.; Davis, T. N.; Del Bianco, C.; Aster, J. C.; Blacklow, 
S. C.; Kung, A. L.; Gilliland, D. G.; Verdine, G. L.; Bradner, J. E. Direct Inhibition 
of the NOTCH Transcription Factor Complex. Nature 2009, 462, 182–188. 
(46)  Grossmann, T. N.; Yeh, J. T.-H.; Bowman, B. R.; Chu, Q.; Moellering, R. E.; 
 263 
Verdine, G. L. Inhibition of Oncogenic Wnt Signaling through Direct Targeting of 
β-Catenin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 17942–17947. 
(47)  Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; 
Pavletich, N. P. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor 
Suppressor Transactivation Domain. Science (80-. ). 1996, 274, 948–953. 
(48)  Vassilev, L. T. In Vivo Activation of the p53 Pathway by Small-Molecule 
Antagonists of MDM2. Science (80-. ). 2004, 303, 844–848. 
(49)  Chang, Y. S.; Graves, B.; Vassilev, L. T.; Sawyer, T. K.; Guerlavaisa, V.; Tovarb, 
C.; Packmanb, K.; Tob, K.-H.; Olsona, K. A.; Kesavana, K.; et al. Stapled α-Helical 
Peptide Drug Development: A Potent Dual Inhibitor of MDM2 and MDMX for p53-
Dependent Cancer Therapy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E3445-54. 
(50)  Baek, S.; Kutchukian, P. S.; Verdine, G. L.; Huber, R.; Holak, T. A.; Lee, K. W.; 
Popowicz, G. M. Structure of the Stapled p53 Peptide Bound to Mdm2. J. Am. 
Chem. Soc. 2012, 134, 103–106. 
(51)  Kim, W.; Bird, G. H.; Neff, T.; Guo, G.; Kerenyi, M. a; Walensky, L. D.; Orkin, S. 
H. Targeted Disruption of the EZH2-EED Complex Inhibits EZH2-Dependent 
Cancer. Nat. Chem. Biol. 2013, 1–10. 
(52)  Long, Y.-Q.; Huang, S.-X.; Zawahir, Z.; Xu, Z.-L.; Li, H.; Sanchez, T. W.; Zhi, Y.; 
De Houwer, S.; Christ, F.; Debyser, Z.; et al. Design of Cell-Permeable Stapled 
Peptides as HIV-1 Integrase Inhibitors. J. Med. Chem. 2013, 56, 5601–5612. 
(53)  Chapuis, H.; Slaninová, J.; Bednárová, L.; Monincová, L.; Buděšínský, M.; 
Čeřovský, V. Effect of Hydrocarbon Stapling on the Properties of α-Helical 
Antimicrobial Peptides Isolated from the Venom of Hymenoptera. Amino Acids 
2012, 43, 2047–2058. 
(54)  Phillips, C.; Roberts, L. R.; Schade, M.; Bazin, R.; Bent, A.; Davies, N. L.; Moore, 
R.; Pannifer, A. D.; Pickford, A. R.; Prior, S. H.; et al. Design and Structure of 
Stapled Peptides Binding to Estrogen Receptors. J. Am. Chem. Soc. 2011, 133, 
9696–9699. 
(55)  Bhattacharya, S.; Zhang, H.; Debnath, A. K.; Cowburn, D. Solution Structure of a 
Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-Terminal 
Domain of HIV-1 Capsid. J. Biol. Chem. 2008, 283, 16274–16278. 
(56)  Danial, N. N.; Walensky, L. D.; Zhang, C.-Y.; Choi, C. S.; Fisher, J. K.; Molina, A. 
J. A.; Datta, S. R.; Pitter, K. L.; Bird, G. H.; Wikstrom, J. D.; et al. Dual Role of 
Proapoptotic BAD in Insulin Secretion and Beta Cell Survival. Nat Med 2008, 14, 
144–153. 
(57)  Green, B. R.; Klein, B. D.; Lee, H.-K.; Smith, M. D.; Steve White, H.; Bulaj, G. 
Cyclic Analogs of Galanin and Neuropeptide Y by Hydrocarbon Stapling. Bioorg. 
Med. Chem. 2013, 21, 303–310. 
(58)  Budwick, D. Aileron Therapeutics Successfully Completes First-Ever Stapled 
Peptide Clinical Trial http://www.aileronrx.com/pdf/Aileron-ALRN-
5281Ph1PRFINAfor5713.pdf. 
(59)  Henchey, L. K.; Kushal, S.; Dubey, R.; Chapman, R. N.; Olenyuk, B. Z.; Arora, P. 
S. Inhibition of Hypoxia Inducible Factor 1-Transcription Coactivator Interaction 
by a Hydrogen Bond Surrogate Alpha-Helix. J. Am. Chem. Soc. 2010, 132, 941–
943. 
 264 
(60)  Wang, D.; Liao, W.; Arora, P. S. Enhanced Metabolic Stability and Protein-Binding 
Properties of Artificial α Helices Derived from a Hydrogen-Bond Surrogate: 
Application to Bcl-xL. Angew. Chemie Int. Ed. 2005, 44, 6525–6529. 
(61)  Mahon, A. B.; Arora, P. S. Design, Synthesis and Protein-Targeting Properties of 
Thioether-Linked Hydrogen Bond Surrogate Helices. Chem. Commun. 2012, 48, 
1416–1418. 
(62)  Boutureira, O.; Bernardes, G. J. L. Advances in Chemical Protein Modification. 
Chem. Rev. 2015, 115, 2174–2195. 
(63)  Fairlie, D. P.; Dantas de Araujo, A. Review Stapling Peptides Using Cysteine 
Crosslinking. Biopolymers 2016, 106, 843–852. 
(64)  Wang, Y.; Chou, D. H.-C. A Thiol-Ene Coupling Approach to Native Peptide 
Stapling and Macrocyclization. Angew. Chem. Int. Ed. Engl. 2015, 54, 10931–
10934. 
(65)  Brunel, F. M.; Dawson, P. E. Synthesis of Constrained Helical Peptides by Thioether 
Ligation: Application to Analogs of gp41. Chem. Commun. 2005, 2552–2554. 
(66)  Kumita, J. R.; Smart, O. S.; Woolley, G. A. Photo-Control of Helix Content in a 
Short Peptide. Proc. Natl. Acad. Sci.  2000, 97, 3803–3808. 
(67)  Nevola, L.; Martín-Quirós, A.; Eckelt, K.; Camarero, N.; Tosi, S.; Llobet, A.; Giralt, 
E.; Gorostiza, P. Light-Regulated Stapled Peptides to Inhibit Protein–Protein 
Interactions Involved in Clathrin-Mediated Endocytosis. Angew. Chemie Int. Ed. 
2013, 52, 7704–7708. 
(68)  Micewicz, E. D.; Sharma, S.; Waring, A. J.; Luong, H. T.; McBride, W. H.; Ruchala, 
P. Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-
Alkylation. Int. J. Pept. Res. Ther. 2016, 22, 67–81. 
(69)  Spokoyny, A. M.; Zou, Y.; Ling, J. J.; Yu, H.; Lin, Y.-S.; Pentelute, B. L. A 
Perfluoroaryl-Cysteine SNAr Chemistry Approach to Unprotected Peptide Stapling. 
J. Am. Chem. Soc. 2013, 135, 5946–5949. 
(70)  Brown, S. P.; Smith, A. B. Peptide/Protein Stapling and Unstapling: Introduction of 
S-Tetrazine, Photochemical Release, and Regeneration of the Peptide/Protein. J. 
Am. Chem. Soc. 2015, 137, 4034–4037. 
(71)  Goto, N. K.; Zor, T.; Martinez-Yamout, M.; Dyson, H. J.; Wright, P. E. 
Cooperativity in Transcription Factor Binding to the Coactivator CREB-Binding 
Protein (CBP). The Mixed Lineage Leukemia Protein (MLL) Activation Domain 
Binds to an Allosteric Site on the KIX Domain. J. Biol. Chem. 2002, 277, 43168–
43174. 
(72)  Ansari, A. Z.; Reece, R. J.; Ptashne, M. A Transcriptional Activating Region with 
Two Contrasting Modes of Protein Interaction. Proc. Natl. Acad. Sci. U. S. A. 1998, 
95, 13543–13548. 
(73)  Mapp, A.; Majmudar, C.; Wang, B.; Jenifer, L.; Håkansson, K. A High-Resolution 
Interaction Map of Three Transcriptional Activation Domains with a Key 
Coactivator from Photo-Cross-Linking and Multiplexed Mass Spectrometry. 
Angew. Chem. Int. Ed. Engl. 2009, 48, 7021–7024. 
(74)  Korkmaz, E. N.; Nussinov, R.; Haliloğlu, T. Conformational Control of the Binding 
of the Transactivation Domain of the MLL Protein and c-Myb to the KIX Domain 
of CREB. PLoS Comput. Biol. 2012, 8, e1002420. 
 265 
(75)  Ernst, P.; Jing, W.; Mary, H.; Richard H., G.; Stanley J., K. MLL and CREB Bind 
Cooperatively to the Nuclear Coactivator CREB-Binding Protein. Mol. Cell. Biol. 
2001, 21, 2249–2258. 
(76)  Sakamoto, K. M.; Frank, D. a. CREB in the Pathophysiology of Cancer: 
Implications for Targeting Transcription Factors for Cancer Therapy. Clin. Cancer 
Res. 2009, 15, 2583–2587. 
(77)  Shankar, D. B.; Cheng, J. C.; Sakamoto, K. M. Role of Cyclic AMP Response 
Element Binding Protein in Human Leukemias. Cancer 2005, 104, 1819–1824. 
(78)  Giri, R.; Morrone, A.; Toto, A.; Brunori, M.; Gianni, S. Structure of the Transition 
State for the Binding of c-Myb and KIX Highlights an Unexpected Order for a 
Disordered System. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 14942–14947. 
(79)  Pagel, K.; Koksch, B. Following Polypeptide Folding and Assembly with 
Conformational Switches. Curr. Opin. Chem. Biol. 2008, 12, 730–739. 
(80)  Bock, J. E.; Gavenonis, J.; Kritzer, J. a. Getting in Shape: Controlling Peptide 
Bioactivity and Bioavailability Using Conformational Constraints. ACS Chem. Biol. 
2013, 8, 488–499. 
(81)  Vakser, I. Protein-Protein Interfaces Are Special. Structure 2004, 12, 910–912. 
(82)  Radhakrishnan, I.; Pérez-Alvarado, G. C.; Parker, D.; Dyson, H. J.; Montminy, M. 
R.; Wright, P. E. Solution Structure of the KIX Domain of CBP Bound to the 
Transactivation Domain of CREB: A Model for Activator:coactivator Interactions. 
Cell 1997, 91, 741–752. 
(83)  Best, J. L.; Amezcua, C. a; Mayr, B.; Flechner, L.; Murawsky, C. M.; Emerson, B.; 
Zor, T.; Gardner, K. H.; Montminy, M. Identification of Small-Molecule 
Antagonists That Inhibit an Activator: Coactivator Interaction. Proc. Natl. Acad. 
Sci. U. S. A. 2004, 101, 17622–17627. 
(84)  Wagner, B. L. Stimulus-Specific Interaction between Activator-Coactivator 
Cognates Revealed with a Novel Complex-Specific Antiserum. J. Biol. Chem. 2000, 
275, 8263–8266. 
(85)  Zor, T.; De Guzman, R. N.; Dyson, H. J.; Wright, P. E. Solution Structure of the 
KIX Domain of CBP Bound to the Transactivation Domain of c-Myb. J. Mol. Biol. 
2004, 337, 521–534. 
(86)  Frangioni, J. V; LaRiccia, L. M.; Cantley, L. C.; Montminy, M. R. Minimal 
Activators That Bind to the KIX Domain of p300/CBP Identified by Phage Display 
Screening. Nat. Biotechnol. 2000, 18, 1080–1085. 
(87)  Brüschweiler, S.; Konrat, R.; Tollinger, M. Allosteric Communication in the KIX 
Domain Proceeds through Dynamic Re-Packing of the Hydrophobic Core. ACS 
Chem. Biol. 2013. 
(88)  Shaywitz, A. J.; Greenberg, M. E. CREB: A Stimulus -Induced Transcription Factor 
Activated By A Diverse Array Of Extracellular Signals. Annu. Rev. Biochem. 1999, 
821–861. 
(89)  Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The next Generation. Cell 
2011, 144, 646–674. 
(90)  Cheng, J. C.; Kinjo, K.; Judelson, D. R.; Chang, J.; Wu, W. S.; Schmid, I.; Shankar, 
D. B.; Kasahara, N.; Stripecke, R.; Bhatia, R.; et al. CREB Is a Critical Regulator of 
Normal Hematopoiesis and Leukemogenesis. Blood 2008, 111, 1182–1192. 
 266 
(91)  Darnell, J. E. Transcription Factors as Targets for Cancer Therapy. Nat. Rev. Cancer 
2002, 2, 740–749. 
(92)  Majmudar, C. Y.; Højfeldt, J. W.; Arevang, C. J.; Pomerantz, W. C.; Gagnon, J. K.; 
Schultz, P. J.; Cesa, L. C.; Doss, C. H.; Rowe, S. P.; Vásquez, V.; et al. Sekikaic 
Acid and Lobaric Acid Target a Dynamic Interface of the Coactivator CBP/p300. 
Angew. Chemie Int. Ed. 2012, 51, 11258–11262. 
(93)  Law, S. M.; Gagnon, J. K.; Mapp, A. K.; Brooks, C. L. Prepaying the Entropic Cost 
for Allosteric Regulation in KIX. Proc. Natl. Acad. Sci.  2014, 111, 12067–12072. 
(94)  Arai, M.; Dyson, H. J.; Wright, P. E. Leu628 of the KIX Domain of CBP Is a Key 
Residue for the Interaction with the MLL Transactivation Domain. FEBS Lett. 2010, 
584, 4500–4504. 
(95)  De Guzman, R. N.; Goto, N. K.; Dyson, H. J.; Wright, P. E. Structural Basis for 
Cooperative Transcription Factor Binding to the CBP Coactivator. J. Mol. Biol. 
2006, 355, 1005–1013. 
(96)  National Cancer Institute. SEER STAT Fact Sheets: Acute Myeloid Leukemia. 
http://seer.cancer.gov/statfacts/html/amyl.html. 
(97)  Howlader, N.; Noone, A.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; 
Altekruse, S.; Kosary, C.; Ruhl, J.; Tatalovich, Z.; et al. SEER Cancer Statistics 
Review 1975-2008 National Cancer Institute SEER Cancer Statistics Review 1975-
2008 National Cancer Institute. Cancer 2011, 2006, 1992–2008. 
(98)  Explore Active Clinical Trials http://keynoteclinicaltrials.com/researchers 
(accessed Jun 4, 2017). 
(99)  Adult Acute Myeloid Leukemia Treatment 
https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-
pdq#section/_73 (accessed Jun 4, 2017). 
(100)  Denis, C. M.; Chitayat, S.; Plevin, M. J.; Wang, F.; Thompson, P.; Liu, S.; Spencer, 
H. L.; Ikura, M.; LeBrun, D. P.; Smith, S. P. Structural Basis of CBP/p300 
Recruitment in Leukemia Induction by E2A-PBX1. Blood 2012, 120, 3968–3977. 
(101)  Paulsen, C. E.; Carroll, K. S. Cysteine-Mediated Redox Signaling: Chemistry, 
Biology, and Tools for Discovery. Chem. Rev. 2013, 113, 4633–4679. 
(102)  Giles, N. M.; Watts, A. B.; Giles, G. I.; Fry, F. H.; Littlechild, J. A.; Jacob, C. Metal 
and Redox Modulation of Cysteine Protein Function. Chem. Biol. 2003, 10, 677–
693. 
(103)  Moskovitz, J.; Bar-Noy, S.; Williams, W. M.; Requena, J.; Berlett, B. S.; Stadtman, 
E. R. Methionine Sulfoxide Reductase (MsrA) Is a Regulator of Antioxidant 
Defense and Lifespan in Mammals. Proc. Natl. Acad. Sci.  2001, 98, 12920–12925. 
(104)  Levine, R. L.; Berlett, B. S.; Moskovitz, J.; Mosoni, L.; Stadtman, E. R. Methionine 
Residues May Protect Proteins from Critical Oxidative Damage. Mech. Ageing Dev. 
1999. 
(105)  Reid, K. S. C.; Lindley, P. F.; Thornton, J. M. Sulphur-Aromatic Interactions in 
Proteins. FEBS Lett. 1985. 
(106)  Tatko, C. D.; Waters, M. L. Investigation of the Nature of the Methionine-Pi 
Interaction in Beta-Hairpin Peptide Model Systems. Protein Sci. 2004, 13, 2515–
2522. 
(107)  Viguera, A. R.; Serrano, L. Side-Chain Interactions between Sulfur-Containing 
 267 
Amino Acids and Phenylalanine in  ??-Helices. Biochemistry 1995. 
(108)  Yamaotsu, N.; Moriguchi, I.; Hirono, S. Estimation of Stabilities of Staphylococcal 
Nuclease Mutants (Met32 → Ala and Met32 → Leu) Using Molecular 
Dynamics/free Energy Perturbation. Biochim. Biophys. Acta - Protein Struct. Mol. 
Enzymol. 1993, 1203, 243–250. 
(109)  Dougherty, D. A. The Cation-Pi Interaction. Acc. Chem. Res. 2013. 
(110)  Kearney, P. C.; Mizoue, L. S.; Kumpf, R. A.; Forman, J. E.; McCurdy, A.; 
Dougherty, D. A. Molecular Recognition in Aqueous Media. New Binding Studies 
Provide Further Insights into the Cation-.pi. Interaction and Related Phenomena. J. 
Am. Chem. Soc. 1993, 115, 9907–9919. 
(111)  Salonen, L. M.; Ellermann, M.; Diederich, F. Aromatic Rings in Chemical and 
Biological Recognition: Energetics and Structures. Angew. Chemie Int. Ed. 2011, 
50, 4808–4842. 
(112)  Tsuzuki, S. Interactions with Aromatic Rings BT  - Intermolecular Forces and 
Clusters I. In; Wales, D. J., Ed.; Springer Berlin Heidelberg: Berlin, Heidelberg, 
2005; pp. 149–193. 
(113)  Dougherty, D. A. Cation-Pi Interactions in Chemistry and Biology: A New View of 
Benzene, Phe, Tyr, and Trp. Science (80-. ). 1996. 
(114)  Tavares, X. D. S.; Blum, A. P.; Nakamura, D. T.; Puskar, N. L.; Shanata, J. A. P.; 
Lester, H. A.; Dougherty, D. A. Variations in Binding Among Several Agonists at 
Two Stoichiometries of the Neuronal, α4β2 Nicotinic Receptor. J. Am. Chem. Soc. 
2012, 134, 11474–11480. 
(115)  Valley, C. C.; Cembran, A.; Perlmutter, J. D.; Lewis, A. K.; Labello, N. P.; Gao, J.; 
Sachs, J. N. The Methionine-Aromatic Motif Plays a Unique Role in Stabilizing 
Protein Structure. J. Biol. Chem. 2012, 287, 34979–34991. 
(116)  Zauhar, R. J.; Colbert, C. L.; Morgan, R. S.; Welsh, W. J. Evidence for a Strong 
Sulfur-Aromatic Interaction Derived from Crystallographic Data. Biopolymers 
2000. 
(117)  Pranata, J. Sulfur–Aromatic Interactions: A Computational Study of the Dimethyl 
Sulfide–Benzene Complex. Bioorg. Chem. 1997. 
(118)  MORGAN, R. S.; McADON, J. M. PREDICTOR FOR SULFUR???AROMATIC 
INTERACTIONS IN GLOBULAR PROTEINS. Int. J. Pept. Protein Res. 1980. 
(119)  Morgan, R. S.; Tatsch, C. E.; Gushard, R. H.; Mcadon, J. M.; Warme, P. K. CHAINS 
OF ALTERNATING SULFUR AND  ?????BONDED ATOMS IN EIGHT SMALL 
PROTEINS. Int. J. Pept. Protein Res. 1978. 
(120)  Viguera, A. R.; Serrano, L. Side-Chain Interactions between Sulfur-Containing 
Amino Acids and Phenyalanine in .alpha.-Helixes. Biochemistry 1995, 34, 8771–
8779. 
(121)  Shechter, Y.; Burstein, Y.; Patchornik, A. Selective Oxidation of Methionine 
Residues in Proteins. Biochemistry 1975. 
(122)  Hoshi, T.; Heinemann, S. Regulation of Cell Function by Methionine Oxidation and 
Reduction. J Physiol 2001. 
(123)  Kim, G.; Weiss, S. J.; Levine, R. L. Methionine Oxidation and Reduction in 
Proteins. Biochimica et Biophysica Acta - General Subjects, 2014. 
(124)  Arakawa, T.; Kita, Y.; Timasheff, S. N. Protein Precipitation and Denaturation by 
 268 
Dimethyl Sulfoxide. Biophys. Chem. 2007. 
(125)  Scott, J.; Asami, M.; Tanaka, K. Novel Chromogenic, Guest-Sensitive Host 
Compounds. New J. Chem. 2002. 
(126)  Rose, G. D.; Geselowitz, A. R.; Lesser, G. J.; Lee, R. H.; Zehfus, M. H. 
Hydrophobicity of Amino Acid Residues in Globular Proteins. Science (80-. ). 1985. 
(127)  Bogan, A. A.; Thorn, K. S. Anatomy of Hot Spots in Protein interfaces11Edited by 
J. Wells. J. Mol. Biol. 1998, 280, 1–9. 
(128)  Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR Chemical Shifts of Common 
Laboratory Solvents as Trace Impurities. J. Org. Chem. 1997. 
(129)  Butterfield, S. M.; Patel, P. R.; Waters, M. L. Contribution of Aromatic Interactions 
to α-Helix Stability. J. Am. Chem. Soc. 2002. 
(130)  Marqusee, S. Helix Stabilization by Glu-... Lys+ Salt Bridges in Short Peptides of 
de Novo Design. Proc. Natl. Acad. Sci. 1987. 
(131)  Pearson, K. On Lines and Planes of Closest Fit to Systems of Points in Space. 
London, Edinburgh, Dublin Philos. Mag. J. Sci. 1901. 
(132)  Yin, D.; Kuczera, K.; Squier, T. C. The Sensitivity of Carboxyl-Terminal 
Methionines in Calmodulin Isoforms to Oxidation by H2O2 Modulates the Ability 
to Activate the Plasma Membrane Ca-ATPase. Chem. Res. Toxicol. 2000. 
(133)  Sacksteder, C. A.; Whittier, J. E.; Xiong, Y. J.; Li, J. H.; Galeva, N. A.; Jacoby, M. 
E.; Purvine, S. O.; Williams, T. D.; Rechsteiner, M. C.; Bigelow, D. J.; et al. Tertiary 
Structural Rearrangements upon Oxidation of methionine(145) in Calmodulin 
Promotes Targeted Proteasomal Degradation. Biophys. J. 2006. 
(134)  Gao, J.; Yao, Y.; Squier, T. C. Oxidatively Modified Calmodulin Binds to the 
Plasma Membrane Ca-ATPase in a Nonproductive and Conformationally 
Disordered Complex. Biophys. J. 2001. 
(135)  Gao, J.; Yin, D. H.; Yao, Y.; Sun, H.; Qin, Z.; Schoneich, C.; Williams, T. D.; 
Squier, T. C. Loss of Conformational Stability in Calmodulin upon Methionine 
Oxidation. Biophys. J. 1998. 
(136)  Boschek, C. B.; Jones, T. E.; Smallwood, H. S.; Squier, T. C.; Bigelow, D. J. Loss 
of the Calmodulin-Dependent Inhibition of the RyR1 Calcium Release Channel 
upon Oxidation of Methionines in Calmodulin. Biochemistry 2008. 
(137)  Bartlett, R. K.; Urbauer, R. J. B.; Anbanandam, A.; Smallwood, H. S.; Urbauer, J. 
L.; Squier, T. C. Oxidation of Met144 and Met145 in Calmodulin Blocks 
Calmodulin Dependent Activation of the Plasma Membrane Ca-ATPase. 
Biochemistry 2003. 
(138)  Babu, Y. S.; Bugg, C. E.; Cook, W. J. Structure of Calmodulin Refined at 2.2 Å 
Resolution. J. Mol. Biol. 1988. 
(139)  Kuboniwa, H.; Tjandra, N.; Grzesiek, S.; Ren, H.; Klee, C. B.; Bax, A. Solution 
Structure of Calcium-Free Calmodulin. Nat. Struct. Biol. 1995. 
(140)  Mukherjea, P.; Maune, J. F.; Beckingham, K. Interlobe Communication in Multiple 
Calcium-Binding Site Mutants of Drosophila Calmodulin. Protein Sci. 1996. 
(141)  Anbanandam, A.; Bieber Urbauer, R. J.; Bartlett, R. K.; Smallwood, H. S.; Squier, 
T. C.; Urbauer, J. L. Mediating Molecular Recognition by Methionine Oxidation: 
Conformational Switching by Oxidation of Methionine in the Carboxyl-Terminal 
Domain of Calmodulin. Biochemistry 2005. 
 269 
(142)  Jeschke, G. DEER Distance Measurements on Proteins. Annu. Rev. Phys. Chem. 
2012. 
(143)  Ilardi, E. A.; Vitaku, E.; Njardarson, J. T. Data-Mining for Sulfur and Fluorine: An 
Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and 
Discovery. J. Med. Chem. 2014, 57, 2832–2842. 
(144)  Vasquez, M.; Pincus, M. R.; Scheraga, H. A. Helix–coil Transition Theory 
Including Long-Range Electrostatic Interactions: Application to Globular Proteins. 
Biopolymers 1987, 26, 351–371. 
(145)  Greenfield, N. J. Using Circular Dichroism Collected as a Function of Temperature 
to Determine the Thermodynamics of Protein Unfolding and Binding Interactions. 
Nat. Protoc. 2007. 
(146)  Fealey, M. E.; Gauer, J. W.; Kempka, S. C.; Miller, K.; Nayak, K.; Sutton, R. B.; 
Hinderliter, A. Negative Coupling as a Mechanism for Signal Propagation between 
C2 Domains of Synaptotagmin I. PLoS One 2012. 
(147)  Horovitz, A. Double-Mutant Cycles: A Powerful Tool for Analyzing Protein 
Structure and Function. Fold. Des. 1996. 
(148)  Horovitz, A.; Serrano, L.; Avron, B.; Bycroft, M.; Fersht, A. R. Strength and Co-
Operativity of Contributions to Surface Salt Bridges to Protein Stability. J. Mol. 
Biol. 1990. 
(149)  Serrano, L.; Bycroft, M.; Fersht, A. R. Aromatic-Aromatic Interactions and Protein 
Stability. Investigation by Double-Mutant Cycles. J. Mol. Biol. 1991. 
(150)  Balog, E. M.; Lockamy, E. L.; Thomas, D. D.; Ferrington, D. A. Site-Specific 
Methionine Oxidation Initiates Calmodulin Degradation by the 20S Proteasome. 
Biochemistry 2009. 
(151)  Klein, J. C.; Burr, A. R.; Svensson, B.; Kennedy, D. J.; Allingham, J.; Titus, M. a; 
Rayment, I.; Thomas, D. D. Actin-Binding Cleft Closure in Myosin II Probed by 
Site-Directed Spin Labeling and Pulsed EPR. Proc. Natl. Acad. Sci. U. S. A. 2008. 
(152)  Etemadi, N.; Holien, J. K.; Chau, D.; Dewson, G.; Murphy, J. M.; Alexander, W. 
S.; Parker, M. W.; Silke, J.; Nachbur, U. Lymphotoxin α Induces Apoptosis, 
Necroptosis and Inflammatory Signals with the Same Potency as Tumour Necrosis 
Factor. In FEBS Journal; 2013. 
(153)  Frisch, M. J. et al. Gaussian 09, Revision D.01. Gaussian 09, Revision D.01, 2009. 
(154)  Boys, S.; Bernardi, F. The Calculation of Small Molecular Interactions by the 
Differences of Separate Total Energies. Some Procedures with Reduced Errors. Mol. 
Phys. 1970. 
(155)  Zhao, Y.; Truhlar, D. G. A New Local Density Functional for Main-Group 
Thermochemistry, Transition Metal Bonding, Thermochemical Kinetics, and 
Noncovalent Interactions. J. Chem. Phys. 2006. 
(156)  Reed, A. E.; Curtiss, L. a; Weinhold, F. Intermolecular Interactions from a Natural 
Bond Orbital, Donor-Acceptor Viewpoint. Chem. Rev. (Washington, DC, United 
States) 1988. 
(157)  Mulliken, R. S. Electronic Population Analysis on LCAO–MO Molecular Wave 
Functions. I. J. Chem. Phys. 1955. 
(158)  Cramer, C. J. Essentials of Computational Chemistry Theories and Models; 2004. 
(159)  Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, 
 270 
C.; Skeel, R. D.; Kalé, L.; Schulten, K. Scalable Molecular Dynamics with NAMD. 
Journal of Computational Chemistry, 2005. 
(160)  Banner, D. W.; Darcy, A.; Janes, W.; Gentz, R.; Schoenfeld, H. J.; Broger, C.; 
Loetscher, H.; Lesslauer, W. Crystal Structure of the Soluble Human 55 Kd TNF 
Receptor- Human TNF-Beta Complex - Implications for TNF Receptor Activation. 
Cell 1993. 
(161)  Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. 
Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. 
Phys. 1983. 
(162)  MacKerell, A.; Bashford, D. All-Atom Empirical Potential for Molecular Modeling 
and Dynamics Studies of Proteins. J. Phys. Chem. B 1998. 
(163)  MacKerell, A. D.; Feig, M.; Brooks, C. L. Improved Treatment of the Protein 
Backbone in Empirical Force Fields. J. Am. Chem. Soc. 2004. 
(164)  Best, R. B.; Zhu, X.; Shim, J.; Lopes, P. E. M.; Mittal, J.; Feig, M.; MacKerell, A. 
D. Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting 
Improved Sampling of the Backbone  ??,  ?? And Side-Chain  ?? 1 and  ?? 2 Dihedral 
Angles. J. Chem. Theory Comput. 2012. 
(165)  Martyna, G. J.; Tobias, D. J.; Klein, M. L. Constant Pressure Molecular Dynamics 
Algorithms. J. Chem. Phys. 1994. 
(166)  Jas, G. S.; Kuczera, K. Free-Energy Simulations of the Oxidation of C-Terminal 
Methionines in Calmodulin. Proteins Struct. Funct. Genet. 2002. 
(167)  Darden, T.; Perera, L.; Li, L.; Lee, P. New Tricks for Modelers from the 
Crystallography Toolkit: The Particle Mesh Ewald Algorithm and Its Use in Nucleic 
Acid Simulations. Structure 1999. 
(168)  Tuckerman, M.; Berne, G. J.; Martyna, B. J. Reversible Multiple Time Scale 
Molecular Dynamics. J. Chem. Phys. 1992. 
(169)  Andersen, H. C. Rattle: A “velocity” version of the Shake Algorithm for Molecular 
Dynamics Calculations. J. Comput. Phys. 1983. 
(170)  Lewis, A. K.; Dunleavy, K. M.; Senkow, T. L.; Her, C.; Horn, B. T.; Jersett, M. A.; 
Mahling, R.; McCarthy, M. R.; Perell, G. T.; Valley, C. C.; et al. Oxidation Increases 
the Strength of the Methionine-Aromatic Interaction. Nat Chem Biol 2016, 12, 860–
866. 
(171)  Fry, D. C.; Vassilev, L. T. Targeting Protein-Protein Interactions for Cancer 
Therapy. J. Mol. Med. 2005, 83, 955–963. 
(172)  Bird, G. H.; Madani, N.; Perry, A. F.; Princiotto, A. M.; Supko, J. G.; He, X.; 
Gavathiotis, E.; Sodroski, J. G.; Walensky, L. D. Hydrocarbon Double-Stapling 
Remedies the Proteolytic Instability of a Lengthy Peptide Therapeutic. Proc. Natl. 
Acad. Sci. U. S. A. 2010, 107, 14093–14098. 
(173)  Verdine, G. L.; Hilinski, G. J. Stapled Peptides for Intracellular Drug Targets.; 1st 
ed.; Elsevier Inc., 2012; Vol. 503. 
(174)  Henchey, L. K.; Jochim, A. L.; Arora, P. S. Contemporary Strategies for the 
Stabilization of Peptides in the Alpha-Helical Conformation. Curr. Opin. Chem. 
Biol. 2008, 12, 692–697. 
(175)  Kalhor-Monfared, S.; Jafari, M. R.; Patterson, J. T.; Kitov, P. I.; Dwyer, J. J.; Nuss, 
J. M.; Derda, R. Rapid Biocompatible Macrocyclization of Peptides with 
 271 
Decafluoro-Diphenylsulfone. Chem. Sci. 2016, 7, 3785–3790. 
(176)  Jo, H.; Meinhardt, N.; Wu, Y.; Kulkarni, S.; Hu, X.; Low, K. E.; Davies, P. L.; 
DeGrado, W. F.; Greenbaum, D. C. Development of α-Helical Calpain Probes by 
Mimicking a Natural Protein–Protein Interaction. J. Am. Chem. Soc. 2012, 134, 
17704–17713. 
(177)  Bird, G. H.; Mazzola, E.; Opoku-Nsiah, K.; Lammert, M. A.; Godes, M.; Neuberg, 
D. S.; Walensky, L. D. Biophysical Determinants for Cellular Uptake of 
Hydrocarbon-Stapled Peptide Helices. Nat Chem Biol 2016, 12, 845–852. 
(178)  Wang, J.; Iwasaki, H.; Krivtsov, A.; Febbo, P. G.; Thorner, A. R.; Ernst, P.; 
Anastasiadou, E.; Kutok, J. L.; Kogan, S. C.; Zinkel, S. S.; et al. Conditional MLL-­‐
CBP Targets GMP and Models Therapy-­‐related Myeloproliferative Disease. EMBO 
J. 2005, 24, 368 LP-381. 
(179)  Palazzesi, F.; Barducci, A.; Tollinger, M.; Parrinello, M. The Allosteric 
Communication Pathways in KIX Domain of CBP. Proc. Natl. Acad. Sci.  2013, 
110, 14237–14242. 
(180)  Holland, H. L.; Andreana, P. R.; Brown, F. M. Biocatalytic and Chemical Routes to 
All the Stereoisomers of Methionine and Ethionine Sulfoxides. Tetrahedron: 
Asymmetry 1999, 10, 2833–2843. 
(181)  Schenck, H. L.; Dado, G. P.; Gellman, S. H. Redox-Triggered Secondary Structure 
Changes in the Aggregated States of a Designed Methionine-Rich Peptide. J. Am. 
Chem. Soc. 1996, 118, 12487–12494. 
(182)  Marenich, A. V; Cramer, C. J.; Truhlar, D. G. Generalized Born Solvation Model 
SM12. J. Chem. Theory Comput. 2013, 9, 609–620. 
(183)  Gunzburg, M. J.; Kulkarni, K.; Watson, G. M.; Ambaye, N. D.; Del Borgo, M. P.; 
Brandt, R.; Pero, S. C.; Perlmutter, P.; Wilce, M. C. J.; Wilce, J. A. Unexpected 
Involvement of Staple Leads to Redesign of Selective Bicyclic Peptide Inhibitor of 
Grb7. Sci. Rep. 2016, 6, 27060. 
(184)  Phillips, C.; Roberts, L. R.; Schade, M.; Bazin, R.; Bent, A.; Davies, N. L.; Moore, 
R.; Pannifer, A. D.; Pickford, A. R.; Prior, S. H.; et al. Design and Structure of 
Stapled Peptides Binding. J. Am. Chem. Soc. 2011, 133, 9696–9699. 
(185)  Speltz, T. E.; Fanning, S. W.; Mayne, C. G.; Fowler, C.; Tajkhorshid, E.; Greene, 
G. L.; Moore, T. W. Stapled Peptides with γ-Methylated Hydrocarbon Chains for 
the Estrogen Receptor/Coactivator Interaction. Angew. Chemie Int. Ed. 2016, 55, 
4252–4255. 
(186)  Ernst, P.; Wang, J.; Huang, M.; Goodman, R. H.; Korsmeyer, S. J. MLL and CREB 
Bind Cooperatively to the Nuclear Coactivator CREB-Binding Protein. Mol. Cell. 
Biol. 2001, 21, 2249–2258. 
(187)  Kim, Y.-W.; Kutchukian, P. S.; Verdine, G. L. Introduction of All-Hydrocarbon 
i,i+3 Staples into Alpha-Helices via Ring-Closing Olefin Metathesis. Org. Lett. 
2010, 12, 3046–3049. 
(188)  Checco, J. W.; Lee, E. F.; Evangelista, M.; Sleebs, N. J.; Rogers, K.; 
Pettikiriarachchi, A.; Kershaw, N. J.; Eddinger, G. A.; Belair, D. G.; Wilson, J. L.; 
et al. Α/β-Peptide Foldamers Targeting Intracellular Protein-Protein Interactions 
with Activity in Living Cells. J. Am. Chem. Soc. 2015, 137, 11365–11375. 
(189)  Zhang, Q.; Jiang, F.; Zhao, B.; Lin, H.; Tian, Y.; Xie, M.; Bai, G.; Gilbert, A. M.; 
 272 
Goetz, G. H.; Liras, S.; et al. Chiral Sulfoxide-Induced Single Turn Peptide α-
Helicity. Sci. Rep. 2016, 6, 38573. 
(190)  Gee, C. T.; Koleski, E. J.; Pomerantz, W. C. K. Fragment Screening and 
Druggability Assessment for the CBP/p300 KIX Domain through Protein-Observed 
19F NMR Spectroscopy. Angew. Chem. Int. Ed. Engl. 2015, 54, 3735–3739. 
(191)  Pomerantz, W. C.; Wang, N.; Lipinski, A. K.; Wang, R.; Cierpicki, T.; Mapp, A. K. 
Profiling the Dynamic Interfaces of Fluorinated Transcription Complexes for 
Ligand Discovery and Characterization. ACS Chem. Biol. 2012, 7, 1345–1350. 
(192)  Gee, C. T.; Arntson, K. E.; Urick, A. K.; Mishra, N. K.; Hawk, L. M. L.; Wisniewski, 
A. J.; Pomerantz, W. C. K. Protein-Observed 19F-NMR for Fragment Screening, 
Affinity Quantification and Druggability Assessment. Nat. Protoc. 2016, 11, 1414–
1427. 
(193)  Jo, H.; Meinhardt, N.; Wu, Y.; Kulkarni, S.; Hu, X.; Low, K. E.; Davies, P. L.; 
DeGrado, W. F.; Greenbaum, D. C. Development of α-Helical Calpain Probes by 
Mimicking a Natural Protein-Protein Interaction. J. Am. Chem. Soc. 2012, 134, 
17704–17713. 
(194)  Mitchell, D. J.; Steinman, L.; Kim, D. T.; Fathman, C. G.; Rothbard, J. B. 
Polyarginine Enters Cells More Efficiently than Other Polycationic Homopolymers. 
J. Pept. Res. 2000, 56, 318–325. 
(195)  Bertucci, C.; Domenici, E. Reversible and Covalent Binding of Drugs to Human 
Serum Albumin: Methodological Approaches and Physiological Relevance. Curr 
Med Chem 2002. 
(196)  Basken, N. E.; Mathias, C. J.; Green, M. A. Elucidation of the Human Serum 
Albumin (HSA) Binding Site for the Cu-PTSM and Cu-ATSM 
Radiopharmaceuticals. J. Pharm. Sci. 2009, 98, 2170–2179. 
(197)  SUDLOW, G.; BIRKETT, D. J.; WADE, D. N. The Characterization of Two 
Specific Drug Binding Sites on Human Serum Albumin. Mol. Pharmacol. 1975, 11, 
824 LP-832. 
(198)  Mishra, N. K.; Urick, A. K.; Ember, S. W. J.; Schönbrunn, E.; Pomerantz, W. C. 
Fluorinated Aromatic Amino Acids Are Sensitive 19F NMR Probes for 
Bromodomain-Ligand Interactions. ACS Chem. Biol. 2014, 9, 2755–2760. 
(199)  Richards, K. L.; Rowe, M. L.; Hudson, P. B.; Williamson, R. A.; Howard, M. J. 
Combined Ligand-Observe 19F and Protein-Observe 15N,1H-HSQC NMR 
Suggests Phenylalanine as the Key Δ-Somatostatin Residue Recognized by Human 
Protein Disulfide Isomerase. Sci. Rep. 2016. 
(200)  Naik, P. N.; Chimatadar, S. A.; Nandibewoor, S. T. Interaction between a Potent 
Corticosteroid Drug – Dexamethasone with Bovine Serum Albumin and Human 
Serum Albumin: A Fluorescence Quenching and Fourier Transformation Infrared 
Spectroscopy Study. J. Photochem. Photobiol. B Biol. 2010, 100, 147–159. 
(201)  Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, 
S. Structural Basis of the Drug-Binding Specificity of Human Serum Albumin. J. 
Mol. Biol. 2005, 353, 38–52. 
(202)  Shao, Y.; Gan, Z.; Epifanovsky, E.; Gilbert, A. T. B.; Wormit, M.; Kussmann, J.; 
Lange, A. W.; Behn, A.; Deng, J.; Feng, X.; et al. Advances in Molecular Quantum 
Chemistry Contained in the Q-Chem 4 Program Package. Mol. Phys. 2015, 113, 
 273 
184–215. 
(203)  Devlin, F. J.; Finley, J. W.; Stephens, P. J.; Frisch, M. J. Ab Initio Calculation of 
Vibrational Absorption and Circular Dichroism Spectra Using Density Functional 
Force Fields: A Comparison of Local, Nonlocal, and Hybrid Density Functionals. J. 
Phys. Chem. 1995, 99, 16883–16902. 
(204)  Becke, A. D. Density-Functional Exchange-Energy Approximation with Correct 
Asymptotic Behavior. Phys. Rev. A 1988, 38, 3098–3100. 
(205)  Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti Correlation-
Energy Formula into a Functional of the Electron Density. Phys. Rev. B 1988, 37, 
785–789. 
(206)  Becke, A. D. Density-­‐functional Thermochemistry. III. The Role of Exact 
Exchange. J. Chem. Phys. 1993, 98, 5648–5652. 
(207)  Marenich, A. V; Jerome, S. V; Cramer, C. J.; Truhlar, D. G. Charge Model 5: An 
Extension of Hirshfeld Population Analysis for the Accurate Description of 
Molecular Interactions in Gaseous and Condensed Phases. J. Chem. Theory Comput. 
2012, 8, 527–541. 
(208)  Holland, H. L.; Andreana, P. R.; Brown, F. M. Biocatalytic and Chemical Routes to 
All the Stereoisomers of Methionine and Ethionine Sulfoxides. Tetrahedron: 
Asymmetry 1999, 10, 2833–2843. 
(209)  Muchmore, D. C.; McIntosh, L. P.; Russell, C. B.; Anderson, D. E.; Dahlquist, F. 
W. Expression and Nitrogen-15 Labeling of Proteins for Proton and Nitrogen-15 
Nuclear Magnetic Resonance. In; 1989; pp. 44–73. 
(210)  Pace, C. N.; Vajdos, F.; Fee, L.; Grimsley, G.; Gray, T. How to Measure and Predict 
the Molar Absorption Coefficient of a Protein. Protein Sci. 1995, 4, 2411–2423. 
(211)  Hu, K.; Sun, C.; Yang, D.; Wu, Y.; Shi, C.; Chen, L.; Liao, T.; Guo, J.; Liu, Y.; Li, 
Z. A Precisely Positioned Chiral Center in an I, I + 7 Tether Modulates the Helicity 
of the Backbone Peptide. Chem. Commun. 2017, 53, 6728–6731. 
(212)  Aimetti, A.; Shoemaker, R. K.; Lin, C.-C.; Anseth, K. S. On-Resin Peptide 
Macrocyclization Using Thiol-Ene Click Chemistry. Chem. Commun. 2010, 46, 
4061–4063. 
(213)  Piccirillo, G.; Pepe, A.; Bedini, E.; Bochicchio, B. Photoinduced Thiol-Ene 
Chemistry Applied to the Synthesis of Self-Assembling Elastin-Inspired 
Glycopeptides. Chem. – A Eur. J. 2017, 23, 2648–2659. 
(214)  Kramer, J. R.; Deming, T. J. Glycopolypeptides with a Redox-Triggered Helix-to-
Coil Transition. J. Am. Chem. Soc. 2012, 134, 4112–4115. 
(215)  Campos, L. M.; Killops, K. L.; Sakai, R.; Paulusse, J. M. J.; Damiron, D.; 
Drockenmuller, E.; Messmore, B. W.; Hawker, C. J. Development of Thermal and 
Photochemical Strategies for Thiol−Ene Click Polymer Functionalization. 
Macromolecules 2008, 41, 7063–7070. 
(216)  Chen, B.; Skoumbourdis, A. P.; Guo, P.; Bednarz, M. S.; Kocy, O. R.; Sundeen, J. 
E.; Vite, G. D.; Lett, A. T. A Facile Method for the Transformation of N-(Tert-
Butoxycarbonyl) Alpha-Amino Acids to N-Unprotected Alpha-Amino Methyl 
Esters. J. Org. Chem. 1999, 9294–9296. 
(217)  Salvatore, R. N.; Smith, R. a.; Nischwitz, A. K.; Gavin, T. A Mild and Highly 
Convenient Chemoselective Alkylation of Thiols Using Cs2CO3–TBAI. 
 274 
Tetrahedron Lett. 2005, 46, 8931–8935. 
(218)  Cochrane, S. A.; Huang, Z.; Vederas, J. C. Investigation of the Ring-Closing 
Metathesis of Peptides in Water. Org. Biomol. Chem. 2013, 11, 630–639. 
(219)  Biron, E.; Kessler, H. Convenient Synthesis of N-Methylamino Acids Compatible 
with Fmoc Solid-Phase Peptide Synthesis. J. Org. Chem. 2005, 70, 5183–5189. 
(220)  Rogers, G. a; Shaltiel, N.; Boyer, P. D. Facile Alkylation of Methionine by Benzyl 
Bromide and Demonstration of Fumarase Inactivation Accompanied by Alkylation 
of a Methionine Residue. J. Biol. Chem. 1976, 251, 5711–5717. 
(221)  Kyte, J.; Degen, J.; Harkins, R. N. Purification of Peptides That Contain Methionine 
Residues. Methods Enzymol. 1983, 91, 367–377. 
(222)  Kornberg, R. D.; Thonmas, J. O. Chromatin Structure: Oligomers of the Histones. 
Science (80-. ). 1974, 184, 865 LP-868. 
(223)  Sharma, S.; Kelly, T. K.; Jones, P. A. Epigenetics in Cancer. Carcinogenesis 2010, 
31, 27–36. 
(224)  Kornberg, R. D.; Lorch, Y. Twenty-Five Years of the Nucleosome, Fundamental 
Particle of the Eukaryote Chromosome. Cell 1999, 98, 285–294. 
(225)  Martin, C.; Zhang, Y. The Diverse Functions of Histone Lysine Methylation. Nat 
Rev Mol Cell Biol 2005, 6, 838–849. 
(226)  Brown, Z. Z.; Müller, M. M.; Jain, S. U.; Allis, C. D.; Lewis, P. W.; Muir, T. W. 
Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on 
Mapping Its Interaction with the Methyltransferase PRC2. J. Am. Chem. Soc. 2014, 
136, 13498–13501. 
(227)  Prinjha, R. K.; Witherington, J.; Lee, K. Place Your BETs: The Therapeutic 
Potential of Bromodomains. Trends Pharmacol. Sci. 2017, 33, 146–153. 
(228)  Tamkun, J. W.; Deuring, R.; Scott, M. P.; Kissinger, M.; Pattatucci, A. M.; 
Kaufman, T. C.; Kennison, J. A. Brahma: A Regulator of Drosophila Homeotic 
Genes Structurally Related to the Yeast Transcriptional Activator SNF2 SWI2. Cell 
1992, 68, 561–572. 
(229)  Ferri, E.; Petosa, C.; McKenna, C. E. Bromodomains: Structure, Function and 
Pharmacology of Inhibition. Biochem. Pharmacol. 2016, 106, 1–18. 
(230)  Sanchez, R.; Zhou, M.-M. The Role of Human Bromodomains in Chromatin 
Biology and Gene Transcription. Curr. Opin. Drug Discov. Dev. 2009, 12, 659–665. 
(231)  Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, 
E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; et al. Selective Inhibition of BET 
Bromodomains. Nature 2010, 468, 1067–1073. 
(232)  Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.; 
Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; et al. Suppression of 
Inflammation by a Synthetic Histone Mimic. Nature 2010, 468, 1119–1123. 
(233)  Shi, J.; Vakoc, C. R. The Mechanisms behind the Therapeutic Activity of BET 
Bromodomain Inhibition. Mol. Cell 2014, 54, 728–736. 
(234)  Pan, L. N.; Lu, J.; Huang, B. HDAC Inhibitors: A Potential New Category of Anti-
Tumor Agents. Cell. Mol. Immunol. 2007, 4, 337–343. 
(235)  Ruijter, A. J. M. de; Gennip, A. H. van; Caron, H. N.; Kemp, S.; Kuilenburg, A. B. 
P. van. Histone Deacetylases (HDACs): Characterization of the Classical HDAC 
Family. Biochem. J. 2003, 370, 737 LP-749. 
 275 
(236)  Grant, S.; Easley, C.; Kirkpatrick, P. Vorinostat. Nat Rev Drug Discov 2007, 6, 21–
22. 
(237)  Talbert, P. B.; Henikoff, S. Histone Variants-Ancient Wrap Artists of the 
Epigenome. Nat Rev Mol Cell Biol 2010, 11. 
(238)  Iouzalen, N.; Moreau, J.; Méchali, M. H2A.ZI, a New Variant Histone Expressed 
during Xenopus Early Development Exhibits Several Distinct Features from the 
Core Histone H2A. Nucleic Acids Res. 1996, 24, 3947–3952. 
(239)  Zlatanova, J.; Thakar, A. H2A.Z: View from the Top. Structure 2008, 16. 
(240)  Obri, A.; Ouararhni, K.; Papin, C.; Diebold, M.-L.; Padmanabhan, K.; Marek, M.; 
Stoll, I.; Roy, L.; Reilly, P. T.; Mak, T. W.; et al. ANP32E Is a Histone Chaperone 
That Removes H2A.Z from Chromatin. Nature 2014, 505, 648–653. 
(241)  Mao, Z.; Pan, L.; Wang, W.; Sun, J.; Shan, S.; Dong, Q.; Liang, X.; Dai, L.; Ding, 
X.; Chen, S.; et al. Anp32e, a Higher Eukaryotic Histone Chaperone Directs 
Preferential Recognition for H2A.Z. Cell Res 2014, 24, 389–399. 
(242)  Petter, M.; Lee, C. C.; Byrne, T. J.; Boysen, K. E.; Volz, J.; Ralph, S. A.; Cowman, 
A. F.; Brown, G. V; Duffy, M. F. Expression of P. Falciparum Var Genes Involves 
Exchange of the Histone Variant H2A.Z at the Promoter. PLOS Pathog. 2011, 7, 
e1001292. 
(243)  Fan, Q.; An, L.; Cui, L. Plasmodium Falciparum Histone Acetyltransferase, a Yeast 
GCN5 Homologue Involved in Chromatin Remodeling. Eukaryot. Cell 2004, 3, 
264–276. 
(244)  Srivastava, S.; Bhowmick, K.; Chatterjee, S.; Basha, J.; Kundu, T. K.; Dhar, S. K. 
Histone H3K9 Acetylation Level Modulates Gene Expression and May Affect 
Parasite Growth in Human Malaria Parasite Plasmodium Falciparum. FEBS J. 2014, 
281, 5265–5278. 
(245)  Hardy, S.; Jacques, P. E.; Gevry, N.; Forest, A.; Fortin, M. E.; Laflamme, L.; 
Gaudreau, L.; Robert, F. The Euchromatic and Heterochromatic Landscapes Are 
Shaped by Antagonizing Effects of Transcription on H2A.Z Deposition. PLoS 
Genet. 2009, 5. 
(246)  Abbott, D. W.; Ivanova, V. S.; Wang, X.; Bonner, W. M.; Ausio, J. Characterization 
of the Stability and Folding of H2A.Z Chromatin Particles: Implications for 
Transcriptional Activation. J Biol Chem 2001, 276, 41945–41949. 
(247)  Santisteban, M. S.; Kalashnikova, T.; Smith, M. M. Histone H2A.Z Regulates 
Transcription and Is Partially Redundant with Nucleosome Remodeling Complexes. 
Cell 2000, 103, 411–422. 
(248)  Hu, G.; Cui, K.; Northrup, D.; Liu, C.; Wang, C.; Tang, Q.; Ge, K.; Levens, D.; 
Crane-Robinson, C.; Zhao, K. H2A.Z Facilitates Access of Active and Repressive 
Complexes to Chromatin in Embryonic Stem Cell Self-Renewal and Differentiation. 
Cell Stem Cell 2013, 12, 180–192. 
(249)  Subramanian, V.; Mazumder, A.; Surface, L. E.; Butty, V. L.; Fields, P. A.; Alwan, 
A.; Torrey, L.; Thai, K. K.; Levine, S. S.; Bathe, M.; et al. H2A.Z Acidic Patch 
Couples Chromatin Dynamics to Regulation of Gene Expression Programs during 
ESC Differentiation. PLOS Genet. 2013, 9, e1003725. 
(250)  Rudnizky, S.; Bavly, A.; Malik, O.; Pnueli, L.; Melamed, P.; Kaplan, A. H2A.Z 
Controls the Stability and Mobility of Nucleosomes to Regulate Expression of the 
 276 
LH Genes. 2016, 7, 12958. 
(251)  Zhang, C.; Gao, S.; Molascon, A. J.; Liu, Y.; Andrews, P. C. Quantitative 
Proteomics Reveals Histone Modifications in Crosstalk with H3 Lysine 27 
Methylation. Mol. Cell. Proteomics 2014, 13, 749–759. 
(252)  Barski, A.; Cuddapah, S.; Cui, K.; Roh, T. Y.; Schones, D. E.; Wang, Z.; Wei, G.; 
Chepelev, I.; Zhao, K. High-Resolution Profiling of Histone Methylations in the 
Human Genome. Cell 2007, 129, 823–837. 
(253)  Ku, M.; Jaffe, J. D.; Koche, R. P.; Rheinbay, E.; Endoh, M.; Koseki, H.; Carr, S. A.; 
Bernstein, B. E. H2A.Z Landscapes and Dual Modifications in Pluripotent and 
Multipotent Stem Cells Underlie Complex Genome Regulatory Functions. Genome 
Biol. 2012, 13, R85. 
(254)  Valdes-Mora, F.; Song, J. Z.; Statham, A. L.; Strbenac, D.; Robinson, M. D.; Nair, 
S. S.; Patterson, K. I.; Tremethick, D. J.; Stirzaker, C.; Clark, S. J. Acetylation of 
H2A.Z Is a Key Epigenetic Modification Associated with Gene Deregulation and 
Epigenetic Remodeling in Cancer. Genome Res 2012, 22, 307–321. 
(255)  Millar, C. B.; Xu, F.; Zhang, K.; Grunstein, M. Acetylation of H2AZ Lys 14 Is 
Associated with Genome-Wide Gene Activity in Yeast. Genes Dev.  2006, 20, 711–
722. 
(256)  Vardabasso, C.; Gaspar-Maia, A.; Hasson, D.; Pünzeler, S.; Valle-Garcia, D.; 
Straub, T.; Keilhauer, E. C.; Strub, T.; Dong, J.; Panda, T.; et al. Histone Variant 
H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Mol. 
Cell 2015, 59, 75–88. 
(257)  Vardabasso, C.; Gaspar-Maia, A.; Hasson, D.; Pünzeler, S.; Valle-Garcia, D.; 
Straub, T.; Keilhauer, E. C.; Strub, T.; Dong, J.; Panda, T.; et al. Histone Variant 
H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Mol. 
Cell 2017, 59, 75–88. 
(258)  Yang, H. D.; Kim, P.-J.; Eun, J. W.; Shen, Q.; Kim, H. S.; Shin, W. C.; Ahn, Y. M.; 
Park, W. S.; Lee, J. Y.; Nam, S. W. Oncogenic Potential of Histone-Variant 
H2A.Z.1 and Its Regulatory Role in Cell Cycle and Epithelial-Mesenchymal 
Transition in Liver Cancer. Oncotarget 2016, 7, 11412–11423. 
(259)  Kobor, M. S.; Venkatasubrahmanyam, S.; Meneghini, M. D.; Gin, J. W.; Jennings, 
J. L.; Link, A. J.; Madhani, H. D.; Rine, J. A Protein Complex Containing the 
Conserved Swi2/Snf2-Related ATPase Swr1p Deposits Histone Variant H2A.Z into 
Euchromatin. PLOS Biol. 2004, 2, e131. 
(260)  Mizuguchi, G.; Shen, X.; Landry, J.; Wu, W.-H.; Sen, S.; Wu, C. ATP-Driven 
Exchange of Histone H2AZ Variant Catalyzed by SWR1 Chromatin Remodeling 
Complex. Science (80-. ). 2004, 303, 343–348. 
(261)  Altaf, M.; Auger, A.; Monnet-Saksouk, J.; Brodeur, J.; Piquet, S.; Cramet, M.; 
Bouchard, N.; Lacoste, N.; Utley, R. T.; Gaudreau, L.; et al. NuA4-Dependent 
Acetylation of Nucleosomal Histones H4 and H2A Directly Stimulates 
Incorporation of H2A.Z by the SWR1 Complex. J. Biol. Chem. 2010, 285, 15966–
15977. 
(262)  Raisner, R. M.; Hartley, P. D.; Meneghini, M. D.; Bao, M. Z.; Liu, C. L.; Schreiber, 
S. L.; Rando, O. J.; Madhani, H. D. Histone Variant H2A.Z Marks the 5` Ends of 
Both Active and Inactive Genes in Euchromatin. Cell 2005, 123, 233–248. 
 277 
(263)  Kusakabe, M.; Oku, H.; Matsuda, R.; Hori, T.; Muto, A.; Igarashi, K.; Fukagawa, 
T.; Harata, M. Genetic Complementation Analysis Showed Distinct Contributions 
of the N-Terminal Tail of H2A.Z to Epigenetic Regulations. Genes to Cells 2016, 
21, 122–135. 
(264)  Landry, J. W.; Banerjee, S.; Taylor, B.; Aplan, P. D.; Singer, A.; Wu, C. Chromatin 
Remodeling Complex NURF Regulates Thymocyte Maturation. Genes Dev.  2011, 
25, 275–286. 
(265)  Mayes, K.; Alkhatib, S. G.; Peterson, K.; Alhazmi, A.; Song, C.; Chan, V.; Blevins, 
T.; Roberts, M.; Dumur, C. I.; Wang, X.-Y.; et al. BPTF Depletion Enhances T-cell–
Mediated Antitumor Immunity. Cancer Res. 2016, 76, 6183 LP-6192. 
(266)  Dai, M.; Lu, J.-J.; Guo, W.; Yu, W.; Wang, Q.; Tang, R.; Tang, Z.; Xiao, Y.; Li, Z.; 
Sun, W. BPTF Promotes Tumor Growth and Predicts Poor Prognosis in Lung 
Adenocarcinomas. Oncotarget 2015, 6, 33878–33892. 
(267)  Dar, A. A.; Nosrati, M.; Bezrookove, V.; de Semir, D.; Majid, S.; Thummala, S.; 
Sun, V.; Tong, S.; Leong, S. P. L.; Minor, D.; et al. The Role of BPTF in Melanoma 
Progression and in Response to BRAF-Targeted Therapy. J. Natl. Cancer Inst. 2015, 
107, djv034-djv034. 
(268)  Chen, I.-Y.; Lypowy, J.; Pain, J.; Sayed, D.; Grinberg, S.; Alcendor, R. R.; 
Sadoshima, J.; Abdellatif, M. Histone H2A.z Is Essential for Cardiac Myocyte 
Hypertrophy but Opposed by Silent Information Regulator 2alpha. J. Biol. Chem. 
2006, 281, 19369–19377. 
(269)  Richart, L.; Carrillo-de Santa Pau, E.; Río-Machín, A.; de Andrés, M. P.; Cigudosa, 
J. C.; Lobo, V. J. S.-A.; Real, F. X. BPTF Is Required for c-MYC Transcriptional 
Activity and in Vivo Tumorigenesis. Nat. Commun. 2016, 7, 10153. 
(270)  Richart, L.; Real, F. X.; Sanchez-Arevalo Lobo, V. J. C-MYC Partners with BPTF 
in Human Cancer. Mol. Cell. Oncol. 2016, 3, e1152346. 
(271)  Kim, K.; Punj, V.; Choi, J.; Heo, K.; Kim, J.-M.; Laird, P. W.; An, W. Gene 
Dysregulation by Histone Variant H2A.Z in Bladder Cancer. Epigenetics Chromatin 
2013, 6, 34. 
(272)  Goldman, J. A.; Garlick, J. D.; Kingston, R. E. Chromatin Remodeling by Imitation 
Switch (ISWI) Class ATP-Dependent Remodelers Is Stimulated by Histone Variant 
H2A.Z. J. Biol. Chem.  2010, 285, 4645–4651. 
(273)  Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-
Lovejoy, D.; Felletar, I.; Volkmer, R.; Müller, S.; Pawson, T.; et al. Histone 
Recognition and Large-Scale Structural Analysis of the Human Bromodomain 
Family. Cell 2012, 149, 214–231. 
(274)  Ruthenburg, A. J.; Li, H.; Milne, T. A.; Dewell, S.; McGinty, R. K.; Yuen, M.; 
Ueberheide, B.; Dou, Y.; Muir, T. W.; Patel, D. J.; et al. Recognition of a 
Mononucleosomal Histone Modification Pattern by BPTF via Multivalent 
Interactions. Cell 2016, 145, 692–706. 
(275)  Arntson, K. E.; Pomerantz, W. C. K. Protein-Observed Fluorine NMR: A 
Bioorthogonal Approach for Small Molecule Discovery. J. Med. Chem. 2016, 59, 
5158–5171. 
(276)  Norton, S. R.; Leung, W. E.; Chandrashekaran, R. I.; MacRaild, A. C. Applications 
of 19F-NMR in Fragment-Based Drug Discovery. Molecules 2016, 21, 860. 
 278 
(277)  Bruce, K.; Myers, F. A.; Mantouvalou, E.; Lefevre, P.; Greaves, I.; Bonifer, C.; 
Tremethick, D. J.; Thorne, A. W.; Crane-Robinson, C. The Replacement Histone 
H2A.Z in a Hyperacetylated Form Is a Feature of Active Genes in the Chicken. 
Nucleic Acids Res 2005, 33, 5633–5639. 
(278)  Urick, A. K.; Calle, L. P.; Espinosa, J. F.; Hu, H.; Pomerantz, W. C. K. Protein-
Observed Fluorine NMR Is a Complementary Ligand Discovery Method to 1H 
CPMG Ligand-Observed NMR. ACS Chem. Biol. 2016, 11, 3154–3164. 
(279)  Sudhamalla, B.; Dey, D.; Breski, M.; Nguyen, T.; Islam, K. Site-Specific Azide-
Acetyllysine Photochemistry on Epigenetic Readers for Interactome Profiling. 
Chem. Sci. 2017, 8, 4250–4256. 
(280)  Albert, I.; Mavrich, T. N.; Tomsho, L. P.; Qi, J.; Zanton, S. J.; Schuster, S. C.; Pugh, 
B. F. Translational and Rotational Settings of H2A.Z Nucleosomes across the 
Saccharomycescerevisiae Genome. Nature 2007, 446, 572–576. 
(281)  Babiarz, J. E.; Halley, J. E.; Rine, J. Telomeric Heterochromatin Boundaries Require 
NuA4-Dependent Acetylation of Histone Variant H2A.Z in 
Saccharomycescerevisiae. Genes Dev.  2006, 20, 700–710. 
(282)  Dryhurst, D.; Ishibashi, T.; Rose, K. L.; Eirín-López, J. M.; McDonald, D.; Silva-
Moreno, B.; Veldhoen, N.; Helbing, C. C.; Hendzel, M. J.; Shabanowitz, J.; et al. 
Characterization of the Histone H2A.Z-1 and H2A.Z-2 Isoforms in Vertebrates. 
BMC Biol. 2009, 7, 86. 
(283)  Li, S.; Shogren-Knaak, M. A. The Gcn5 Bromodomain of the SAGA Complex 
Facilitates Cooperative and Cross-Tail Acetylation of Nucleosomes. J. Biol. Chem. 
2009, 284, 9411–9417. 
(284)  Owen, D. J.; Ornaghi, P.; Yang, J.; Lowe, N.; Evans, P. R.; Ballario, P.; Neuhaus, 
D.; Filetici, P.; Travers, A. A. The Structural Basis for the Recognition of Acetylated 
Histone H4 by the Bromodomain of Histone Acetyltransferase Gcn5p. EMBO J. 
2000, 19, 6141–6149. 
(285)  Hudson, B. P.; Martinez-Yamout, M. A.; Dyson, H. J.; Wright, P. E. Solution 
Structure and Acetyl-Lysine Binding Activity of the GCN5 bromodomain1 . J. Mol. 
Biol. 2000, 304, 355–370. 
(286)  Perell, G.; Staebell, R.; Hairani, M.; Cembran, A.; Pomerantz, W. C. K. Tuning 
Sulfur Oxidation States on Thioether-Bridged Peptide Macrocycles for Modulation 
of Protein Interactions. ChemBioChem 2017, Accepted Author Manuscript. 
(287)  Crowley, P. B.; Kyne, C.; Monteith, W. B. Simple and Inexpensive Incorporation 
of 19F-Tryptophan for Protein NMR Spectroscopy. Chem. Commun. 2012, 48, 
10681–10683. 
(288)  Philpott, M.; Yang, J.; Tumber, T.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; 
Picaud, S.; Keates, T.; Felletar, I.; Ciulli, A.; et al. Bromodomain-Peptide 
Displacement Assays for Interactome Mapping and Inhibitor Discovery. Mol. 
Biosyst. 2011, 7, 2899–2908. 
(289)  Coon, J. J.; Ueberheide, B.; Syka, J. E.; Dryhurst, D. D.; Ausio, J.; Shabanowitz, J.; 
Hunt, D. F. Protein Identification Using Sequential Ion/ion Reactions and Tandem 
Mass Spectrometry. Proc Natl Acad Sci USA 2005, 102. 
(290)  Ishibashi, T.; Dryhurst, D.; Rose, K. L.; Shabanowitz, J.; Hunt, D. F.; Ausio, J. 
Acetylation of Vertebrate H2A.Z and Its Effect on the Structure of the Nucleosome. 
 279 
Biochemistry 2009, 48. 
(291)  Matsuda, R.; Hori, T.; Kitamura, H.; Takeuchi, K.; Fukagawa, T.; Harata, M. 
Identification and Characterization of the Two Isoforms of the Vertebrate H2A.Z 
Histone Variant. Nucleic Acids Res. 2010, 38, 4263–4273. 
(292)  Paz, J. C.; Park, S.; Phillips, N.; Matsumura, S.; Tsai, W.-W.; Kasper, L.; Brindle, 
P. K.; Zhang, G.; Zhou, M.-M.; Wright, P. E.; et al. Combinatorial Regulation of a 
Signal-Dependent Activator by Phosphorylation and Acetylation. Proc. Natl. Acad. 
Sci.  2014, 111, 17116–17121. 
(293)  Anand, P.; Brown, J. D.; Lin, C. Y.; Qi, J.; Zhang, R.; Artero, P. C.; Alaiti, M. A.; 
Bullard, J.; Alazem, K.; Margulies, K. B.; et al. BET Bromodomains Mediate 
Transcriptional Pause Release in Heart Failure. Cell 2013, 154, 569–582. 
(294)  Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; 
Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; et al. BET Bromodomain 
Inhibition as a Therapeutic Strategy to Target c-Myc. Cell 2011, 146, 904–917. 
(295)  Hewings, D. S.; Rooney, T. P. C.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; 
Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the Development and 
Application of Small Molecule Inhibitors of Bromodomain–Acetyl-Lysine 
Interactions. J. Med. Chem. 2012, 55, 9393–9413. 
(296)  Gerona-navarro, G.; Mujtaba, S.; Frasca, A.; Patel, J.; Zeng, L.; Plotnikov, A. N.; 
Osman, R.; Zhou, M. Rational Design of Cyclic Peptide Modulators of the 
Transcriptional Coactivator CBP: A New Class of p53 Inhibitors. J. Am. Chem. Soc. 
2011, 133, 2040–2043. 
(297)  Rooney, T. P. C.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.; Cortopassi, W. A.; 
Hay, D. A.; Martin, S.; Tumber, A.; Rogers, C. M.; Philpott, M.; et al. A Series of 
Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized 
by a Cation–π Interaction. Angew. Chemie Int. Ed. 2014, 53, 6126–6130. 
(298)  Hay, D. A.; Fedorov, O.; Martin, S.; Singleton, D. C.; Tallant, C.; Wells, C.; Picaud, 
S.; Philpott, M.; Monteiro, O. P.; Rogers, C. M.; et al. Discovery and Optimization 
of Small-Molecule Ligands for the CBP/p300 Bromodomains. J. Am. Chem. Soc. 
2014, 136, 9308–9319. 
(299)  Fong, C. Y.; Gilan, O.; Lam, E. Y. N.; Rubin, A. F.; Ftouni, S.; Tyler, D.; Stanley, 
K.; Sinha, D.; Yeh, P.; Morison, J.; et al. BET Inhibitor Resistance Emerges from 
Leukaemia Stem Cells. Nature 2015, 525, 538–542. 
(300)  Ayoub, A. M.; Hawk, L. M. L.; Herzig, R. J.; Jiang, J.; Wisniewski, A. J.; Gee, C. 
T.; Zhao, P.; Zhu, J.-Y.; Berndt, N.; Offei-Addo, N. K.; et al. BET Bromodomain 
Inhibitors with One-Step Synthesis Discovered from Virtual Screen. J. Med. Chem. 
2017. 
 
